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1AbSTRACT
ABSTRACT
Osteoarthritis (OA) is thought to be the most prevalent of the musculoskeletal 
diseases, with a huge socio-economic impact. This chronic, usually progressive, 
disease involves the whole joint in a degenerative process. The dominant symptom 
is pain, which is typically described as activity related or mechanical, and in more 
advanced OA may become more persistent and also occur at rest and at night. 
Despite being the most frequent self-reported chronic pain aetiology, and the 
reason for patients to seek medical care, pain management in OA is far from 
optimal. This is partially due to the lack of knowledge regarding its source and 
mechanisms. 
The studies that comprise this dissertation aimed to contribute to unravel 
the underlying nociceptive mechanisms in OA. For that purpose, we used an 
experimental model of OA, consisting of sodium monoiodoacetate (MIA) injection 
into the knee joint of rats, which has been described as the best model for the 
study of nociception in this pathology.
Since evaluation of nociception is of crucial importance, the first objective of 
this dissertation was to develop nociceptive behavioural tests that would measure 
movement-evoked nociception of the knee joint in the MIA model of OA, in a 
consistent and clinically relevant way. In the first study we evaluated behavioural 
responses related to movement-evoked nociception directly in or near the affected 
joint, and compared them with commonly used referred nociception tests. The 
following tests were assessed: Knee-Bend, pin-prick, CatWalk, von Frey filaments 
and Randall-Selitto. Behavioural nociceptive responses were evaluated in animals 
injected with two different doses of MIA. Knee-Bend and CatWalk behavioural tests 
were effective in evaluating the joint movement-related nociception, characteristic 
of OA symptomatology. 
The sensitivity of Knee-Bend and CatWalk tests for measuring OA-induced 
nociception was evaluated in the second study, by testing the effect of the analgesic 
drugs lidocaine, diclofenac and morphine, administered at an early inflammatory 
stage and at a late/chronic phase of OA progression. The three drugs reverted the 
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movement-induced nociceptive behaviour in both tests in the early inflammatory 
stage. In the late/chronic phase, morphine had a complete antinociceptive effect, 
lidocaine efficacy was essentially observed in the Knee-Bend test, and diclofenac 
had almost no effect. These data allowed us to conclude that, in this model of OA, 
analgesic drugs used in the clinical setting change the behavioural responses 
elicited by movement-induced nociception, as detected by the Knee-Bend and 
CatWalk tests, supporting their usefulness for evaluating joint movement-related 
nociception. Furthermore, the effects of lidocaine and diclofenac, particularly 
prominent at an early stage and not as so in the late one, suggest an important 
contribution of intra-articular nerve terminals as the drive for movement-induced 
nociception and a role for inflammation at this early stage of OA progression. 
The second objective of this dissertation was to contribute to unravel some 
of the peripheral mechanisms underlying pain in OA. For that purpose, in the third 
study we evaluated changes in the sensory neurons innervating the knee joint of 
rats with 31 days of OA, by using immunohistochemical techniques to label primary 
afferent neurons in the dorsal root ganglia. The total number of dorsal root ganglia 
neurons, the total number of sensory neurons innervating the knee joint and the 
expression of the phenotypic markers calcitonin gene-related peptide (CGRP), 
isolectin B4 (IB4), and neurofilament 200 (NF200) in the latter neurons was studied. 
A decrease in the number of sensory neurons innervating OA knee joints was 
observed, but no decrease in the total number of dorsal root ganglia neurons was 
found, suggesting the occurrence of changes in the afferent fibres rather than loss 
of neurons. Since a small, albeit not statistically significant, increase in the total 
number of dorsal root ganglia neurons in OA animals was found, the occurrence of 
neurogenesis was investigated through bromodeoxyuridine incorporation, but no 
neurogenesis was identified. An increase in the percentage of CGRP in the sensory 
neurons innervating the knee joint of OA animals was also found. Furthermore, 
we observed that a subpopulation of large-diameter dorsal root ganglia neurons 
express CGRP in OA animals. This could be due to de novo expression or reflect 
swelling/hypertrophy of smaller neurons that expressed these peptides all along. 
The shift observed in the total number of dorsal root ganglia neurons to larger 
cell sizes, in the absence of neuronal death and neurogenesis, also suggests the 
occurrence of perikarya hypertrophy. The observations of this third study suggest 
alterations in the sensory neurons innervating OA joints that can be interpreted as 
a neuronal response to axonal injury. 
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In order to assess the possible existence of neuronal damage in primary 
afferent neurons innervating OA joints, in the fourth study we evaluated the 
expression of two commonly used markers of neuronal damage, activating 
transcription factor 3 (ATF-3) and neuropeptide y (NPy), in primary afferent 
neurons at different time-points of disease progression, following injection of 
different doses of MIA. ATF-3 and NPy expression was dose and time-dependent 
and showed a biphasic pattern, especially evident on ATF-3 expression, which 
suggests the presence of peripheral neuronal injury in this model of OA. Since 
changes observed in neurons after peripheral axonal injury might relate mostly 
to cell survival and regeneration rather than degeneration and cell death, the 
expression of the growth-associated protein (GAP)-43 was also analysed. A 
massive increased expression of GAP-43 in ATF-3 positive cells was observed 
from day 7 onwards, suggesting the occurrence of a regeneration process as part 
of a neuronal response to the injury of peripheral nerves.
Taken together, the studies included in this dissertation contributed to 
broaden our knowledge on the mechanisms of pain in OA, and may have potential 
clinical implications, not only for the assessment of new analgesic drugs but also 
in the design of new strategies for the therapeutic management of OA pain.
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RESUMO
A osteoartrose (OA) é uma das patologias músculo-esqueléticas com 
maior prevalência, tendo um elevado impacto socioeconómico. Esta patologia 
crónica, habitualmente progressiva, envolve toda a articulação num processo 
degenerativo. A dor é o seu sintoma mais frequente, sendo tipicamente descrita 
como associada ao movimento ou mecânica, mas em estadios mais avançados 
de OA pode tornar-se mais persistente e ocorrer em repouso e à noite. Apesar de 
ser a etiologia causadora de dor crónica que os pacientes mais frequentemente 
referem, e a razão pela qual recorrem aos cuidados de saúde, o tratamento da 
dor na OA está longe de ser eficaz. Isto deve-se em parte à falta de conhecimento 
acerca da sua origem e mecanismos. 
Os estudos incluídos nesta dissertação tiveram como objetivo geral contribuir 
para o esclarecimento dos mecanismos nocicetivos associados à OA. Para esse 
propósito foi utilizado um modelo experimental de OA que tem sido descrito como 
o melhor modelo para o estudo da nociceção nesta patologia, o qual consiste na 
injeção de mono-iodoacetato de sódio (MIA) na articulação do joelho de ratos. 
Uma vez que a avaliação da nociceção é de extrema importância, o objetivo 
do primeiro estudo incluído nesta dissertação compreendeu o desenvolvimento de 
testes comportamentais que permitissem a avaliação da nociceção associada ao 
movimento da articulação do joelho, no modelo OA-MIA, de uma forma consistente 
e clinicamente relevante. Para o efeito, avaliamos as respostas comportamentais 
relacionadas com a nociceção associada ao movimento, diretamente ou próximo 
da articulação afetada, e comparamos com os testes de nociceção referida 
habitualmente utilizados. Analisaram-se os seguintes testes em animais injetados 
com duas doses diferentes de MIA: Knee-Bend, pin-prick, CatWalk, filamentos 
von Frey e Randall-Selitto. Os testes comportamentais de Knee-Bend e CatWalk 
demonstraram ser eficazes na avaliação da nociceção associada ao movimento 
da articulação, característica da sintomatologia da OA. 
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A sensibilidade dos testes Knee-Bend e CatWalk para avaliação da nociceção 
induzida pela OA foi analisada no segundo estudo, através da avaliação do efeito dos 
fármacos analgésicos lidocaína, diclofenaco e morfina, administrados numa fase 
inicial inflamatória e numa fase tardia/crónica de progressão da OA. Na fase inicial 
inflamatória, os três fármacos reverteram o comportamento nociceptivo associado 
ao movimento em ambos os testes. Na fase tardia/crónica, a morfina demonstrou 
um efeito antinocicetivo absoluto, a lidocaína mostrou-se essencialmente eficaz 
no teste Knee-Bend, e o diclofenaco teve um efeito muito reduzido. Estes dados 
permitiram concluir que, neste modelo de OA, fármacos analgésicos usados na 
prática clínica alteram as respostas comportamentais causadas pela nociceção 
induzida pelo movimento, detetada pelos testes Knee-Bend e CatWalk, o que 
sustenta a utilidade destes testes para avaliar a nociceção relacionada com o 
movimento da articulação. Adicionalmente, os efeitos particularmente marcados 
da lidocaína e do diclofenaco na fase inicial, mas não na fase tardia, sugerem uma 
contribuição importante dos terminais nervosos articulares como impulsores 
da nociceção associada ao movimento na fase inicial da progressão da OA, bem 
como um papel para a inflamação neste estadio. 
O segundo objectivo desta dissertação consistiu em contribuir para o 
esclarecimento de alguns dos mecanismos periféricos associados à dor na 
OA. Com este intuito, no terceiro estudo analisamos alterações nos neurónios 
sensitivos que inervam as articulações do joelho de ratos com 31 dias de OA, 
através de técnicas de imunohistoquímica que permitem a marcação dos neurónios 
aferentes primários presentes nos gânglios dorsais raquidianos. Avaliou-se o 
número total de neurónios presentes nos gânglios dorsais raquidianos, o número 
total de neurónios sensitivos que inervam a articulação do joelho, e a expressão 
dos marcadores neuroquímicos peptídeo relacionado com o gene da calcitonina 
(CGRP), isolectina B4 (IB4), e neurofilamento 200 (NF200) nos neurónios sensitivos 
que inervam a articulação do joelho. Observou-se uma diminuição do número de 
neurónios sensitivos que inervam a articulação do joelho com OA, apesar de não 
haver uma redução do número total de neurónios presentes nos gânglios dorsais 
raquidianos, o que sugere um fenómeno de alterações nas fibras aferentes 
e não de perda neuronal. Tendo em conta que foi observado um aumento, 
embora não significativo, do número total de neurónios presentes nos gânglios 
dorsais raquidianos nos animais OA, a possível ocorrência de neurogénese foi 
investigada, através da incorporação de bromodeoxiuridina, mas não foi detetada 
neurogénese nestes animais. Observou-se ainda um aumento da percentagem 
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de CGRP nos neurónios sensitivos que inervam a articulação do joelho de animais 
OA. Adicionalmente verificou-se que nos animais OA existia uma subpopulação de 
neurónios dos gânglios dorsais raquidianos de grande diâmetro que expressavam 
CGRP. Esta expressão pode ser devida a uma síntese de novo de CGRP, ou 
resultar de uma hipertrofia de neurónios mais pequenos que habitualmente já 
expressam este peptídeo. A deslocação para diâmetros maiores observada na 
contagem do número total de neurónios dos gânglios dorsais raquidianos, na 
ausência de morte neuronal e neurogénese, sugere igualmente a ocorrência de 
um fenómeno de hipertrofia dos pericários. No seu conjunto, estas observações 
sugerem a existência de alterações nos neurónios sensitivos que inervam as 
articulações com OA, que podem ser interpretadas como uma resposta neuronal 
a lesão axonal. 
De modo a avaliar a possível existência de dano neuronal nos neurónios 
aferentes primários que inervam as articulações com OA, no quarto estudo 
analisámos a expressão de dois marcadores habitualmente utilizados para sinalizar 
dano neuronal, o fator de ativação da transcrição 3 (ATF-3) e o neuropeptídeo y 
(NPy), nos neurónios aferentes primários em tempos diferentes de evolução da 
patologia e após injeção de doses diferentes de MIA. A expressão de ATF-3 e NPy 
dependia da dose e do tempo de evolução da OA, e mostrou um comportamento 
bifásico, especialmente evidente na expressão de ATF-3, o que sugere a presença 
de dano neuronal periférico neste modelo da OA. Uma vez que as alterações 
observadas nos neurónios após lesão axonal periférica podem ser atribuídas a 
uma resposta de regeneração e sobrevivência da célula em vez de degeneração 
e morte celular, a expressão da proteína associada ao crescimento (GAP)-43 foi 
igualmente analisada. Um grande aumento da expressão de GAP-43 em células 
ATF-3 positivas foi observado a partir do dia 7, sugerindo a ocorrência de um 
processo de regeneração como resposta neuronal a uma lesão dos terminais 
sensitivos dos nervos periféricos. 
No seu conjunto, os estudos incluídos na presente dissertação contribuíram 
para expandir o conhecimento acerca dos mecanismos da dor na OA, e poderão ter 
possíveis implicações clinicas, quer na avaliação de novos fármacos analgésicos 
quer na escolha de novas estratégias terapêuticas no tratamento da dor na OA.
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ABBREvIATIONS
ACC - anterior cingulate cortex
ACEA - receptor agonist arachidonyl-2-chloroethylamide
ACR - American College of Rheumatology
ADAmTS - A Disintegrin And Metalloproteinase with Thrombospondin motifs
AH - A-fibres heat-sensitive
Am - A-fibres mechanosensitive
AmH - A-fibres heat- and mechanosensitive
ASIC - acid-sensing ion channel
ATF - activating transcription factor
ATP - adenosine triphosphate 
bmP7 - bone morphogenetic protein 7
brdU - bromodeoxyuridine
c-ret - tyrosine kinase receptor Ret 
Cb1 - cannabinoid receptor subtype 1
CFA - Complete Freund’s adjuvant
CGRP - calcitonin gene-related peptide
CH - C-fibres heat-responsive
CmHs - C-fibres mechano-heat nociceptors
CmiHi – C-fibres mechano- and heat-insensitive 
CNS – Central Nervous system
COX - cyclooxygenase
DAP - depolarizing after potential
Ddr2 - discoidin domain receptor 2
DRG - dorsal root ganglia 
EULAR - European League Against Rheumatism
FG - fluorogold
FRAP - fluoride-resistant acid phosphatase
GAP - growth-associated protein
GDF5 - growth/differentiation factor 5
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GDNF - glial cell-derived neurotrophic factor
HCN - hyperpolarization-activated cyclic nucleotide-gated channels
HIF-2α - hypoxia-inducible factor 2α
HtrA1 - serine proteinase high temperature requirement A1
IASP - International Association for the Study of Pain
Ib4 – isolectin B4
IL - interleukin 
K2P - two-pore K+ channels
LTms - low threshold mechanoreceptors
mIA - sodium monoiodoacetate
miRNAs – small non-coding RNAs
mmP - matrix metalloproteinase
mrgAs - Mas-related genes As 
mrgD - Mas-related genes D
mRI - magnetic resonance imaging
(N/OFQ) - nociceptin/orphanin 
Na - voltage-gated Na+ channel
NF200 - neurofilament 200 kDa,
NGF - nerve growth factor 
NHANES III - National Health and Nutrition Examination Survey III
NK-A - neurokinin A
NPY – neuropeptide y
NSAIDs - nonsteroidal anti-inflammatory drugs
OA - Osteoarthritis
PAG - periaqueductal grey matter 
PGE2 - prostaglandins E2
PGI2 - prostaglandin I2
PPARA - peroxisome proliferator-activated receptor alpha
PWT - Paw withdrawal thresholds
ROS - reactive oxygen species
RT97 – clone RT97 of neurofilament 200 kDa,
RUNX2 - runt-related transcription factor 2
S1 - secondary somatosensory cortex
S2 - secondary somatosensory cortex
SOm - somatostatin
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SP - substance P
TGF- transforming growth factor
TNF - tumour necrosis factor 
trkA - tyrosine kinase receptor A
TRP - transient receptor potential ion channels
TRPA1 - transient receptor potential cation channel subfamily A member 1
TRPm8 - transient receptor potential cation channel subfamily M member 8
TRP1 - transient receptor potential vanilloid 1 channel
TTX - tetrodotoxin
EGF - vascular endothelial growth factor
IP - vasoactive intestinal peptide
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1. PAIN
1.1. PAIN DEFINITION/CLASSIFICATION AND ASSOCIATED TERMINOLOGy
According to the International Association for the Study of Pain (IASP), pain is 
defined as “an unpleasant sensory and emotional experience associated with actual 
or potential tissue damage, or described in terms of such damage”(Merskey and 
Bogduk, 1994). Pain is always subjective. It is a conscious experience influenced 
by memories, emotional, pathological and cognitive factors (Tracey, 2005). In the 
great majority of pain states an adequate stimulus is necessary to elicit pain, 
which is traditionally called a noxious stimulus. However, pain has also been 
reported in the absence of tissue damage or any likely pathophysiological cause, 
but nevertheless it should be accepted as pain (Merskey and Bogduk, 1994).
A noxious stimulus is an event that is damaging or threatens damage to 
normal tissues (Merskey and Bogduk, 1994 updated by the IASP Taxonomy 
Working Group). The possibility of a potential tissue damage event elicit activity in 
the nociceptive system is of outmost importance since it functions as a warning 
sign to the organism, signalling impending tissue damage before it occurs 
(Treede, 2009). Noxious stimuli may be of thermal, mechanical or chemical 
modality. Nonetheless, because there are some types of noxious stimuli that are 
not detected by the nociceptive system, a new term, nociceptive stimulus, was 
proposed to refer to an actually or potentially tissue damaging event transduced 
and encoded by nociceptors (Cervero and Merskey, 1996; Merskey and Bogduk, 
1994 updated by the IASP Taxonomy Working Group). 
Pain that is concerned only with the detection/transduction and processing 
of noxious stimuli it is called nociceptive pain (Woolf, 2010). It is an early-warning 
physiological protective process that is only activated in the presence of intense 
stimuli, being mediated by high-threshold unmyelinated C or thinly myelinated 
Aδ primary sensory neurons (Costigan et al., 2009). Being essential to detect and 
avoid contact with damaging or noxious events, the lack of nociceptive pain, such 
as congenital insensitivity to pain, is a problem leading to self-mutilation, multiple 
scars, bone fractures, amputations and early death (Woolf, 2010). Its protective 
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function is enhanced by the phenomenon of sensitization of the nociceptive system, 
where after repeated or intense noxious stimuli the threshold for its activation 
lowers and the responses to subsequent stimuli are amplified (Latremoliere and 
Woolf, 2009). In the absence of ongoing tissue injury this state returns to normal. 
Whenever tissue injury or infection leads to the activation of the immune 
system, inflammatory pain may occur (Woolf, 2010). There is an increased 
sensory sensitivity that discourages physical contact and movement, therefore 
assisting in the healing and repair of the injured body part (Woolf, 2010). This 
heightened sensitivity may occur both in the inflamed areas and in the contiguous 
non-inflamed areas as a result of plasticity in peripheral and central nociceptive 
pathways (Costigan et al., 2009). Because the pain system is sensitized, it begins 
to be activated not only by noxious stimuli, but also by low-threshold innocuous 
inputs, both producing pain responses more exaggerated and prolonged (Costigan 
et al., 2009). Usually, inflammatory pain disappears after resolution of the initial 
tissue injury, but in chronic disorders, in which inflammation is permanently 
active, the pain persists (Costigan et al., 2009). In fact, by the standard definition, 
when pain persists past the healing phase following injury it is called chronic pain 
(Merskey and Bogduk, 1994). However, determining the end of the healing phase 
is difficult, and it has been suggested that the transition from acute to chronic pain 
involves a time dependent neural reorganization that initiates a series of events 
that potentiate one pathway at the cost of the other, and where the condition shifts 
from viewing a painful percept as a sign of external threat into an indication of an 
internalized disease state (Apkarian et al., 2009).
There is also a type of pain that results from abnormal functioning of the 
nervous system, neither protecting nor supporting healing or repair. When pain 
is caused by lesion or disease of the somatosensory nervous system it is called 
neuropathic pain (Merskey and Bogduk, 1994 updated by the IASP Taxonomy 
Working Group). In addition, there are conditions where no identifiable noxious 
stimuli nor any detectable inflammation or damage to the nervous system is 
observed, this group of clinical syndromes being called dysfunctional pain (Woolf, 
2010). In both there is temporal summation with a progressive build-up of pain in 
response to repeated stimuli, spatial diffuseness, and reduced pain thresholds 
(Staud et al., 2007). This type of pain results from amplified sensory signals in the 
central nervous system (Woolf, 2010).
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Hyperalgesia and allodynia are the main symptoms of many chronic pain 
conditions (Cervero, 2009). Allodynia consists of pain due to a stimulus that does not 
normally provoke pain (Merskey and Bogduk, 1994 updated by the IASP Taxonomy 
Working Group). It involves a change in the quality of a sensation, whether tactile, 
thermal, or of any other sort. The original stimulus is normally non-painful, but the 
response is painful. Hyperalgesia consists of increased pain from a stimulus that 
normally provokes pain (Merskey and Bogduk, 1994 updated by the IASP Taxonomy 
Working Group). There are two forms of hyperalgesia: primary and secondary. In 
primary hyperalgesia the increased pain sensitivity occurs at the site of the injury, 
as a consequence of nociceptor sensitization, while in secondary hyperalgesia 
the increased sensitivity to pain occurs away from the lesion, in areas adjacent or 
even remote, as a result of alterations in central pain signalling neurons (Treede 
et al., 1992).
1.2. MECHANISMS OF PAIN
The first process in the neurobiological mechanisms of pain is triggered when 
a noxious stimulus, of mechanical, thermal or chemical nature, responsible for the 
initial signalling of injury, activates nociceptors. The activated ion channels present 
on nociceptor terminals then act as transducers to depolarize these neurons, 
setting off nociceptive impulses along the pain pathway. Subsequent peripheral 
changes in the nociceptive system may occur. But, nociceptor activity per se does 
not lead to pain perception, being mandatory that peripheral information reach 
higher centres. Nociceptive signals are conducted via unmyelinated C fibres or 
thinly myelinated Aδ fibres. 
The afferent fibres from nociceptors terminate predominantly in laminae I, II 
and V of the dorsal horn of the spinal cord on relay neurons and local interneurons 
(second-order neurons). Nociceptors release a variety of substances from their 
central terminals, such as glutamate, substance P (SP) and calcitonin gene-
related peptide (CGRP), that have the potential to excite these second-order 
neurons (Dubin and Patapoutian, 2010). Primary afferent neurons encode stimulus 
modality, intensity, location and duration, and this is relayed with enormous 
fidelity to second-order neurons (Woolf and Costigan, 1999). Local inhibitory and 
excitatory interneurons in the dorsal horn, as well as descending inhibitory and 
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facilitatory pathways originating in the brain, modulate the transmission of these 
nociceptive signals (Dubin and Patapoutian, 2010). The relay neurons then project 
to specific brain centres. 
Relay or projection neurons within lamina I and V comprise the major output 
from the dorsal horn of the spinal cord to the brain (Basbaum and Jessell, 2000), to 
the thalamus via the spinothalamic tract and to the medulla and mesencephalon 
via spinoreticular and spinomesencephalic tracts (Dostrovsky and Craig, 2006). 
These tracts serve different purposes. Projections to the brainstem are mainly 
concerned with the integration of nociceptive activity with homeostatic, arousal, and 
autonomic processes, but they also provide an indirect route to convey nociceptive 
information to forebrain regions after brainstem processing, suggesting a central 
role in mediating changes in pain perception (Tracey and Mantyh, 2007). Projections 
to the thalamus follow two routes, one mainly from lamina I to the ventrobasal 
and posterior thalamus, and another mainly from lamina V to the intralaminar 
nuclei, also with projections to the reticular formation, medulla, midbrain, the 
periaqueductal grey matter (PAG) and the limbic system (Flor and Turk, 2011). 
The first is thought to mediate sensory-discriminative aspects of pain, while 
the second contributes to the motivational-affective pain experience (Flor and 
Turk, 2011). The affective pain components also include the spinoreticular and 
spinomesencephalic tracts previously mentioned (Flor and Turk, 2011). 
In addition to the brain areas mentioned above, an extensive cortical network 
is associated with pain processing. This network consistently includes the primary 
(S1) and secondary somatosensory cortices (S2), the agranular insular cortex, the 
anterior cingulate cortex (ACC) and the prefrontal cortex (Tracey and Mantyh, 
2007). These cortical areas seem to contribute to different dimensions of the pain 
experience. The S1 cortex is mainly involved in discriminative aspects of pain 
(Bushnell MC et al., 1999), while the S2 cortex seems to have an important role in 
recognition, learning, and memory of painful events (Schnitzler and Ploner, 2000). 
The insula has been proposed to be involved in autonomic reactions to noxious 
stimuli, like anxiety and fear, and in pain-related learning and memory, and the 
ACC is closely related to pain affect and may subserve the integration of general 
affect, cognition, and response selection (Schnitzler and Ploner, 2000). 
Activation of the nociceptive system does not inevitably results in transmission 
of signals to the cortex where conscious awareness of pain experience occurs 
(Woolf, 2010). There are modulatory circuits, both excitatory and inhibitory, that 
19
INTRODUCTION  |  PAIN
profoundly change pain experience and that are conditioned by the emotional 
state, degree of anxiety, attention and distraction, past experiences, memories, 
cognitive function, and many other factors (Ossipov et al., 2010). The descending 
pain modulatory system arises from several areas including the frontal lobe, 
hypothalamus, insula, amygdala and the rostral ACC that project to the PAG, 
and then outputs to the medulla (Ossipov et al., 2010; Tracey and Manthyh, 2007). 
Neurons within the rostral ventromedial medulla then project to the spinal or 
medullary dorsal horns to directly or indirectly influence nociceptive transmission, 
and thus pain experience (Ossipov et al., 2010). 
Persistent pain derived from diseases or injury can be associated with 
alterations of the properties of both peripheral and central neurons (Basbaum et al., 
2009). These neuronal changes can lead to peripheral and central sensitization.
In peripheral sensitization there is a reduction in activation threshold 
and amplification of the sensitivity of nociceptors, which commonly results 
from inflammation-associated changes in the vicinity of peripheral terminals 
(Latremoliere and Woolf, 2009). It is therefore restricted to the site of injury 
and contributes to inflammatory pain hypersensivity at inflamed areas (primary 
hyperalgesia) (Latremoliere and Woolf, 2009). Nevertheless, it is a form of pain 
elicited by nociceptor activation, though one with a lower threshold, that normally 
requires ongoing peripheral pathology for its maintenance. 
In central sensitization, there is a central amplification of the nociceptive 
signals, being responsible for the enhanced excitability and synaptic efficacy in 
central nociceptive pathways that comes with persistent pain states (Woolf, 2011). 
Additionally, inputs arising from activity in the low-threshold sensory fibres can 
access the nociceptive system and evoke pain sensations. These large-diameter 
myelinated sensory fibres conduct rapid nociceptive signals after inflammatory 
or neuropathic insults and begin to express neuropeptides like SP and CGRP 
(Cheng, 2010). As a consequence, peripheral sensory inputs to the spinal cord 
are substantially increased and pain perception is therefore exaggerated (Cheng, 
2010). Glial cells present in the spinal cord are also activated and contribute 
to enhance neuronal excitability (Cheng, 2010). These alterations concur to 
pain hypersensitivity even in non-inflamed tissues, particularly dynamic tactile 
allodynia, secondary punctate or pressure hyperalgesia, aftersensations, and 
enhanced temporal summation (Woolf, 2011). Increased pain sensitivity exists 
long after the originating source may have disappeared. Hence, the pain is no 
longer coupled to the presence of peripheral stimuli, being instead an abnormal 
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state of responsiveness of the somatosensory system, contributing to neuropathic 
and inflammatory pain (Latremoliere and Woolf, 2009). 
1.3. NOCICEPTORS
Nociceptors are a subpopulation of peripheral nerve fibres from the 
somatosensory nervous system, with high thresholds for activation and capable 
of transducing and encoding intense thermal, mechanical or chemical noxious 
stimuli, a process called nociception (Basbaum and Jessell, 2000; Merskey 
and Bogduk, 1994 updated by IASP Task Force on Taxonomy). Their stimulation 
threshold is just below tissue-damaging intensity since their function is to 
inform the central nervous system (CNS) of tissue-threatening events (Mense, 
2009). Innocuous stimuli do not activate nociceptors in normal circumstances. 
Nociceptors are integrators since they receive a diverse pattern of inputs but 
produce a single output pattern of action potentials (Reichling and Levine, 1999). 
They are also extremely diverse and a dynamic entity, shifting their properties 
according to the environment (Schmidt et al., 1994).
1.3.1. Structure and anatomy
The nociceptors have their soma located in the dorsal root ganglia (DRG) or 
trigeminal ganglia. They are pseudo-unipolar neurons, since from the cell body 
a single process emanates bifurcating afterwards in a peripheral and central 
process. Both processes terminate in a branching pattern referred to as a terminal 
arbour. The extent of the terminal arbour of the peripheral processes depends on 
the afferent type and site of innervation (Gold and Caterina, 2009). C fibres are 
believed to terminate exclusively in free nerve endings while Aδ fibres end both in 
free nerve endings and encapsulated by non-neuronal structures (Mense, 2009). 
Nonetheless, with exception of the free nerve endings in the epidermis, the majority 
are not free in the strict sense since they are ensheathed by Schwann cells, with 
only small areas uncovered (Mense, 2009). These areas, that expose the axonal 
membrane, together with the end bulb, are assumed to be the site where external 
stimuli act (Mense, 2009). The free nerve ending consists of several branches or 
terminals that altogether form the receptive ending equipped with many receptive 
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sites that have the appearance of varicosities. This receptor ending together with 
its afferent fibre is an afferent unit (Mense, 2009).
Nociceptive endings are present in almost all tissues and organs of the 
organism, except in the brain, lung parenchyma, liver, lens and cartilage. There 
are two major classes of nociceptors, the medium diameter myelinated Aδ 
afferents and the small diameter unmyelinated C fibres. The first elicit fast acute 
well-localized first pain, while the second mediate a slow, poorly localized second 
pain. However, there seems to be also a small proportion of cutaneous/somatic 
A-fibre nociceptors with conduction velocities in the Aβ fibres range (Djouhri and 
Lawson, 2004). 
Slowly conducting C fibres have small soma size while low threshold 
mechanoreceptors (LTMs) Aα/Aβ fibres have large perikarya in the DRG. Although 
there is some overlap in cell size among DRG neurons with C, Aδ and Aα/β fibres 
(Harper and Lawson, 1985), a higher proportion of small than large neurons is 
nociceptive since the majority of nociceptive free nerve endings will originate from 
small diameter DRG cells, and therefore a small size indicates a higher probability 
of nociceptive function (Djouhri and Lawson, 2004). However, not all the small 
DRG cells give origin to nociceptive endings, and conversely there are relatively 
large somata that possess nociceptive terminals (Mense, 2009).
The central processes of the nociceptors synapse on second-order neurons 
in the dorsal horn of the spinal cord or the trigeminal subnucleus caudalis. Most 
of the unmyelinated and thinly myelinated afferents enter the spinal cord through 
the dorsal root. However, some unmyelinated afferent sensory fibres are also 
found in the ventral root with their soma located in the DRG (Applebaum et al., 
1976). The central processes of nociceptive afferents that express SP and/or CGRP, 
called peptidergic (see below), terminate mostly in lamina I, the outer lamina II 
and lamina V of the spinal cord dorsal horn (Ribeiro-da-Silva and De Koninck, 
2009). The non-peptidergic nociceptive afferents terminate mostly in the middle 
third of lamina II (Ribeiro-da-Silva and De Koninck, 2009).
1.3.2. Neurochemistry
Nociceptors can be categorized by the molecular markers expressed in their 
cell bodies or on their cell membrane. Nociceptive afferents have been classified 
either as peptidergic or non-peptidergic. Peptidergic cells express SP and/or CGRP 
or somatostatin (SOM). The presence of CGRP does not distinguish between high 
22
NEUROBIOLOGICAL MECHANISMS OF PAIN ASSOCIATED WITH OSTEOARTHRITIS
and low threshold mechanosensitive C-fibres, since this neuropeptide was found 
in both types (Hoheisel, 1994). Peptidergic cells also express the receptor for 
nerve growth factor (NGF), tyrosine kinase receptor A (trkA), which suggest that 
they are NGF dependent (Ringkamp and Meyer, 2009). Additionally, they express 
the transient receptor potential vanilloid 1 channel (TRPV1) that is activated by 
protons (Tominaga et al., 1998), certain endogenous arachidonic acid derivatives 
(Hwang et al., 2000; Zygmunt et al., 1999) and noxious heat (Caterina et al., 1997), 
and express predominantly tetrodotoxin (TTX)-sensitive Na+ channels (Mense, 
2009).
Non-peptidergic cells possess membrane associated glycoconjugates that 
bind to the lectin (IB4) of the plant Griffonia simplicifolia and contain fluoride-
resistant acid phosphatase (FRAP) activity. These cells are dependent of the glial 
cell-derived neurotrophic factor (GDNF) through the expression of the tyrosine 
kinase receptor Ret (c-ret) and GDNF receptors α1-4 (Ringkamp and Meyer, 2009). 
In addition, they express the purinergic P2X3 receptor, a ligand-gated ion channel 
activated by adenosine triphosphate (ATP) and express more TTX-resistant Na+ 
channels (Ringkamp and Meyer, 2009). IB4 positive (IB4+) sensory neurons also 
express Mas-related genes As and D (mrgAs and mrgD) (Dong et al., 2001). These 
cells are also c-ret+, however the level of expression of c-ret is variable, being 
lower in the mrgA positive cells and often restricted to the perimeter of the cell 
body (Dong et al., 2001). Therefore, mrgAs and mrgD might be expressed by distinct 
subsets of IB4+ neurons, which differ in their level of c-ret expression, suggesting 
different physiological properties (Dong et al., 2001). Also, mrgD+ neurons co-
express the P2X3 receptor, but in contrast most mrgA
+ cells do not co-express 
this receptor (Dong et al., 2001). Therefore the expression of mrgAs and mrgD 
is segregated in adulthood, mrgA+ neurons are c-retlow and mostly P2X3
−, while 
mrgD+ cells are c-rethigh and P2X3
+ (Dong et al., 2001).
While this classification is widely used, there is some overlap of marker 
expression between peptidergic and non-peptidergic neurons, as for instance 
some IB4+ neurons express TRPV1 or CGRP (Ringkamp and Meyer, 2009). Also, 
the expression of these markers changes during inflammation or nerve injury. 
However, it should be noted that classical synaptic transmitter of nociceptors is 
glutamate, which is present in both peptidergic and non-peptidergic nociceptors 
(Battaglia and Rustioni, 1988; Ribeiro-da-Silva and De Koninck, 2009).
Large neurons can be labelled with RT97, an antibody against a neurofilament 
protein (NF200). Only some of the small cells can be labelled with this antibody 
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and more likely represent perykarya of Aδ fibres (Ringkamp and Meyer, 2009). 
Like C-nociceptors, Aδ nociceptors are glutamatergic.
1.3.3. Physiology
Nociceptors can be classified based on the conduction velocity of their parent 
axon, which is directly correlated with the diameter of the axons, and whether 
or not they are myelinated. The small diameter unmyelinated axons of C-fibre 
nociceptors have conduction velocities of 0.4–1.4 m/s while the thinly myelinated 
axons of the A-fibre nociceptors support conduction velocities of approximately 
5–30 m/s (Djouhri and Lawson, 2004; Dubin and Patapoutian, 2010). Nociceptive 
fibres can also be classified based on their sensitivity and threshold to noxious 
mechanical (M), heat (H) and chemical (C) stimuli. Units responding to the three 
types of stimuli are called polymodal and are the most common C-fibre, at least 
in fibre recordings (Raja et al., 1988; Van Hees and Gybels, 1981). There are also 
nociceptors that are normally insensitive to mechanical and heat stimulation, or 
have very high thresholds, and are referred as silent nociceptors. These afferents 
become sensitized to noxious mechanical or thermal stimuli only after being 
sensitized by inflammatory mediators (Dubin and Patapoutian, 2010; Schmidt et 
al. 1995).
Although most C-fibres are polymodal, different classes of C nociceptors 
have been described, which seem to subserve different functions in pain and 
hyperalgesia, in particular mechano-responsive and mechano-insensitive 
nociceptors (Weidner et al., 1999). C-fibres mechano-heat nociceptors (CMHs) 
are responsive to mechanical and heat stimuli but have little sensitivity to algesic 
chemical agents (Mense, 2009). In what concerns the mechanical modality, CMHs 
do not respond to blunt objects, but to the application of sharp objects, and their 
receptive field consists of multiple punctate regions of high mechanical sensitivity, 
probably at the location of receptor terminals, surrounded by areas of lesser 
sensitivity (Ringkamp and Meyer, 2009). The heat response of CMHs increases 
monotonically with skin temperatures above threshold and is strongly influenced 
by stimulus history, since upon identical heat stimuli there is a decrement in the 
response, called fatigue (Ringkamp and Meyer, 2009). However, fatigue to one 
stimulus modality can be produced by a stimulus of a different modality, being 
the recovery in this case much faster (Ringkamp and Meyer, 2009). In contrast, 
tissue injury leads to an increase response of nociceptors. Additionally, there 
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is a subpopulation of C-polymodal nociceptors that is sensitive to noxious low 
temperature, being activated by cooling below about 19°C, and may thus contribute 
to cold pain (Campero et al., 1996).
The mechano-insensitive units either do not respond to heating, and are 
thus regarded as silent nociceptors or CMiHi (mechano- and heat-insensitive C 
unit), or respond to heating and are named CH (heat-responsive C units) (Weidner 
et al., 1999). Many of these mechano-insensitive fibres are more responsive to 
chemical stimuli, such as histamine and capsaicin (Ringkamp and Meyer, 2009), 
and often become responsive to natural stimuli, such as tonic pressure and heat, 
when sensitized (Schmidt et al., 1995). For this reason they have been named 
“silent” nociceptors (Schaible and Schmidt, 1988). These mechano-insensitive 
nociceptors also differ from mechanically sensitive afferents in their conductive 
properties, showing a more pronounced activity-dependent slowing (Weidner et 
al., 1999). 
A-fibre nociceptors are predominately heat- and/or mechanosensitive (AMH, 
AH, AM), but sensitivity to noxious cold is also observed. A-fibre nociceptors are 
of two distinct types with regard to the response to heat stimuli. Type I fibres 
are responsive to mechanical and chemical stimuli. They have a slow, wind-up 
response to heat stimuli (Treede et al., 1998). This slow response is not only to 
intense heat stimulus but also to less intense ones. Also a sensitizing stimulus is 
not needed for these afferents to respond to heat (Treede et al., 1998). These fibres 
have conduction velocities around 25 m/s, with some fibres having conduction 
velocities as high as 55 m/s (Aβ-range) (Ringkamp and Meyer, 2009). Type II 
afferents have an adapting response to heat stimuli that resemble that seen in C-
fibre nociceptors (Treede et al., 1998). This is true in mechanically sensitive fibres 
(Treede et al. 1995), as well as in mechanically insensitive ones (Treede et al., 
1998). Additionally, heat response of both C-fibre and type II A-fibre nociceptors, 
exhibit fatigue to repeated heat stimuli (Treede et al., 1998). These fibres have 
slower conduction velocities, of about 15 m/s, always within the Aδ-range, and 
their heat threshold is much lower than those of type I (Ringkamp and Meyer, 
2009). 
The mechanical sensitivity of types I and II A-fibre nociceptors is markedly 
different, with type II afferents showing higher mechanical thresholds than do type 
I, or even being insensitive to mechanical stimuli (Treede et al., 1998). Both types 
I and II afferents respond to chemical stimuli (Davis et al., 1993; Ringkamp et al. 
1997). Type I afferents may be primarily responsible for the first pain sensation, 
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signalling sharp and/or pricking pain to mechanical stimuli (Treede et al., 1998) 
and were shown previously to account for the heat hyperalgesia that follows a 
burn to the hand (Meyer and Campbell, 1981). Type II afferents are suggested to 
signal heat-induced pain (Treede et al., 1998).
1.3.4. Activation/ Transduction
Activation of nociceptors initiates with transduction, a process in which the 
adequate stimulus induces conformational changes in the structure of specific 
proteins located on nociceptor terminals that trigger the opening or closing of 
ion channels (Gold and Caterina, 2009). This will produce an ionic flow across the 
membrane and consequently a change in the membrane potential, referred as 
a generator potential. If the peripheral terminals are depolarized with sufficient 
amplitude and duration, action potential firing ensues, and it is propagated to 
the central terminal of the sensory neurons in order to evoke neurotransmitter 
release necessary to activate postsynaptic spinal cord neurons. 
Although recent evidence suggest that transduction may occur in cells 
surrounding nociceptive terminals, such as urothelial cells and keratinocytes 
(Birder, 2005; Khodorova et al., 2003; Peier et al., 2002), nociceptors are generally 
not associated with specialised cells, therefore seem to have themselves the 
machinery necessary for the transduction process (Gold and Caterina, 2009). 
And if this machinery is present in nociceptive terminals, transduction may 
occur whenever and wherever these transducers are appropriately placed in the 
cell membrane, and probably at multiple sites in the terminal arbour (Gold and 
Caterina, 2009). This suggests there might be multiple sites of spike initiation. 
Sensory transduction in the mammalian somatosensory nervous system 
arises from membrane depolarization. The resting membrane potential of 
nociceptors is moderately hyperpolarized owing to a large K+ conductance, 
through both voltage-insensitive and voltage-gated K+ channels, working against 
a relatively high membrane permeability to depolarizing cations such as Na+ 
and Ca2+ (Baumann et al., 2004; Kirchhoff et al., 1992). Opening of channels 
permeable to these ions will cause the membrane potential to depolarize, since 
their electrochemical gradients are more positive than the resting membrane 
potential in sensory neurons. The closure of K+ channels also depolarizes the 
membrane since its electrochemical gradient is more negative than the resting 
potential (Gold and Caterina, 2009).
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Nociceptors express a multitude of cell surface proteins that are involved 
in the transduction process, such as ion channels involved in the transduction of 
extracellular signals, ion channels that influence passive membrane properties 
and ion channels underlying active membrane processes (Gold and Caterina, 
2009). 
Well-studied examples of ion channels involved in the transduction of 
extracellular signals are the P2X adenosine triphosphate-gated ion channels, 
proton-gated ion channels and the transient receptor potential ion channels 
(TRP). The ATP-gated ion-channels of the P2X family are activated by extracellular 
ATP released upon cell damage (Gold and Caterina, 2009). They are typically non-
selective cation channels with considerable permeability to Na+ and Ca2+ ions. 
Although seven P2X subtypes have been cloned in mammals, P2X2 and P2X3 appear 
to be the most prominently expressed in sensory neurons (Lewis et al., 1995). 
Reductions in tissue pH that accompanies ischemia and most forms of 
inflammation can activate nociceptors through the acid-sensing ion channel 
(ASIC) family (Waldmann, 2001). Upon activation these channels mediate a 
prominent and rapidly desensitizing Na+ current, which in some subtypes (ASIC3) 
is followed by a more sustained current that includes Ca2+ ions (Waldmann et al., 
1999; Waldmann, 2001). The role of ASICs in mechanosensation has been issue of 
some controversy (Gold and Caterina, 2009). 
In what concerns the TRP family, the most well known member is the TRPV1 
channel, being the only one activated by capsaicin. TRPV1 is also activated by 
noxious heat (>43°C), low pH, voltage and various lipids (Rosenbaum and Simon, 
2007). TRPV2 is also activated by extremely hot temperatures (Caterina et al, 1999). 
Cold stimuli can also activate at least two other TRP channels, transient receptor 
potential cation channel subfamily M member 8 (TRPM8) and transient receptor 
potential cation channel subfamily A member 1 (TRPA1), with the latter being also 
activated by certain irritant chemicals (Gold and Caterina, 2009). 
A number of ion channels influence passive membrane properties, and 
thus resting input resistance. The best described are the two-pore K+ channels 
(K2P) and a member of the voltage-gated Na
+ channel family, NaV1.9 (Gold and 
Caterina, 2009). The best-studied polymodal K2P is the K2P2.1 (or TREK-1), which 
can be activated by arachidonic acid, membrane stretch, osmotic welling and 
molecules that caused membrane crenation (Gold and Caterina, 2009). NaV1.9 
channel appears to be a voltage-gated channel with atypical properties. This 
channel has very low threshold for activation and its activation and inactivation 
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curves are widely overlapping around the resting potential, enabling it to produce 
a persistent sodium current component (Coste et al., 2004; Cummins et al., 1999). 
It has been proposed that it could contribute to the setting of the electrogenic 
properties of small DRG neurons, by modulating both resting potential and 
response to subthreshold stimuli (Herzog et al., 2001). Furthermore, the NaV1.9 
current is potentiated by inflammatory mediators that may contribute to increased 
excitability of nociceptors during peripheral inflammation (Maingret et al., 2008).
The ion channels underlying active membrane processes may be responsible 
for action potential upstroke, action potential downstroke and after potential. 
Voltage-gated Na+ channels are crucial for the upstroke rapid depolarization 
phase of neuronal action potential (Gold and Caterina, 2009). NaV1.8 seems to be 
responsible for spike initiation in the terminals and cell body of nociceptors while 
NaV1.6 and NaV1.7 appear to be involved in action potential conduction, although 
the latter may also play a role in action potential generation in terminals (Gold 
and Caterina, 2009). The action potential falling phase is the result of inactivation 
of voltage-gated Na+ channels and activation of K+ channels, specially sustained 
voltage-gated K+ channels (Gold and Caterina, 2009). The large conductance Ca2+-
activated K+ channel (BK channel) also contributes to membrane repolarization 
(Gold and Caterina, 2009). Following an action potential the majority of nociceptive 
neurons undergo a membrane hyperpolarization but a depolarizing after potential 
(DAP) may also occur. Hyperpolarization is mediated, among others, by sustained 
voltage-gated K+ channels, A-type K+ channels and hyperpolarization-activated 
cyclic nucleotide-gated (HCN) channels (Cardenas et al., 1995; Fowler et al., 1985; 
Robinson and Siegelbaum, 2003). The DAP involves a T-type voltage-gated Ca2+ 
channel, and apparently a Ca2+-dependent Cl- current (Mayer, 1985; White et al., 
1989). 
1.3.5. Efferent function 
In addition to the afferent function of signalling pain sensation, nociceptors 
also mediate efferent effects. Whenever a nociceptor is excited it releases the 
neuropeptides, which are stored in vesicles in the varicosities of the peripheral 
terminal, into the interstitial tissue (Mense, 2009). In this sense a nociceptor is 
not a passive sensor of noxious stimuli, but an active cell that influences the 
microcirculation and chemical composition of the interstitial tissue surrounding 
it (Mense, 2009). 
28
NEUROBIOLOGICAL MECHANISMS OF PAIN ASSOCIATED WITH OSTEOARTHRITIS
When a noxious stimulus excites a nociceptor ending, the action potentials 
generated in this region, besides propagating toward the CNS, can propagate 
antidromically into peripheral branches of the nerve fibre (Mense, 2009). These 
would cause the release of neuropeptides in the terminals from both excited and 
unexcited branches. This process, called axon reflex, is thought to be responsible 
for the wheal and flare around a cutaneous lesion (Mense, 2009).
The peripherally released neuropeptides include SP, neurokinin A (NK-A), 
CGRP, vasoactive intestinal peptide (VIP) and SOM (Ringkamp and Meyer, 2009). 
These substances evoke numerous autocrine and paracrine effects on endothelial, 
epithelial and resident immune cells, which lead to arteriolar vasodilatation 
(“flare”) and/or increased vascular permeability and plasma extravasation from 
venules (oedema) (Dubin and Patapoutian, 2010). The release of SP and NK-A 
enhances vascular permeability, whereas CGRP primarily causes vasodilation 
of the blood vessels around the nociceptive ending, although there is evidence 
that CGRP also potentiates the plasma extravasation induced by SP and NK-
A (Gamse and Saria, 1985; Mense, 2009). As a result, there is a shift of blood 
plasma from the intravascular to the interstitial space, with tissue oedema 
and infiltration by immune cells with release of enzymes (e.g., kallikreins) that 
further contribute to the accumulation of inflammatory mediators characteristic 
of neurogenic inflammation. It seems that stimulation of both Aδ and C fibres 
can elicit vasodilation, but increases in vascular permeability and plasma 
extravasation are only achieved by stimulation of C-fibres (Mense, 2009). The 
release of neuropeptides/neurotransmitters from the sensory nerve endings has 
been shown to contribute to neurogenic inflammation, to the tissue repair and 
maintenance of pain and hyperalgesia (Willis, 1999). In fact, glutamate is also 
released into the periphery, acting on glutamate receptors on peripheral primary 
afferents, leading to further activation of these afferents (deGroot et al., 2000). 
Besides the inflammatory effects, there seems also to be a role for nociceptors 
in releasing bioactive substances with the potential to exert trophic effects on their 
innervations targets. It has been shown that CGRP and VIP, through receptors 
located in osteoblasts and osteoclasts, regulate cellular activity underlying 
bone formation and resorption, critical processes for healthy bone maintenance 
(Lerner, 2002).
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2. OSTEOARTHRITIS
2.1. DEFINITION AND CLASSIFICATION
Osteoarthritis (OA) is a group of overlapping distinct diseases, which may have 
different aetiologies that, nonetheless, have similar biological, morphological and 
clinical outcomes (Flores and Hochberg, 2003). This, usually progressive, disease 
of synovial joints involves the entire joint, including articular cartilage, subchondral 
bone, ligaments, capsule, synovial membrane, peripheral nerves and periarticular 
muscles (Lane et al., 2011). OA diseases are a result of mechanical and biological 
events that destabilize the normal balance between degradation and synthesis 
of extracellular matrix, by articular cartilage chondrocytes, and subchondral 
bone, representing the failure of the joint as an organ (Arden and Nevitt, 2006; 
Flores and Hochberg, 2003). This failure of joint homeostasis ultimately manifests 
by morphological, biochemical, molecular and biomechanical alterations of 
all tissues of the joint, being the softening, fibrillation, ulceration and loss of 
articular cartilage, sclerosis and eburnation of subchondral bone, osteophytes 
and subchondral cysts the most striking features (Arden and Nevitt, 2006; Flores 
and Hochberg, 2003). OA diseases may be initiated by multiple factors, including 
genetic, developmental, metabolic and traumatic, in any of the synovial joint 
tissues (Flores and Hochberg, 2003). It may be localized to a single joint, a few 
joints, or generalized, and the factors that originate OA probably vary according 
to the affected joint (Lane et al., 2011). OA diseases are characterized clinically 
by joint pain, tenderness, stiffness and functional disability, crepitus, occasional 
effusion and variable degrees of localized inflammation (Flores and Hochberg, 
2003; Lane et al., 2011).
OA can be classified according to its aetiology, into idiopathic (primary) 
or secondary (Arden and Nevitt, 2006). This is based on the knowledge that OA 
may result from some recognizable causative factors, and OA coursing with 
an underlying disease that appear to have caused it is classified as secondary 
OA (Flores and Hochberg, 2003). In fact, several disorders are recognized as 
causes of secondary OA, and they can be divided into different categories such as 
30
NEUROBIOLOGICAL MECHANISMS OF PAIN ASSOCIATED WITH OSTEOARTHRITIS
traumatic, congenital or developmental, metabolic, endocrine, inflammatory and 
calcium deposition diseases (Arden and Nevitt, 2006; Flores and Hochberg, 2003). 
Idiopathic OA is divided into localized and generalized forms (Flores and Hochberg, 
2003). The generalized form represents the condition described by Kellgren 
and Moore (1952) involving three or more joint groups, therefore a polyarticular 
disease (Arden and Nevitt, 2006). This form may be nodal or non-nodal if it occurs 
with or without Heberden’s and Bouchard’s nodes (Flores and Hochberg, 2003). It 
shows a tendency for polyarticular hand involvement, a marked preponderance in 
middle-aged women and early inflammatory symptoms. Furthermore, symmetry 
of joint involvement is prominent (Arden and Nevitt, 2006). Nonetheless, the 
distinction between primary and secondary OA it is not always obvious since some 
risk factors for idiopathic OA, such as obesity, may also be considered causes of 
secondary OA (Flores and Hochberg, 2003). 
Another system for OA classification relates to the number and distribution of 
articular joints affected (Arden and Nevitt, 2006). This pathology shows particular 
preference for the knee, hip, the distal interphalangeal joints of the hand, the 
thumb base and the intervertebral facet joint (Arden and Nevitt, 2006). It is common 
the involvement of more than one joint, with a great association between hand and 
knee OA in Caucasians (Arden and Nevitt, 2006). 
A novel classification of OA has been proposed, based on the anatomical 
sites of the earliest discernible joint abnormality (McGonagle et al., 2010). In this 
classification, the categories are the joint structure involved, such as cartilage-, 
bone-, ligament-, meniscal-, and synovial-related, together with the disease that 
is multifocal in origin (McGonagle et al., 2010). 
2.2. PATHOBIOLOGy
Although the concept of OA as a disease of the whole joint as an organ 
has become more evident, the tissue that has attracted most attention in the 
pathogenesis of OA is articular cartilage, mostly because it is the tissue that 
shows more striking changes along the evolution of this pathology. 
Condrocytes are subject to mechanical and osmotic stresses and recent 
evidence has shown that they act as mechano-sensors and osmo-sensors, altering 
their metabolism in response to changes in the microenvironment (Abramson and 
Attur, 2009). Abnormal mechanical load, as well as other systemic factors, likely 
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contributes to deregulation of the equilibrium between the catabolic and anabolic 
activities of the chondrocytes in remodelling the extracellular matrix, leading to 
matrix degradation and down-regulation of cartilage repair processes (Goldring 
and Goldring, 2007). In the early phase of OA, there is evidence of increased 
synthetic activity which can be an attempt to regenerate the matrix. However, 
after entering a point of no return in which damage overrides synthesis, a vicious 
cycle of progressive damage ensues (Bijlsma et al., 2011; Goldring and Goldring, 
2007). 
Many of the chondrocytes receptors for extracellular matrix components 
are also responsive to mechanical stimulation (Loeser et al., 2012). Activation of 
these receptors can stimulate the production of matrix-degrading proteinases 
and inflammatory cytokines and chemokines (Loeser et al., 2012). The matrix-
degrading proteinases found in OA joints include the members of the matrix 
metalloproteinase (MMP) family, collagenases and aggrecanases, as well as 
several serine and cysteine proteinases (Loeser et al., 2012). Degradation of 
aggrecan and collagen is central to OA pathology, although other less abundant 
molecules are also likely to contribute to disease progression (Heinegard and 
Saxne, 2011).
Aggrecan is the major cartilage proteoglycan, whose function is to draw water 
into the cartilage matrix, giving it the ability to withstand compression (Troeberg 
and Nagase, 2012). Aggrecan degradation is an early event in the development of 
OA, and the enzymes responsible are aggrecanases from the A Disintegrin And 
Metalloproteinase with Thrombospondin motifs (ADAMTS) family of proteinases 
(Tortorella et al, 1999). ADAMTS-4 and ADAMTS-5 are considered to be the major 
enzymes responsible for pathological cleavage of aggrecan, the later being the 
most active at least in vitro (Bau et al., 2002; Gendron et al., 2007). Adamts5 
knockout mice develop less severe cartilage damage in a murine surgical model 
of OA (Glasson et al., 2005) and in a model of inflammatory arthritis (Stanton et 
al., 2005). Adamts1 and Adamts4 knockout mice are not protected in the same 
way, indicating that ADAMTS5 is the principal aggrecanase in mice (Glasson et 
al., 2004; Little et al., 2005). In human cartilage, however, there is evidence that 
ADAMTS4 may also play an important role in the degradation of aggrecan (Naito et 
al., 2007; Song et al., 2007). MMPs seem to have also a proteolytic activity against 
aggregan (Lark et al., 1997).
Degradation of collagen is also a central feature of OA (Billinghurst et al., 
1997; Lohmander et al., 2003). Several in vitro studies on cartilage explants suggest 
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that type II collagen degradation only occurs after depletion of aggrecan and that 
its presence protects the collagen from degradation (Fell et al., 1976; Pratta et al., 
2003). MMP-13 is considered the principal collagenase in OA, both in human OA 
chondrocytes and in rodent OA models (Bau et al., 2002; Billinghurst et al., 1997; 
Neuhold et al., 2001). Nevertheless, MMP-13 seems to be only up-regulated in 
late stages of OA, while MMP-3, which is the most strongly expressed MMP in OA 
cartilage, is strongly down-regulated in late-stage OA (Bau et al., 2002). MMP-3 is 
known to be involved in the activation of others MMPs, such as MMP-13, raising 
the hypothesis that it may contribute to OA by activating latent collagenases and 
MMP mediated aggrecan cleavage (Durigova et al., 2011; Troeberg and Nagase, 
2012; Van Meurs et al., 1999). Conversely, it has been suggested that MMP-3 may 
also have a protective role on cartilage in some circumstances (Clements et al., 
2003). 
Recent studies have also suggested a role for the serine proteinase HtrA1 
(high temperature requirement A1) in initiating the disruption of the pericellular 
matrix network, where little or no type II collagen exists (Polur et al., 2010). This 
would expose chondrocytes to native type II collagen fibrils, leading to alteration 
of chondrocytes metabolism, such as activation of the discoidin domain receptor 
2 (Ddr2) that in turn will induce MMP-13 expression (Xu et al., 2010).
Several factors seem to increase (modulate) the activity of these enzymes in 
OA. The expression of runt-related transcription factor 2 (RUNX2) and of several 
of its target genes increases in early OA (Wang et al., 2004). Mmp13 is a known 
RUNX2 target gene and adamts4 and adamts5 are also thought to be (Tetsunaga et 
al., 2011; Thirunavukkarasu et al., 2006). This transcription factor can be induced 
by mechanical stimuli, hypoxia-inducible factor 2α (HIF-2α) and Indian hedgehog, 
factors that promote OA development, and may be a central factor increasing 
expression of several OA-promoting genes (Lin et al., 2009; Troeberg and Nagase, 
2012; Wong et al., 2003). Small non-coding RNAs (microRNAs, miRNAs) also seem 
to have a role in OA pathogenesis. For instance, miR-455, through suppression 
of the Smad2/3 pathway, seems to exacerbate cartilage destruction contributing 
to OA development (Swingler et al., 2012). Also, miR-22 was shown to increase 
expression of MMP-13 possibly via regulation of PPARA (peroxisome proliferator-
activated receptor alpha) and BMP7 (bone morphogenetic protein 7) proteins 
(Iliopoulos et al., 2008).
Recent evidence has also implicated a number of inflammatory mediators 
in the pathogenesis of OA. There is increased production of the pro-inflammatory 
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cytokines interleukin (IL)-1β and tumour necrosis factor (TNF)-α, by articular 
chondrocytes, that in an autocrine/paracrine way, stimulate their own production 
and induce chondrocytes to produce proteases such as MMP-1, MMP-13, ADAMTS4 
and ADAMTS5 (Abramson and Attur, 2009; Troeberg and Nagase, 2012). IL-1β and 
TNF-α also induce the production of other inflammatory mediators such as IL-8, 
IL-6, prostaglandin E2 (PGE2) and nitric oxide (Abramson and Attur, 2009; Goldring 
and Goldring, 2007). The increased production of PGE2, via cyclooxygenase (COX)-
2 expression induction and also of microsomal PGE synthase 1, in OA cartilage 
explants, decreases proteoglycan synthesis and enhances degradation of aggrecan 
and type II collagen (Attur et al, 2008; Masuko-Hongo et al., 2004; Whiteman et 
al., 2006). Nitric oxide is a major catabolic factor produced by chondrocytes and 
it seems to play a role in perpetuation of cartilage destruction in this pathology 
(Abramson and Attur, 2009). This molecule exerts various effects on chondrocytes, 
such as inhibition of collagen and proteoglycan synthesis, activation of MMPs, 
increased susceptibility to injury by other oxidants and apoptosis (Scher et al., 
2007). Several other cytokines and chemokines also seem to participate in the 
catabolic cascade that leads to articular damage (Abramson and Attur, 2009).
As reviewed by Loeser (2008), several studies have also provided evidence of 
the role of reactive oxygen species (ROS) in the pathogenesis of OA, where increased 
ROS activity activates catabolic signalling and inhibits anabolic pathways. 
The alterations of bone in OA have also been recognised, with osteophyte 
formation and sclerosis of subchondral bone being hallmarks of the disease 
(Abramson and Attur, 2009). It has been hypothesized that osteophytes are a result 
of increased vascularity into the basal layers of degenerative cartilage (Gilbertson, 
1975), and production of growth factors such as transforming growth factor (TGF)-
β and bone morphogenetic protein 2 is observed in osteophytes of patients with 
OA (Uchino et al., 2000; Zoricic et al., 2003). 
Based on bone scintigraphy studies, authors have suggested that the activity 
of the subchondral bone may determine loss of cartilage (Dieppe et al., 1993). The 
sclerosis of subchondral bone, reported in more advanced OA, add stress to the 
overlying cartilage inducing further damage to it (Bijlsma et al., 2011). In addition, 
subchondral bone alterations are observed in the early phase of OA, which might 
play a role in cartilage degeneration progression (Intema et al., 2010; Sniekers et 
al., 2008). Increased production of several factors in OA subcondral bone, such 
as urokinase plaminogen activator, insulin-like growth factor, MMP-3, MMP-9 
and the cytokines TNF-α, IL-1α, IL-8 and IL-10, has been reported (Hilal et al., 
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1998; Hulejová et al., 2007). These are potential candidates to act on deep-zone 
articular chondrocytes and influence metabolism of deep cartilage leading to its 
breakdown (Bijlsma et al., 2011). However, whether bone changes are a cause or 
a consequence of other changes in OA remains controversial (Neogi, 2012). 
Cartilage breakdown products can also induce the release of collagenase 
and other hydrolytic enzymes from synovial cells, as well as provoke the release 
of synovial IL-1β and TNF-α that are possible contributors of the degradative 
cascade (Abramson and Attur, 2009). Nevertheless, synovitis associated with OA is 
generally of low grade as compared to rheumatoid arthritis (Krenn et al., 2006). 
2.3. EPIDEMIOLOGy AND RISk FACTORS
OA is thought to be the most prevalent of the musculoskeletal diseases 
(ACR, 2000; Picavet and Hazes, 2003). The WHO Scientific Group on Rheumatic 
Diseases has estimated that 10% of the world’s population who are 60 years or 
older have significant clinical problems that can be attributed to OA (Woolf and 
Pfleger, 2003).
In the United States, the National Arthritis Data Workgroup estimates the 
prevalence of clinical OA among adults age 25 and older as 26.9 million in 2005 
(Lawrence et al., 2008). These data were based from three different studies: 
the National Health and Nutrition Examination Survey III (NHANES III; Dillon et 
al. 2006), the Framingham Osteoarthritis Study (Felson et al., 1987; Haugen et 
al., 2011) and the Johnston County Osteoarthritis Project (Jordan et al., 2007; 
Jordan et al., 2009). Some heterogeneity in estimates is observed because the 
epidemiology of OA is dependent on the definition used and on the joint evaluated. 
The most commonly used definitions are radiographic OA and symptomatic OA 
(Suri et al., 2012). Symptomatic OA is more restrictive, as it is generally defined by 
the presence of radiographic OA along with the symptoms such as pain, aching or 
stiffness in the affected joint (Suri et al., 2012). 
The prevalence of radiographic and symptomatic knee OA in adults 45 years 
or older was 19.2% and 6.7% in the Framingham study, respectively, and 27.8% 
and 16.7% in the Johnston Project, respectively (Lawrence et al., 2008). In both 
studies there was a remarkable increase in prevalence with increasing age, with 
adults 80 years or older showing a prevalence of 44% of radiographic knee OA 
in the Framingham study (Felson et al., 1987). Adults 75 years or older of the 
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Johnston Project showed a prevalence of 50% in the radiographic knee OA and 
33% in symptomatic knee OA (Jordan et al., 2007). The prevalence among adults 
60 years or older was 37.4% and 12.1% in radiographic and symptomatic knee OA 
respectively, in the NHANESIII (Dillon et al., 2006).
The prevalence of radiographic and symptomatic hip OA in the Johnston 
County adults 45 years or older was 27.6% and 9.7%, respectively (Jordan et al., 
2009). Prevalence was generally higher among adults age 75 years or older, with 
values of 42.9% and 17% for radiographic and symptomatic hip OA respectively 
(Jordan et al., 2009). The prevalence of radiographic hand OA in Framingham 
adults 45 years and older was 41%, but only 11% were symptomatic (Haugen et 
al., 2011; Suri et al., 2012). 
OA, besides becoming more common with age, affects women more frequently 
than men (Lawrence et al., 2008). The lifetime risk of developing symptomatic 
knee OA, in Johnston County, has been estimated at 47% for women and 40% for 
men, whereas for hip OA was 29% for women and 19% for men (Suri et al., 2012).
The increase in prevalence of OA cannot be fully explained by the aging of the 
population, and other risk factors have also to be considered. In fact, the disease 
is frequently the product of interplay between systemic and local factors (Felson 
et al., 2000). However, the relative importance of each risk factor may vary for 
different joints, different stages of disease and according to individual features 
(Zhang and Jordan, 2010).
Age is one of the strongest risk factors for OA of all joints, probably as a 
consequence of age-related increases in, and cumulative exposure to, a variety 
of risk factors (Zhang and Jordan, 2010). Female gender has increased risk of 
OA, particularly for knee and hand and in multiple joints (Arden and Nevitt, 2006). 
Consequently, a possible role of hormonal factors in the development of OA was 
suggested, but no consistent evidence of this linking exists (Arden and Nevitt, 2006). 
The frequency and characteristics of OA also vary among racial and ethnic groups, 
but the relative contributions of lifestyle, biological and socio-economic factors to 
these differences are unclear (Felson et al., 2000; Suri et al., 2012). OA appears to 
be strongly determined by genetic factors and studies have estimated the heritable 
component of OA to be between 50 and 65%, with larger influences for hand and 
hip OA (Felson et al., 2000; Zhang and Jordan, 2010). However, studies have failed 
to identify any single factor that might account for a large proportion of this genetic 
risk and most OA susceptibility alleles discovered contribute only modestly to the 
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overall disease risk (Suri et al., 2012). The most consistently associated gene is, 
so far, GDF5, that codes for the growth/differentiation factor 5 protein, a protein 
from the bone morphogenetic protein family involved in joint formation (Reynard 
and Loughlin, 2012; Suri et al., 2012). In what concerns the obesity factor, persons 
who are overweight have a high prevalence of knee OA, and weight loss is strongly 
associated with a reduced risk (Felson et al., 2000). In fact, this is the modifiable 
risk factor with the greatest potential impact on the population (Suri et al., 2012). 
Other systemic risk factors for OA include high bone mineral density and dietary 
factors such as low vitamin D intake (Felson et al., 2000).
Individual joints may also become more susceptible to OA due to local factors 
acting in the joint. Such local biomechanical factors include joint deformity or 
misalignment, muscle weakness and repeated use of joints due to occupational or 
athletic activities (Suri et al., 2012). But by far the most common and strongest local 
risk factor is injury to a joint. Fractures of articular surfaces, and tears of menisci 
and ligaments might increase joint instability and precede the development of OA 
(Felson et al., 2000). 
2.4. SIGNS AND SyMPTOMS
Signs and symptoms of OA usually develop slowly and are primarily related 
to joint damage rather than inflammation (O’Reilly and Doherty, 2003). 
The dominant symptom in OA is pain, and usually the reason for patients to 
seek medical help (O’Reilly and Doherty, 2003). In Portugal, a population-based 
nationwide study on chronic pain showed that the most frequent self-reported 
chronic pain aetiology was osteoarthritis (Azevedo et al., 2012). Pain is typically 
described as activity related or mechanical, such as with climbing stairs, getting 
out of a chair and walking long distances, and is relieved by rest (Felson, 2006; 
Hunter et al., 2008). Usually of insidious onset, it is often deep and aching and not 
well localized, interspersed by activity-related episodes of sharp and stabbing pain 
(Hunter et al., 2008; Kidd, 2006). In more advanced OA, pain may become more 
persistent and occur also at rest and at night (O’Reilly and Doherty, 2003). Night 
pain might interfere with sleep which further exacerbates pain through associated 
fatigue and lack of well-being (Hunter et al., 2008; O’Reilly and Doherty, 2003). 
Knee pain is generally felt anteriorly or medially, especially after walking 
or prolonged standing, and it may radiate down the shin (Creamer, 2009). Many 
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patients refer a chronic background ache with shorter, sharper bursts of pain on 
certain movements (Creamer, 2009). Pain due to hip OA is felt usually in the groin 
on walking and may radiate to the knee, but it may also be felt in buttock or lateral 
thigh (Creamer, 2009). Hand OA is often asymptomatic, with thumb base OA more 
likely to cause pain than interphalangeal OA, and may be felt diffusely “around the 
wrist” (Creamer, 2009). A diurnal variation has been described in knee and hand 
OA, with pain being worse in the evening (Creamer, 2009).
Most people with symptomatic OA of large joints experience short-lived 
stiffness of the joints affected after inactivity, which wears off in a few minutes 
with use (Dieppe and Lohmander, 2005). Early morning stiffness is occasionally 
severe but most patients complaint of more stiffness latter in the day (O’Reilly and 
Doherty, 2003).
Patients may also complaint of functional impairment (O’Reilly and Doherty, 
2003). Disability may include poor mobility, difficulty with their day-to-day activities, 
social isolation and loss of work opportunities (O’Reilly and Doherty, 2003). 
Anxiety and depression are common in patients with OA, which can amplify 
pain perception and the level of disability (O’Reilly and Doherty, 2003). Bone 
swelling and deformity may also be a source of distress for some patients (O’Reilly 
and Doherty, 2003). 
Common examination findings in OA are crepitus, tenderness, deformity and 
instability of joints and muscle weakness (O’Reilly and Doherty, 2003). Reduced 
range of movement is extremely common in OA joints, accompanied by loss of 
function (O’Reilly and Doherty, 2003). Varying degrees of synovitis evidenced by 
warmth effusion may also be evident (O’Reilly and Doherty, 2003). Many of these 
signs, particularly those of joint damage, are included into diagnostic criteria for 
individual joints (O’Reilly and Doherty, 2003).
2.5. DIAGNOSIS
In clinical practice OA diagnosis should be made on the basis of clinical 
history and physical examination (Hunter et al., 2008). The role of radiography is 
to confirm the clinical suspicion and rule out other suspected conditions (Hunter 
et al., 2008).
In 2009, the European League Against Rheumatism (EULAR) recommended 
the use of 6 criteria – 3 symptoms and 3 signs – for the diagnosis of knee OA 
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(Zhang et al., 2010). The 3 symptoms are persistent knee pain, limited morning 
stiffness and reduced function, and the 3 signs are crepitus, restricted movement 
and bony enlargement (Zhang et al., 2010). These criteria, when all present, 
correctly diagnose 99% of knee OA patients (Zhang et al., 2010).
For the diagnosis of hand OA, the EULAR recommended the use of a composite 
of features, to increase the chance of diagnosis (Zhang et al. 2009). The probability 
of a patient having hand OA was 20% when Heberden nodes alone were present, but 
it increased to 88% when, in addition, the following conditions were met: age over 
40 years old, family history of nodes and joint space narrowing in any finger joint 
(Zhang et al. 2009). The criteria of the American College of Rheumatology (ACR) 
for diagnosing hand OA have a sensitivity of 92% and specificity of 98% (Altman et 
al., 1990). Patients were classified has having clinical hand OA if there was pain, 
aching and stiffness in the hands, plus hard tissue enlargement involving at least 
2 of 10 selected joints, swelling of fewer than 3 metacarpophalangeal joints and 
hard tissue enlargement of at least 2 distal interphalangeal joints or deformity of 
at least 1 of 10 selected joints (Altman et al., 1990).
Criteria of the ACR for hip OA offer several methods of classification (Altman 
et al., 1991). The traditional approach, which yields a sensitivity of 89% and a 
specificity of 91%, requires the presence of pain in combination with at least 2 of 
the following criteria: radiographic evidence of femoral or acetabular osteophytes, 
radiographic evidence of joint space narrowing and an erythrocyte sedimentation 
rate less than 20 mm/hour (Altman et al., 1991).
2.6. TREATMENT/MANAGEMENT
Thus far, no single therapy is adequate for OA, and the major clinical 
guidelines for OA management agree that treatment should involve three modality 
strategies: non-pharmacological, pharmacological and surgical (Altman, 2010). 
Since no effective curative strategies exist, these therapies are directed towards 
controlling the symptoms, preserving function and reducing further joint damage 
(Kidd, 2006). The complexity and variability of OA aetiology also suggests the need 
for patient-specific, aetiology-based treatment.
Non-pharmacological therapies are quite diverse and include educational 
approaches to encourage change of some lifestyle patterns, such as weight loss, 
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and physical activities to improve muscle strengthening, range-of-motion of 
joints and aerobic condition (Altman, 2010). Measures such as bracing or taping 
a joint, to immobilize and realign it, use of proper footwear, for instance to lower 
knee adduction moment, and application of local heat may also be recommended 
(Altman, 2010; Felson, 2009). 
Pharmacological treatments include analgesics, such as paracetamol and 
opioids, and anti-inflammatory agents with analgesic properties, for example 
nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors, 
topical NSAIDs and intra-articular corticosteroids (Altman, 2010). Paracetamol 
is regarded as the first line therapy because of its efficacy and safety, and if the 
treatment is successful it may be used for long-term analgesia (Altman, 2010). 
However, patients frequently show little effect with paracetamol, and often 
a NSAID has to be added or in substitution, preferably at the lowest effective 
dose and for the shortest duration (Bijlsma et al., 2011). COX-2 inhibitors have 
been used, in patients with elevated gastrointestinal risk, although evidence of 
increased cardiovascular risk has limited their use (Felson, 2006). An alternative, 
to avoid systemic effects of oral anti-inflammatory drugs, is the use of topical 
NSAIDs and capsaicin, as well as intra-articular corticosteroids (Altman, 2010). 
The use of stronger analgesics, such as opioids, is only indicated when other drugs 
have been ineffective or contraindicated, although strong opioids are discouraged 
except when very severe pain is present (Bijlsma et al., 2011). 
The Food and Drug Administration approved the use of injections of hyaluronic 
acid into the knee joint for the treatment of OA (Felson, 2006). However, data on 
efficacy of this treatment are inconsistent (Felson, 2006). The symptomatic slow-
acting drugs glucosamine sulphate and chondroitin sulphate are also used for 
the treatment of OA, but their mechanism of action is unclear and evidence of 
effectiveness still conflicting (Bijlsma et al., 2011). 
Finally, for patients with severe, intractable symptoms or functional limitation 
associated with a reduced quality of life, despite conservative treatment, joint 
replacement offers an effective long-term solution (Bijlsma et al., 2011). 
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3. PAIN IN OSTEOARTHRITIS
3.1. PERIPHERAL MECHANISMS OF JOINT PAIN
Joint pain is a major clinical problem, with pain from OA being more 
frequent than pain from chronic inflammatory joint disease (Breivik et al., 
2006). Surprisingly, more information is available on the neuronal mechanisms 
underlying inflammatory joint pain (Schaible et al., 2009).
Pain originated from the joint and/or other deep tissues has a character 
different from cutaneous pain, being often dull and aching and poorly localized, 
which may reflect a different neuronal organization (Schaible et al., 2009). Joints 
are innervated by several articular branches of distinct nerves. Approximately 
80% of articular fibres are unmyelinated and studies suggest that half of them 
are C-fibres and the remaining efferent sympathetic neurons (Grubb, 2009). The 
remaining articular afferent fibres, about 20%, are myelinated, with the majority 
being finely myelinated Aδ nociceptors (Grubb, 2009). A small number of large 
diameter myelinated low threshold Aβ fibres also innervate the joint, typically 
associated with corpuscular endings (Grubb, 2009). Post-ganglionic sympathetic 
nerves terminate near articular blood vessels, regulating joint blood flow through 
vasoconstrictor tone (McDougall, 2006). Afferent nerve fibres have been identified 
in all structures of the joint except the normal cartilage (Schaible et al., 2009). 
Therefore, the network of joint primary afferent fibres can detect both non-
noxious and noxious stimuli from all joint structures but cartilage (Schaible et al., 
2009), although stimulation of normal synovial tissue rarely evokes pain (Schaible, 
2009). 
Most fibres belonging to the Aβ conduction velocity range transmit 
proprioceptive signals and show responses to innocuous movements of the joints, 
such as gentle local stimuli and movements in the working range of the knee 
(Dorn et al., 1991). However, a few of those fibres are only activated by noxious 
stimuli applied to the joint, which indicates that they might elicit pain (Grubb, 
2009). Articular afferents belonging to the Aδ and C conduction velocity range 
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show higher thresholds and are most often activated by noxious stimulation, 
such as rotation of the joint against the resistance of the tissue and intense local 
pressure (Schaible et al., 2009). In addition, a further group of mainly C-fibres, 
termed “silent nociceptors”, are unresponsive to local mechanical stimulation 
and to innocuous/noxious movements in the normal joint, but begin to respond to 
mechanical stimulation during inflammation of the joint (Schaible and Schmidt, 
1988). 
Regarding the neuropeptide phenotype, joint nociceptors are predominantly 
peptidergic, with few non-peptidergic IB4 reactive fibres present (Mach et al, 
2002; Ivanavicius et al., 2004; Fernihough et al., 2005). There is also an extensive 
innervation by myelinated fibres, which express RT97, and by post-ganglionic 
sympathetic fibres expressing tyrosine hydroxylase (Mach et al., 2002). 
The current theory about the physiological mechanisms responsible for 
mechanotransduction in joints is that movement of the joint generates shear 
stresses on the plasma membrane of the axonal nerve endings, which causes 
conformational changes in the mechanogated ion channels, resulting in their 
opening (Heppelmann and McDougall, 2005; McDougall, 2006). Consequently, 
there is a depolarization of the nerve terminal and generation of action potentials 
that are then transmitted to the central nervous system (McDougall, 2006). 
Following trauma or damage to the joint there is an increase sensitivity to 
load bearing and movement of the joint within the normal range, and a major 
increase in the sensitivity to any further noxious mechanical stimulation (Grubb, 
2009). Upon development of joint inflammation, articular Aβ afferents show acute 
transient increases of their responses to joint stimulation (Schaible and Schmidt, 
1988). However, since these fibres do not appear to be chemosensitive, their 
increased responses could be a consequence of swelling or other mechanical 
factors (Schaible et al., 2009). High threshold Aδ and C fibres show a reduction of 
their mechanical threshold and enhanced responsiveness to manipulation of the 
joint and often start to show ongoing spontaneous activity at rest (Coggeshall et 
al., 1983; Schaible and Schmidt, 1988). An additional process by which arthritic 
pain is generated is via the silent nociceptors. As previously described, they 
become active and may also show ongoing spontaneous activity (Grubb, 2009). 
Peripheral sensitization with recruitment of “supplementary” input contributes to 
the occurrence of allodynia and hyperalgesia of the arthritic joint (Grubb, 2009). 
The spontaneous firing of joint sensory nerves in the absence of any mechanical 
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stimulation seems to account for the resting pain described by arthritis patients 
(McDougall, 2006).
The factors that promote peripheral sensitization can be divided into two 
separate groups: mechanical factors and inflammatory mediators. 
During joint pathology, plasma proteins may leak through permeable synovial 
blood vessels into the intra-articular space, which promotes fluid exudation into 
the joint due to a shift in the Starling forces (McDougall, 2006). The accumulation 
of the effusion in the joint space generates an increase in the baseline intra-
articular pressure. This is mainly important upon joint flexion or extension, 
where joint pressure can increase considerably, consequently increasing 
stretching of the capsule and surrounding tissues that are densely innervated 
by mechanonociceptors, contributing to the enhanced firing of these afferents 
(Grubb, 2009). The frequency of these neuronal discharges correlates with the level 
of the intra-articular pressure (McDougall, 2006). Altered joint biomechanics, for 
instance after trauma or repetitive stress injuries, might also be responsible for 
pain generation, however the processes by which these occur have not yet been 
fully investigated (McDougall, 2006). Transection of the anterior cruciate ligament 
of the cat’s knee caused increased electric activity in the posterior and medial 
articular nerves in response to passive motion of the knee (Gómez-Barrena et al., 
1997). However, it is unclear if this is due to local release of chemical mediators 
following surgery, or whether the abnormal forces that now act on the remaining 
articular tissues lead to an increase in afferent firing rate (McDougall, 2006). In 
fact, both may occur simultaneously.
A number of inflammatory mediators are released in response to 
tissue damage. It is thought that these inflammatory mediators are the major 
contributors for the peripheral sensitization of articular mechanonociceptors 
(Grubb, 2009). Inflammatory mediators are released into the joint from sources as 
synoviocytes, immunocytes, endothelial cells and nerve terminals, and are part of 
the innate response to the damage to promote healing (McDougall, 2006). These 
mediators might act on joint sensory nerves through activation of receptors in the 
nerve endings, leading to their excitation or sensitization (Schaible et al., 2009). 
Sensitization for mechanical stimuli by application of inflammatory mediators 
was identified in Aδ- and C-fibres, but no changes in the response to mechanical 
stimuli were observed in Aβ-fibres (Schaible et al., 2009). Various mediators have 
been shown to sensitize articular mechanonociceptors such as prostaglandin I2 
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(PGI2), PGE2, bradykinin, serotonin, histamine, nitric oxide, several cytokines and 
neuropeptides (McDougall, 2006), each evoking a particular pattern of sensitization 
(Schaible et al., 2009). 
The better characterized neuropeptides that are associated with joint 
nociception are SP, CGRP and VIP. All have been immunolocalized in joint tissues 
and their levels are altered during arthritis (Ahmed et al., 1993; Ahmed et al., 1995; 
Buma et al., 2000; Hanesch et al., 1991). Electrophysiological recordings have 
shown that administration of SP sensitized Aδ articular afferents, but not C fibres, 
to noxious movements of the joint (Herbert and Schmidt, 2001). Furthermore, 
in inflamed joints SP was found to increase the response of nerve fibres during 
normal movements (Heppelmann and Pawlak, 1997). The effect of CGRP on joint 
afferent activity has not been demonstrated. However, ionophoretic administration 
of CGRP close to spinal cord nociceptive neurons with input from the knee joint 
caused an increase in the firing rate of these neurons, which could be blocked 
by the selective antagonist CGRP8-37 (Neugebauer et al., 1996). Regarding VIP, its 
exogenous local application induces enhanced afferent firing rate during joint 
rotation (Schuelert and McDougall, 2006). A further sensory neuropeptide named 
nociceptin/orphanin (N/OFQ) is also known to alter joint mechanosensitivity, since 
its application caused a sensitization of normal and inflamed knee joint afferents 
in response to movements in the normal working range of the joint (McDougall 
et al., 2000). Conversely, during hyper-rotation of inflamed knees, high doses of 
N/OFQ desensitized joint mechanosensory afferents (McDougall et al., 2000). 
3.2. PATHOPHySIOLOGy OF PAIN IN OA
Neuronal activity in the nociceptive system is the ultimate responsible for 
generation and perpetuation of pain in OA. Although the structural determinants 
of such pain and the mechanical dysfunction in OA are not well understood, it is 
assumed to engage several interactive pathways (Hunter et al., 2008). Pain in OA 
may be primarily nociceptive, with a protective function, alerting the individual 
to mechanical limitations of the joints and a reduced ability of the joint to cope 
with additional stress (Neogi and Scholz, 2009). The fact that the pain is usually 
localized to the affected joint, correlates with movement and weight bearing and 
is relieved during rest, supports the idea that pain plays an important role in 
preventing further structural damage (Neogi and Scholz, 2009). 
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As previously described, besides articular cartilage, all other articular and 
periarticular tissues are richly innervated and may be the source of nociception 
in OA (Hunter et al, 2008). In population studies there is a substantial discordance 
between the radiographic signs of knee OA and knee pain (Hannan et al., 2000). 
One potential reason is that X-rays do not allow the visualization of changes to non-
bony structures, potential sources of pain, such as capsule, synovia or ligaments, 
or that joint damage predisposes patients to pain but is not the root cause (Szebenyi 
et al., 2006; Creamer, 2009). In fact, when other imaging techniques such as 
magnetic resonance imaging (MRI) are used, significant structural alterations 
have been related to knee pain (Hunter et al., 2008). These include bone marrow 
lesions (Felson et al., 2001), sub-articular bone attrition, synovitis and effusion 
(Hill et al., 2001; Torres et al., 2006). Other bone-related causes of pain include 
osteophyte formation (Cicuttini et al., 1996), subchondral microfractures (Burr, 
2004) and intraosseous hypertension (Simkin, 2004), though the particular bone 
pathology most responsible for pain remains unknown (Hunter et al., 2008).
Subchondral bone has been considered for many years one of the most 
important structures in the pain and structural progression of OA (Dieppe, 1999). In 
fact, osteotomy results in immediate pain relief, indicating that bone intervention 
can relieve OA pain (Dieppe, 1999). Thinning and erosion of the cartilage in OA 
decreases the protection of the underlying subchondral bone which becomes 
more vulnerable to physical stresses, especially impact stresses, that are thus 
transmitted more fully to the underlying trabecular bone and bone marrow 
(Bollet, 2001). Afferent nociceptive nerve fibres containing SP were found in the 
subchondral bone of OA patients (Ogino et al., 2009). These nociceptive endings 
can contribute to pain in OA due to activation by biomechanical forces and may 
also be sensitized by inflammatory mediators.
The commonest MRI subchondral abnormality is bone marrow lesion 
(Conaghan, 2009). In one large study, bone marrow lesions were found in 77.5% 
of patients with painful knees compared with 30% with no knee pain, and large 
lesions were present almost exclusively in persons with knee pain (Felson et 
al., 2001). Although in this study the authors failed to find an association of bone 
marrow lesions with pain severity in patients with knee pain (Felson et al., 2001) 
others have reported a contribution of bone marrow lesions to pain severity 
that requires, however, the presence of bone attrition (Torres et al., 2006). In 
another more recent study, it was also reported that bone marrow lesions are 
one source of pain in knees with or without radiographic OA (Felson et al., 2007). 
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Disturbance of venous drainage from justachondral cancellous bone marrow 
has been suggested as a cause of pain, since the resulting venous hypertension 
would increase intraosseous pressure (Bollet, 2001). Such venous hypertension, 
which would contribute to the development of marrow oedema, has been linked 
with pain, supported by the observation that osteotomy or cortical fenestration 
reduces rest pain (Arnoldi, 1971; Bollet, 2001; Kidd, 2003). Dieppe (1999) proposed 
that the severe joint pain associated with OA may originate primarily from primary 
afferents located in the subchondral bone, which are stimulated by increased 
intraosseous pressure. 
Despite the importance of bone marrow lesions as a likely source of knee 
pain, they are not the sole source since many patients develop knee pain without 
any bone marrow lesions (Felson et al., 2007).
Bone attrition refers to loss of bone contour, flattening or depression of the 
articular bone cortex and is typically seen in advanced OA (Conagham, 2009). A 
MRI study showed that 74% of knees with OA had pain if attrition was present and 
58% if it was absent, but no association was found between either attrition/pain 
severity or attrition/nocturnal pain (Hernández-Molina et al., 2008). Moreover, 
attrition often coexisted with other OA features associated with pain such as bone 
marrow lesions and effusions (Hernández-Molina et al., 2008).
In some cases of knee OA, pain can be abolished by intra-articular local 
anaesthetic, suggesting that the structures responsible for pain are in contact with 
the intra-articular environment (Creamer et al., 1996). This supports a role for the 
synovial/capsular contribution to OA pain (Kidd, 2003). Synovitis in OA, although 
secondary, is common (Conaghan, 2009). Change in the synovia, especially in the 
infrapatellar fat pad, has also been correlated with change in knee pain, (Hill et 
al., 2007). Synovial causes of pain include activation of sensory nerve endings 
present in the synovia through osteophytes and inflammation (Hunter et al, 2008). 
Production of IL-1α, IL-1β, and TNF-α was observed in synovial membranes from 
patients with OA, irrespective of the degree of articular cartilage damage (Smith 
et al., 1997). TNF-α immunoreactive sensory fibres were found in the synovia of 
OA patients, and may thus be involved in pathogenesis of pain in OA (Shirai et al., 
2009). It was also observed that IL-1β and TNF-α promote NGF synthesis and 
release from OA synovial cells (Manni et al., 2003). Synovial tissue from OA patients 
have been shown to have sensory nerve fibres immunoreactive for SP and CGRP 
with a ratio one to one (Dirmeier et al., 2008). Interestingly, patients with failed 
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hip arthroplasties that did not feel pain completely lacked these neuropeptide 
containing afferents (Saxler et al., 2007).
The innervation of the normally aneural cartilage and of osteophytes is also 
a potential source of pain (Suri et al., 2007). In patients with knee OA, sensory 
and sympathetic nerve fibres have been observed in the articular cartilage, with 
an exclusively perivascular localization (Suri et al., 2007). These fibres, with a 
morphology characteristic of free nerve terminals, showed immunoreactivity to 
SP, CGRP and to the C-flanking peptide of neuropeptide y (NPy) (Suri et al., 2007). 
Sensory and sympathetic innervation was also observed within the marrow cavities 
of osteophytes, which might explain why radiological grading of osteophytosis 
is associated with reported pain severity (Suri et al., 2007). These authors also 
suggest that nerves grow into these structures from subchondral bone, rather 
than from periosteum or synovia (Suri et al., 2007). Others have shown expression 
of vascular endothelial growth factor (VEGF) in chondrocytes of OA joints, 
predominantly localized to the superficial zone of articular cartilage, and increased 
osteochondral angiogenesis in OA patients (Walsh et al., 2010). Osteochondral 
angiogenesis was also associated with increased NGF expression, which may 
facilitate the sensitization or growth of sensory nerves into articular cartilage 
(Walsh et al., 2010). Therefore, sprouting of new sensory nerve terminations may 
contribute to pain in OA (Hunter et al., 2008).
Increased NGF expression in OA may also increase sensory nerve activity in 
the subchondral bone and thus contribute to pain, both by increased and aberrant 
innervation at the osteochondral junction and through peripheral sensitization 
(Walsh et al., 2010). Further evidence of the role of NGF in OA comes from the 
use of a humanized neutralizing monoclonal antibody directed against NGF in 
patients with knee OA (Neogi and Scholz, 2009). This antibody provides pain relief 
and improves joint function for up to 3 months (Neogi and Scholz, 2009).
OA is defined as a primarily non-inflammatory disease (Neogi and Scholz, 
2009). However, clinical signs such as swelling, indicative of joint effusion, and 
stiffness of the joint, suggest that inflammation is involved in the persistence 
of OA, if not in its aetiology (Neogi and Scholz, 2009). Inflammation might cause 
pain directly by stimulating primary afferent nociceptive fibres or by sensitizing 
these nociceptive fibres to mechanical or other stimuli (Kidd et al., 2009). The 
inflammation-induced contribution in the activation/sensitization of joint 
nociceptors may be substantial, so that even weak mechanical stimuli such as 
normally innocuous palpation or movement within the normal working range 
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of the joint provoke pain (Neogi and Scholz, 2009). C-reactive protein levels are 
modestly but significantly raised in female patients with early knee OA, and may 
predict future progression of disease (Spector et al.,1997). In another study, 
heightened pain sensitivity among OA patients was associated with elevated C-
reactive protein and IL-6 levels (Lee et al., 2011). 
Thus far it is still unclear which structural lesions actually cause joint pain 
in OA, and what is the nature of that pain (Neogi and Scholz, 2009). Furthermore, 
it is important to bear in mind that mechanisms may vary from joint to joint, and 
data regarding knee OA may not necessarily be valid to other joints (Creamer, 
2009). Each joint as a specificity that is related to the demands made on that joint 
and its ability in terms of structure, function, evolutionary adaptation and genetic 
predisposition (Creamer, 2009). Furthermore, studies correlating structure 
alterations and pain will never fully explain the complex and personal pain process 
in an individual (Conagham, 2009). 
3.2.1. Animal models of OA
The scarcity of data from human studies regarding OA pain mechanisms has 
led to a search for adequate animal models (Kidd et al, 2009). Different animal 
models that mimic the pathologic changes in OA have been described and are 
commonly used for assessment of joint pain, its neurobiological mechanisms 
and analgesic drug effects. They include spontaneous models in specific strains 
and models induced surgically or chemically (Neugebauer et al., 2007). These 
models are very useful to assess the mechanisms responsible for initiation and 
progression of the disease in a way that is not possible in human subjects (Griffiths 
and Schrier, 2003). 
Spontaneous OA occurs in guinea pigs, Syrian hamsters, rats, dogs, 
nonhuman primates and various strains of mice (Griffiths and Schrier, 2003). 
These naturally occurring models potentially provide the most realistic method 
for the study of OA, since they show a slowly progressive disease, with a pathology 
and pathogenesis probably very similar to the most common forms of human 
disease (Bendele, 2001). Spontaneous OA occurs in the medial compartment of the 
guinea pigs knee joint, since they preferentially load the medial aspect of the knee 
joint (Bendele and Hulman, 1988). This is similar to the human condition where 
approximately 75% of the load is performed through the medial aspect of the 
knee (Brown and Shaw, 1984). The lesions are initially present on the medial tibial 
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plateau and consist of focal chondrocyte death, proteoglycan loss and fibrillation, 
but by the time the animals are 1 year old, cartilage degenerative changes are 
usually quite profound and involve all aspects of the medial compartment of 
the knee (Bendele and Hulman, 1988). Chondrocyte and proteoglycan loss with 
fibrillation may extend into the deep zone, subchondral sclerosis is often extensive, 
subchondral bone cysts are present, synovial hypercellularity increases and 
osteophytes may be very large (Bendele, 2001). At this stage, abnormalities in gait 
and inability to extend the knee joint can be detected (Bendele, 2007). Due to the 
similarities to human disease and the predictable manner in which guinea pigs 
develop spontaneous knee OA, this is a good model for studies of pathogenesis 
and of potential therapeutic strategies (Bendele, 2007). The major constraint is 
the fact that the pathology in these models evolves very slowly.
OA is known to develop post-trauma, therefore a number of surgically 
induced models have been developed (Kidd et al., 2009). Joint instability, induced 
by (partial) meniscectomy and/or transection of collateral or cruciate ligaments 
(Neugebauer et al., 2007), has been described in various animal species. They 
include the medial meniscal tear in the rat and guinea pig (Janusz et al., 2002; 
Karahan et al., 2001; Meacock et al., 1990), the meniscetomy in rabbit and dog 
(LeRoux et al, 2000; Shapiro and Glimcher, 1980), and the anterior cruciate ligament 
transaction in dog and rats (Brandt, 1994; Pond and Nuki, 1973; Williams et al., 
1982). An important consideration in the use of surgical instability models is the 
load-bearing (medial vs lateral) pattern of the species being used. Animals that 
predominantly load the medial aspect of the joint will develop more severe lesions 
on the medial side after a medial meniscectomy than on the lateral side after a 
similar insult and vice versa (Bendele, 2001). Traumatic OA does occur in humans 
and therefore these models may mimic those aspects of the pathogenesis and 
pathology. One important difference however is that humans with a traumatic 
injury generally decrease use of the affected limb until recovery, which does not 
happen with animals, especially rodents (Bendele, 2001). Therefore, the disease 
progression is usually much more rapid in animal models. 
The unilateral medial meniscal tear in the rat is commonly used and it 
is performed by transection of the medial collateral ligament just below its 
attachment to the meniscus, and subsequent cut of the meniscus at its narrowest 
point (Janusz et al., 2002). This results in rapid progressive degenerative cartilage 
alterations characterized by chondrocyte and proteoglycan loss, fibrillation, 
osteophyte formation and chondrocyte cloning (Janusz et al., 2002). From the 
50
NEUROBIOLOGICAL MECHANISMS OF PAIN ASSOCIATED WITH OSTEOARTHRITIS
perspective of comparative pathogenesis to human disease, the lesions are 
morphologically similar but occur much more rapidly, within 3-6 weeks (Bendele, 
2001). 
Chemical models involve intra-articular injections of compounds such as 
sodium monoiodoacetate (MIA), papain or collagenase (Bentley, 1971; Kalbhen, 
1987; Rudolphi et al., 2003). Typically they provoke a severe and rapidly progressive 
joint damage, producing behavioural alterations within days (Kidd et al., 2009). 
One drawback of these models is the early inflammatory component developed, 
not always apparent in human OA (Kidd et al., 2009). Intra-articular injection of 
MIA into the knee joints of rat is an extremely used model in pain-related studies 
because it is rapid, reproducible and mimics pathological changes and pain of 
OA in humans (Neugebaeur et al., 2007). MIA is an inhibitor of glyceraldehyde-3-
phosphate dehydrogenase activity (Kalbhen, 1987). Since articular chondrocytes 
derive its metabolism via a glycolitic pathway, MIA leads to a gradual chondrocyte 
death by blocking the glycolytic energy metabolism and synthetic processes in 
articular chondrocytes (Kalbhen, 1987). Similar to human OA, joint pathology is 
characterized by depletion of proteoglycan in the extracellular matrix, chondrocyte 
necrosis with loss of matrix resulting in decreased thickness of the articular 
cartilage and fibrillation of the cartilage surface, separation of the necrotic 
cartilage from the underlying bone with subsequent exposure of the subchondral 
bone, thickening of the subchondral bone, osteophytes formation and hyperplastic 
and fibrotic alterations on the synovia (Fernihough et al., 2004; Guingamp et al., 
1997; Kobayashi et al., 2003). Following MIA injection to the knee, there is an initial 
acute inflammatory reaction in the knee that has largely resolved by day 7, and a 
latter more degenerative type lesion (Bove et al., 2003). The nociceptive reaction 
and the progression and severity of lesions strongly depends on the concentration 
of MIA used, and thus may be easily modulated (Guingamp et al., 1997; Kobayashi 
et al., 2003). 
3.2.2. Pain behaviour in animal models of OA
Most studies use indirect measures to assess knee joint pain such as 
static and dynamic weight bearing (Combe et al., 2004; Fernihough et al., 2004; 
McDougall et al., 2006; Pomonis et al., 2005), and mechanical or heat sensitivity 
of the paw (Combe et al., 2004; Fernihough et al., 2004; McDougall et al., 2006; 
Silva et al., 2008; Vonsy et al., 2009). Measurements of weight bearing have been 
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used in osteoarthritic models induced in the knee joint by MIA (Bove et al., 2003; 
Combe et al., 2004; Fernihough et al., 2004; McDougall et al., 2006; Pomonis et al., 
2005) or papain (Pomonis et al., 2005) and by surgery (partial meniscectomy; Bove 
et al., 2006; Fernihough et al., 2004). The weight distribution on the two hind paws 
is measured as the force exerted by each limb on a transducer plate in the floor 
and a significant shift of weight from the osteoarthritic limb to the contralateral 
one is taken as a pain measure (Combe et al., 2004; McDougall et al., 2006; 
Pomonis et al., 2005). OA animals, as early as 3 days post-surgery or post-MIA 
injection, exhibit significant changes in the hindpaw weight distribution, with a 
shift to the contralateral paw (Bove et al., 2006; Fernihough et al., 2004). These 
static measurements of hind limbs weight bearing typically involve restraining 
the animals, which is a drawback. Spontaneous locomotor activity has also been 
measured in arthritic rats using biotelemetry or photocell-based monitor systems 
in the dark (Gegout-Pottie et al., 1999; Guingamp et al., 1997; Nagase et al., 2012). 
Loss of spontaneous mobility presumably related to pain, such as reduction of 
number of rears, has been detected in rats with knee joint osteoarthritis (Gegout-
Pottie et al., 1999; Guingamp et al., 1997; Nagase et al., 2012). A biphasic pattern 
of reduction of spontaneous nocturnal mobility of rats injected with MIA was 
observed (Guingamp et al., 1997).
Mechanical sensitivity of the hindpaw has been assessed in animals with 
knee joint OA by von Frey filaments and Randall-Selitto analgesiometer (Bove et 
al., 2006; Combe et al., 2004; Fernihough et al., 2004; McDougall et al., 2006). Paw 
withdrawal thresholds (PWT) are assessed in response to increasing pressure 
stimuli applied to the plantar surface by von Frey filaments, as a measure of 
tactile allodynia, or to the dorsal surface by a wedge-shaped probe of a Randall-
Selitto analgesiometer, as a measure of mechanical hyperalgesia (Neugebauer et 
al., 2007). Rats with MIA-induced OA have decreased PWT on the affected limb for 
several weeks, measured with either technique (Combe et al., 2004; Fernihough 
et al., 2004; McDougall et al., 2006), but show little dynamic allodynia, assessed 
by stroking the plantar surface of the paw with a cotton bud (Combe et al., 2004). 
Surgically induced knee joint arthritis appears to be more sensitive to von Frey 
hair testing than to Randall-Selitto analgesiometry (Bove et al., 2006; Fernihough 
et al., 2004). Thermal sensitivity of the paw has been measured in MIA-induced 
OA rats using the hot-plate test and acetone (Silva et al., 2008; Vonsy et al., 2009). 
OA animals significantly reduced the thermal pain threshold from day 10 onwards 
(Silva et al., 2008). Cool hypersensivity was also observed (Vonsy et al., 2009). 
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No thermal hyperalgesia has been found in the surgically induced knee joint OA 
model (Bove et al., 2006). These tests assess secondary hyperalgesia or allodynia, 
which has been reported in patients with osteoarthritis but is not very common 
(Pomonis et al., 2005). 
More recently, behavioural tests that directly assess knee joint pain have been 
developed for inflammatory arthritis (Neugebaeur et al., 2007). However, there 
are still few studies that assess mechanical sensitivity of the knee in OA. In a mice 
OA model, produced by partial medial meniscectomy, an increase in vocalization 
in response to knee compression was observed (Knights et al., 2012).
3.2.3. Peripheral neurobiological mechanisms of nociception in OA animal mo-
dels
Several recent studies in animal models have been performed in order to 
investigate the mechanisms underlying pain in OA. Schuelert and McDougall 
(2006) have presented the first electrophysiological evidence that MIA-induced 
OA causes a dramatic sensitization of knee joint afferents during normal and 
noxious hyper-rotation of the knee joint, with an increased firing rate and reduced 
activation threshold. Sensitization of these peripheral nerves leads to enhanced 
mechanosensation in the affected joint, which leads to allodynia, hyperalgesia, 
and spontaneous pain (Schuelert and McDougall, 2008). In a more recent study, 
the same authors have shown that joint afferent firing frequency was significantly 
enhanced in MIA-induced OA knees compared to saline injected control joints, and 
the magnitude of this sensitization had a direct relationship with the concentration 
of intra-articularly injected MIA (Schuelert and McDougall, 2009). Kelly and 
colleagues (2012), in a recent report using the MIA model, showed that spontaneous 
activity occurred in 50% of C-mechanosensitive fibres from OA animals (Kelly et 
al., 2012). The spontaneous activity firing rates were also significantly higher than 
normal and were correlated with the observed decreased weight bearing (Kelly 
et al., 2012). The A-mechanosensitive fibres did not show any significant increase 
in the percentage of fibres with spontaneous activity (20%) or in their firing rates 
after MIA injection (Kelly et al., 2012). On the contrary, A-mechanosensitive fibres, 
but not C-mechanosensitive fibres, exhibited decreased mechanical threshold 
and increased firing rates in response to suprathreshold mechanical stimulation 
in OA animals (Kelly et al., 2012). These data suggest distinct mechanisms 
in the pathogenesis of pain in OA, spontaneous pain being primarily due to C-
53
INTRODUCTION  |  PAIN IN OSTEOARTHRITIS
fibre activation, and stimulus-evoked pain due to A-mechanosensitive fibres 
activation. 
On the other hand, in a surgical model of OA, Wu and Henry (2010) evaluated 
changes in DRG sensory neurons innervating regions throughout the entire 
hind limb and showed that one month after OA induction Aβ-fibre low threshold 
mechanoreceptors had undergone changes in electrophysiological properties, 
while C- or Aδ-fibre nociceptors only showed minor action potential configuration 
changes. Aβ-fibre mechanoreceptors exhibited a slowing of the dynamics of action 
potential generation, including a wider duration of the action potential and a slower 
maximum rising rate, suggesting a role for Aβ-fibres primary sensory neurons in 
the pathogenesis of OA pain, through a change in sodium currents derived from 
either a functional change or a change in expression (Wu and Henry, 2010). It 
should be noted that the most significant changes were observed in non-knee 
joint afferents. In another study using the same OA model, these authors have 
shown that Aβ-fibre nociceptor-like unresponsive neurons undergo significant 
changes that occur later in the onset of this pathology, which may contribute to 
the mechanisms underlying pain associated with advanced OA (Wu and Henry, 
2009).
The exact mechanisms responsible for sensitization of these peripheral 
receptors are poorly known, but it may be related to early inflammatory reactions 
in the joint (Schuelert and McDougall, 2009). Endogenous release of VIP may 
contribute to afferent sensitization in OA (Schuelert and McDougall, 2006). VIP is 
involved in peripheral sensitization of knee joint afferents to mechanical stimuli, 
enhancing the firing rate of primary afferents during normal and noxious movement, 
with pain behavioural studies showing that intra-articular VIP administration 
leads to increased knee joint allodynia and secondary hyperalgesia (McDougall 
et al., 2006; Schuelert and McDougall, 2006). Consistent with this, administration 
of the VIP receptor antagonist VIP6-28 reduces OA-induced sensitization of knee 
joint afferents and reduces pain behaviour (McDougall et al., 2006; Schuelert and 
McDougall, 2006). This indicates that VIP released into OA knee joints potentially 
contributes to joint pain, maybe due to a VIP-mediated activation of the cAMP-
protein Kinase A metabolic pathway (Schuelert and McDougall, 2006).
Voltage-gated sodium channels are fundamental in regulating the 
excitability of neurons and overexpression of these channels can produce 
abnormal spontaneous firing patterns which underpin chronic pain (Lai et al., 
2004). The subtype Nav1.8 seems to be part of the molecular machinery involved 
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in mechanotransduction of joint pain since intra-arterial injection of a selective 
blocker, A-803467, significantly reduced the firing rate of joint afferents of animals 
injected with MIA during noxious rotation of the joint, but had no effect during non-
noxious rotation (Schuelert and McDougall, 2012). Furthermore, intra-articular 
injection of A-803467 into OA knees attenuated hindlimb incapacitance and 
secondary allodynia (Schuelert and McDougall, 2012). However, A-803467 had no 
significant effect on spontaneous nerve activity in MIA-treated joints, which may 
be due to the fact that articular Nav1.8 channels are only activated by external 
physical stimuli and are unaffected by the sensitizing effect of algogenic agents 
present in the diseased joint (Schuelert and McDougall, 2012).
The TRPV1 channel is also thought to play a role in joint pain. Fernihough 
et al. (2005) have identified an increase in TRPV1 expression in DRG neurons of 
backlabelled joint afferents innervating MIA-induced OA joints. Administration 
of the TRPV1 antagonist AMG9810 effectively blocked thermal hypersensitivity, 
although it failed to block high-dose MIA-induced weight asymmetry or ongoing 
nociception (Okun et al., 2012). Remarkably, pre-treatment with a single intra-
articular administration of capsaicin (0.5%), two weeks before MIA injection, 
although failed to attenuate hyperalgesia in the first 7 days, had a robust effect 
from day 14 to 4 weeks post-MIA injection, abolishing evoked mechanical pain 
and reducing joint pathological changes such as bone erosion and trabecular 
damage (Kalff et al., 2010). These results support the role of capsaicin-sensitive 
sensory neurons in pathogenesis of OA (Kalff et al., 2010). Intra-articular injection 
of 0.5% capsaicin has been shown to induce a selective loss of SP and CGRP 
immunoreactive nerve fibres in the rat knee synovia (Mapp et al., 1996). 
The neuropeptides SP and CGRP, frequently considered neurogenic 
inflammatory mediators, are likely to be involved in the neuro-immune pathways 
that may occur in OA joints (Saxler et al., 2007). An increase in CGRP expression 
in DRG neurons of backlabelled joint afferents innervating osteoarthritic joints 
induced by MIA was observed (Fernihough et al., 2005). In another study, a 
significant increase in SP (44%) and CGRP (29%) gene expression was observed 
in the ipsilateral DRG in MIA-injected rats on day 21 (Ahmed et al., 2012). In MIA-
injected knee joints, abundant SP and CGRP-positive nerve fibres were detected 
in the synovia and in the subchondral bone, both in nerve bundles and as single 
nerve fibres with varicosities (Ahmed et al., 2012). Semi-quantitative analysis 
of whole knee joint demonstrated a 4.7-fold increase in the SP and a 2.1-fold 
increase in CGRP-immunoreactivity in MIA-injected joints of rats as compared to 
55
INTRODUCTION  |  PAIN IN OSTEOARTHRITIS
joints from control animals (Ahmed et al., 2012). These upregulated expressions 
of SP and CGRP in both the knee joint and DRG were normalized and pain behavior 
reduced with a daily administration of the proteasome inhibitor MG132 (Ahmed et 
al., 2012). The mechanism through which proteasome inhibitors modulate pain 
in these pathophysiological conditions may be through attenuation of increased 
synthesis and release of sensory pronociceptive neuropeptides SP and CGRP 
(Ahmed et al., 2012).
NGF is an important regulator of TRPV1 (Ji et al., 2002), SP and CGRP 
(McMahon, 1996) and in a mice model of OA, induced by destabilisation of the 
medial meniscus, NGF mRNA was induced in joints during post-operative (day 
3) and OA (16 weeks) pain, but not in the non-painful stage of disease (8 weeks; 
McNamee et al., 2010). In the post-operative phase of pain, induction of NGF was 
TNF-dependent, but not in late OA joints (McNamee et al., 2010). The soluble 
NGF receptor, TrkAD5, was highly effective at suppressing pain in both phases, 
suggesting an important mediator role of NGF in OA pain (McNamee et al., 
2010). 
The endocannabinoid system is recognized to play an important role in 
regulating a variety of physiological processes, including bone remodelling, and 
thus may play an important role in the pathogenesis of joint disease (Idris and 
Ralston, 2010). Activation of peripheral cannabinoid receptor subtype 1 (CB1), by 
the selective receptor agonist arachidonyl-2-chloroethylamide (ACEA), reduces 
the mechanosensitivity of afferent nerve fibres in control and OA knee joints, albeit 
the antinociceptive effect was greater in the OA joints, probably due to a higher CB1 
expression in OA joints (Schuelert and McDougall, 2008). This desensitizing effect 
was apparent during non-noxious and noxious movement of the knee (Schuelert 
and McDougall, 2008). Although blockade of either the CB1 receptor or the TRPV1 
channel significantly reduced the efficacy of ACEA in control animals, suggesting 
that both receptors are involved in cannabinoid-mediated antinociception, the CB1 
receptor antagonists were unable to block the antinociceptive effect of ACEA in 
OA joints, maybe due to the robust interaction between ACEA and CB1 receptors 
in OA knees (Schuelert and McDougall, 2008). Administration of the CB1 receptor 
antagonist by itself increased mechanosensitivity in the OA knee but had no 
effect on control joint mechanosensitivity, suggesting that endocannabinoids 
are released in OA joints, thus contributing to offset peripheral sensitization and 
nociception, but their levels are negligible in non-arthritic knees (Schuelert and 
McDougall, 2008).
5
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Chronic joint pain originates in the periphery by the activation and sensitization 
of primary afferent nerve fibres innervating the joint leading to heightened 
neuronal activity. However, prolonged bombardment from these primary afferents 
subsequently sensitizes spinal and supraspinal neurons that are also key players 
in the experience of persistent pathological joint pain.
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4. OBJECTIvES
Pain is the most common disabling symptom for patients with osteoarthritis. 
However, standard treatments fail to reduce mean pain levels beyond minimal 
clinically important thresholds (Bjordal et al., 2004). This may be due in part to 
a potential mismatch between the medications used and the underlying pain 
mechanism(s). A better understanding of the mechanisms that underlie joint pain 
and the nature of such pain is mandatory to develop strategies for targeted pain 
management in OA.
Animal models of OA are a valuable tool to study the pain mechanisms and 
evaluate drug effects. However, most behavioural measures used assess referred 
nociception and do not capture movement-induced nociception and nociception 
interfering with physical activities, thus failing to reveal manifestations in OA that 
resemble the human condition. Therefore, and since pain assessment is of utmost 
importance for mechanistic studies as well as for the evaluation of drug efficacy, 
the present dissertation aims at:
i) Developing behavioural tests that would measure movement-evoked 
nociception of the knee joint in a model of OA
ii) Unravelling some of the peripheral mechanisms underlying pain in OA 
This dissertation includes four publications ordered in the sequence of the 
aims stated above. All the studies were performed in a rat model of OA, induced 
by intra-articular injection of MIA in the left knee joint. The first study aimed at 
evaluating behavioural measures that would assess nociception directly in or 
near the affected joint and evaluate movement-evoked nociception (Publication 
I). We used two tests directed at the knee, the Knee-Bend and the pin-prick, to 
assess movement-induced nociception and cutaneous mechanical hyperalgesia, 
respectively. The CatWalk apparatus was also used to evaluate dynamic weight 
bearing in a free-moving walking animal. Additionally, von Frey filaments and the 
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Randall-Selitto test were used to measure secondary mechanical allodynia and 
hyperalgesia, respectively. An additional aim of this study was to verify whether 
there were any differences in the behavioural nociceptive responses of animals 
injected with two different doses of MIA.
The second study aimed at evaluating the sensitivity of the Knee-Bend and 
CatWalk tests for evaluating OA-induced nociception and to verify if analgesic 
drugs affected the movement-induced nociceptive behaviour in this model of 
OA (Publication II). For that purpose we analysed three analgesic drugs from 
different pharmacological classes and with different modes of action, at an early 
inflammatory stage and at a late/chronic phase. Furthermore, the local anaesthetic 
allowed us to evaluate the contribution of intra-articular nerve terminals as the 
primary source of nociception, while with the NSAID we assessed the involvement 
of the inflammatory component. 
The third study aimed at evaluating changes in the sensory neurons 
innervating the knee joints of rats with OA, to better understand and characterize 
the mechanisms that underlie joint pain in OA (Publication III). Sensory neurons 
innervating the joint were identified by retrograde labelling with fluorogold (FG) 
injected into the osteoarthritic knee and neuronal populations were classified 
using antibodies against CGRP, IB4, and NF200. The distribution of these markers 
according to cell size was also analysed. Evaluation of the total number of FG-
backlabelled cells and of the total cell number in L3, L4, and L5 DRG was also 
performed, and the possible occurrence of neurogenesis in the DRGs innervating 
OA joints investigated through bromodeoxyuridine (BrdU) incorporation. Due to 
the alterations in the neurons innervating the affected joints observed in the third 
study, commonly interpreted as a neuronal response to axonal injury, the fourth 
study aimed to determine and characterize the possible occurrence of neuronal 
damage in primary afferent neurons innervating OA joints (Publication I). The 
expression of the activating transcription factor (ATF)-3 and NPy was evaluated 
in DRG neurons at different time-points of disease progression. Additionally, to 
address the possible occurrence of a regeneration process as part of a neuronal 
response to a hypothetical injury of peripheral nerves, the expression of the 
growth-associated protein (GAP)-43 was analysed. Moreover, three different 
doses of MIA were used in this study in order to investigate whether the observed 
effects were dose-dependent. 
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Assessment of Movement-Evoked Pain in Osteoarthritis by the
Knee-Bend and CatWalk Tests: A Clinically Relevant Study
Joana Ferreira-Gomes, Sara Adães, and José M. Castro-Lopes
Institute of Histology and Embryology, Faculty of Medicine and IBMC, University of Porto, Porto, Portugal.
Abstract: Although there are several reports on pain behavioral tests in rat models of knee
osteoarthritis (OA), most of them focus on the paw. The aim of this study was to investigate
pain-related behaviors on the affected knee joint, the primary source of nociception, in animals with
mono-iodoacetate–induced OA, using the knee-bend (which provides information on movement
pain) and pin-prick tests, and to evaluate nociception elicited by walking using the CatWalk test. The
von Frey and Randall-Selitto tests applied to the paw allowed us to compare our study results with
previous studies. A further aim was to compare the behavioral nociceptive responses of the most
used doses of mono-iodoacetate, 2 and 3 mg. Knee-bend score of OA animals was higher than those
of control animals throughout the study (P < .05). At every time point, the ipsilateral hind-paw load
of OA rats, as measured by the CatWalk test, was lower than that of control rats (P < .05), and paw
withdraw threshold to von Frey filaments was also decreased (P < .01). No changes were observed
in pin-prick and Randall-Selitto tests. Results obtained with the 2 doses of mono-iodoacetate were
similar. The knee-bend and CatWalk tests are effective for evaluating movement-related nociception,
a hallmark of clinical OA, which was present throughout the experimental period.
Perspective: Behavioral characterization of models of OA pain is important and useful for use in
future studies to test pharmacological treatments. Furthermore, it is important to find methods that
correlate better with the human symptoms of OA.
© 2008 by the American Pain Society
Key words: Osteoarthritis, pain, catwalk, knee-bend, pin-prick, nociception.
Osteoarthritis (OA) is a highly prevalent, chronic,degenerative joint disorder with large socioeco-nomic impact. The disease involves the whole
joint and is characterized by erosions and loss of the
articular cartilage, overgrowth of subchondral bone, de-
velopment of osteophytes, and synovitis.16,19,37
Pain is the major symptom of OA. It can be present at
rest but typically worsens with weight bearing and activ-
ity or movement of the affected joint,11,13 leading to
disability and reduction of the patients’ quality of
life.35,39 It has been reported that OA accounts for more
trouble with walking and climbing stairs than any other
disease.20 The causes of pain in OA have not been fully
determined, but there are suggestions that the afferent
innervation of the subchondral bone, periosteum, syno-
vium, ligaments, and the joint capsule could be the
source of nociception.21,26,30
Various experimental animal models that mimic hu-
man OA have been developed. The injection of monoso-
dium iodoacetate (MIA) into the rat knee joint is an easy
and rapid method that has been described by several
authors as the best model for the study of nociception in
this pathology.4,9,17,23,32 MIA disturbs the chondrocyte
metabolism through inhibition of glycolysis and proteo-
glycan synthesis, causing marked destruction of the
articular cartilage.14,15 Consequently, animals injec-
ted with MIA into the knee show alterations in hind
limb weight bearing measured by an incapacitance
test.4,9,17,23,32 Secondary mechanical allodynia and hy-
peralgesia were also demonstrated in the hind paw of
animals with knee OA, using von Frey filaments and the
Randall-Selitto test, respectively.9,17 However, to our
knowledge, no study has investigated the occurrence,
characteristics, and time course of allodynia and hyper-
algesia directly in or near the affected joint. For that
Received February 26, 2008; Revised May 15, 2008; Accepted May 20,
2008.
Supported by grant POCI/SAU-NEU/60853/2004, financed by FCT and
POCI 2010 and cofinanced by FEDER.
Address reprint requests to Dr. José M. Castro-Lopes, Institute of Histol-
ogy and Embryology, Faculty of Medicine, Alameda Prof. Hernani Mon-
teiro, 4200-319 Porto, Portugal. E-mail: jclopes@med.up.pt
1526-5900/$34.00
© 2008 by the American Pain Society
doi:10.1016/j.jpain.2008.05.012
The Journal of Pain, Vol 9, No 10 (October), 2008: pp 945-954
Available online at www.sciencedirect.com
945
84
NEUROBIOLOGICAL MECHANISMS OF PAIN ASSOCIATED WITH OSTEOARTHRITIS
purpose, we used modified versions of 2 commonly used
tests, one mostly used in neuropathic pain, the pin-prick,
and the other for inflammatory monoarthritis, the an-
kle-bend test, both of them adapted to the knee joint.
The knee-bend test, in particular, provides important in-
formation regarding pain induced by movement of the
affected joint, which is the most predominant symptom
in OA patients. Additionally, we have used the CatWalk
apparatus to evaluate weight bearing in a free-moving,
walking animal, unlike other methods. Finally, von Frey
filaments and the Randall-Selitto test were used to assess
secondary mechanical allodynia and hyperalgesia, re-
spectively, allowing comparison with previous studies.
A further aim of this study was to verify whether there
were any differences in the behavioral nociceptive re-
sponses of the animals injected with either 2 or 3 mg of
MIA, which are the most used doses for OA induction.
Methods
Animals
Adequate measures were taken to minimize pain or
discomfort of the animals, and all experimental proce-
dures were performed in accordance with the ethical
guidelines for the study of experimental pain in con-
scious animals,42 as well as the European Communities
Council Directive 86/609/EEC. In addition, the work here
reported was approved by the Ethics Committee for
Health of the Hospital S. João, Porto, Portugal.
Adult male Wistar rats (Charles River, Lyon, France)
weighing 230 � 30 g at the time of knee injection were
used for these experiments. Animals were housed in sol-
id-bottom cages, with water and food ad libitum, and
the animal room was kept at a constant temperature of
22°C and controlled lighting (12-hour light/12-hour dark
cycle).
Induction of Osteoarthritis
Under brief isoflurane anaesthesia, animals were in-
jected with the use of a Hamilton syringe (Hamilton,
Reno, NV) inserted through the patellar ligament into
the joint space of the left knee, with 25 �L of either
saline (control group) or 2 or 3 mg of MIA in saline
(Sigma-Aldrich, St. Louis, MO). The amount of MIA was
chosen on the basis of previous reports.9,17,23,32
Histological Analysis of the Knee Joint
At day 31, after the behavioral measurements (see be-
low), all animals were perfused with 4% paraformalde-
hyde with 0.1% of picric acid. Their knee joints were
dissected, postfixed for 72 hours in the same fixative so-
lution, and then decalcified for 8 hours with a decalcifi-
cation buffer containing 7% AlCl3, 5% formic acid, and
8.5% HCl, as described previously.36 Afterward, the joint
was washed in 0.1M phosphate buffer, pH 7.2, and kept
in 30% sucrose with 0.01% sodium azide until they were
cut into 20-�m sections, using a cryostat.
Sections were stained by Fast Green and Safranin-O
methods. They were then mounted with Eukitt (Kindler,
Freiburg, Germany) and photographed with the use of a
Nikon Eclipse E200 microscope with a DFK 41F02 color
digital camera (Imaging Source, Bremen, Germany) at-
tached.
Behavioral Testing
Testing was performed in a blinded manner, so the
experimenter was not aware as to which experimental
group the rat being tested belonged. Animals were ha-
bituated/adapted to the experimenter and to the testing
situation for at least 1 week before the start of the ex-
periment and 5 to 10 minutes before each testing, until
exploration activities ceased. For each rat and each test,
testing was done before the knee injection (day 0), to
assess the baseline response of each animal, and 3, 6, 10,
13, 17, 20, 24, 27, and 31 days after the injection. All tests
were done bilaterally. Testing was done in 2 sets of ex-
periments: In the first set, animals injected with saline
(control rats) or 2 mg of MIA were tested by Randall-
Selitto, von Frey filaments, and pin-prick (n � 4 for con-
trol and n � 6 for OA animals); in the second set of
experiments, animals injected with saline (control rats)
or 2 mg or 3 mg of MIA were tested by CatWalk, knee-
bend, and von Frey filaments (n � 7 per experimental
group).
Knee-Bend Test
To assess the sensitivity to the normal movement of
each knee, a variation of the ankle-bend test of nocicep-
tion for monoarthritic rats7,33 was performed. For this
purpose, animals were gently restrained, allowing access
to both hind limbs while at the same time restricting
movement. The test consisted on the recording of the
number of squeaks and/or struggle reactions in response
to flexion and extension of the knee joint, performed by
the experimenter, within its limits of movement. Each
test consisted of 5 flexions and 5 extensions of the knee
joint, and the total number of vocalizations/struggle was
recorded. The score of the test is determined according
to the type of reaction, squeaks and/or struggle, and the
type of manipulation that originated the reaction, ac-
cording to the following evaluation scale: Score 0 is given
to no responses to any kind of extension or flexion of the
joint; score 0.5 when struggle occurs to maximal flexion/
extension; score 1 when struggle occurs to moderate
flexion/extension and also in vocalizations to maximal
flexion/extension; and score 2 is given to squeak reac-
tions in response to moderate manipulations (flexions
and extensions) of the joint. The sum of the recorded
reactions, giving maximal values of 20, represents the
knee-bend score, an indication of the animal’s nocicep-
tion.
CatWalk
The CatWalk test40 was used to evaluate the disability
induced by themodel bymeasuring the total intensity of
the contact area of each paw. In this test, animals were
placed in a glass platform located in a dark compartment
and allowed to walk freely. A light beam from a fluores-
946 Nociception in Experimental Osteoarthritis
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cent lamp illuminated the platform in such a way that
lightwas reflected downward only at those pointswhere
the paw touched the glass surface, giving a bright, sharp
image of the paw print. The platform was monitored by
a video camera with a wide-angle objective, placed un-
der the glass platform, and connected to a computer
equipped with video acquisition software (Ulead Video
Studio, Freemont, CA). This was done in the darkness to
enhance the contrast of the paw print images. The inten-
sity of the signal depends on the area of the paw in
contact with the platform and increases with the pres-
sure applied by the paw. The higher the pressure applied
and the area of the paw contact, the higher the intensity
and number of pixels associated to the image. ImageJ
1.37 (available at www.tucows.com/preview/510562)
software was used to analyze the images obtained from
6 random frames of the videos recorded during the rat
evaluation, 3 frames with the animal walking and 3
frames with the animal standing still. The number and
intensity of pixels above a defined threshold were quan-
tified, allowing comparing the area/pressure applied by
each paw. Results are expressed in total intensity of the
ipsilateral hind paw as a percentage of the total intensity
of both hind paws.
Pin-Prick
Mechanical hyperalgesia was evaluated through the
pin-prick test, commonly used to assess mechanical hy-
peralgesia resulting from nerve injury.12,38 For this test,
the animal was placed on a grid and the plantar surface
of the hind paw (secondary hyperalgesia) or the knee (pri-
mary hyperalgesia) was quickly stimulated with the
point of a safety pin at an intensity sufficient to produce
a reflex withdrawal response in normal animals but in-
sufficient to penetrate the skin. The duration of the paw
withdrawal, determined as the time interval between
lifting the paw and replacing it to the grid, was recorded
with a timer. The normal paw withdrawal was too brief
to bemeasured accurately, so an arbitrarily minimal time
of 0.5 seconds was defined.38
von Frey Filaments
To assess secondary tactile allodynia, animals were
placed in a Perspex chamber with an opaque floor with
small holes, which allowed the application of von Frey
hairs to the plantar surface of the hind paws without
distracting the rat. This chamber was chosen because
Pitcher et al31 demonstrated that wire mesh may give
some variability in the results, due to stress and tactile
hyperesthesia. Each monofilament of the set of von Frey
hairs was applied for approximately 3 seconds, 5 times,
to the central region of the plantar surface of the ani-
mals’ hind paw, in ascending order of force until the
animal withdrew the paw. The hair was applied only
when the rat was standing still and in all the 4 paws.
When the tested pawwas sharplywithdrawn 4 times, the
response was noted as positive. If withdrawal did not
occur during the testing or occurred less than 4 of 5
times, the response was negative, and the next larger
filament was tested. Lifting of the paw due to normal
locomotor behavior was ignored. The lowest value of
force (in grams) required to elicit a positive response was
considered to be the paw withdrawal threshold (PWT).
The testing procedure was repeated till 3 consecutive
trials matched.
Randall-Selitto
Secondary mechanical hyperalgesia was assessed by
the Randall-Selitto test,34 using an analgesimeter (Ugo-
Basile, Milan, Italy). The animal was handled by the ex-
perimenter and partly restrained, the hind paw was
placed on a flat surface, and a blunt pointer was applied
on the dorsal surface at a steadily increasing pressure.
The PWT was determined when the animal removed the
foot from the apparatus, and the pressure, in grams,
necessary to evoke paw withdrawal was recorded.
Statistics
Animals were randomly assigned to each group. Re-
sults are presented as mean � SEM. Data corresponding
to the time course evaluation were analyzed by repea-
ted-measures ANOVA, followed by the post hoc least
significant differences (LSD) test. The comparison be-
tween both knees was analyzed by means of the paired-
samples t test and the results between groups with the
1-way ANOVA, followed by the post hoc LSD test (when
the 3 groups were compared) or unpaired samples t test
(when only 2 groups were compared). A P value of� .05
was accepted as statistically significant. Correlation anal-
yses between behavioral tests were performed by using
the Pearson correlation test on end-point values.
Results
Histological Analysis of the Knee Joint
Joint histology was assessed in all animals at day 31
through Safranin-O and Fast Green–Green stained sec-
tions. Control animals showed a normal structure of the
cartilage and subchondral bone (Fig 1).
Erosion of the hyaline cartilage was observed in OA
animals at this time, with depletion of chondrocytes and
proteoglycans from the extracellularmatrix, indicated by
the marked reduction of the Safranin-O stain. Addition-
ally, the articular surface showed fissures, and there was
thickening of the subchondral bone (Fig 1). Degenera-
tionwas confirmed in all cases, and the histopathological
changes were similar in all OA animals.
Movement-Evoked Measurements
Knee-Bend Test
There were no statistically significant changes in the
knee-bend score of both knees of control animals
throughout the study (Fig 2A). Nevertheless, the in-
jected knee always showed slightly higher values after
the saline injection, being significantly different from
the contralateral knee at day 13 (P� .05; Fig 2A). In the
OA 2 mg group, there was a statistically significant(P�
947Ferreira-Gomes et al
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.01) increase in the knee-bend score of the injected
knee, from 2.4� 0.8 at day 0 to 13.4� 2.2 at day 3 (first
test day after injection; Fig 2B). Values remained sig-
nificantly elevated throughout the duration of the
Figure 2. Knee-bend scores of animals injected with saline
(control, A) and 2 mg (osteoarthritis [OA] 2 mg), B) or 3 mg of
monosodium iodoacetate (MIA) (OA 3 mg), C). Baseline scores
were determined in both knees for all animals, before injection
(day 0). *P � .05, **P � .01, ***P � .001, significantly different
from baseline levels (repeated-measures ANOVA plus LSD post
hoc test). †P � .05,††P � .01, †††P � .001, significantly different
from the contralateral knee (paired-samples t test).
Figure 1. Histopathology of knee sections of control animals
(A) and animals injected with either 2 mg (B) or 3 mg (C) of
monosodium iodoacetate at day 31 after injection. The sections
were stained with Safranine-O and Fast Green. In the control
animal, the articular cartilage is intact, whereas in both groups
of OA there is a discontinuity (arrows) and erosion of the super-
ficial zone, with full cationic stainmatrix depletion (Safranin-O).
C indicates cartilage; SB, subchondral bone; M, meniscus. Scale
bar, 100 �m.
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study (31 days). Similarly, there was a statistically sig-
nificant (P � .01) increase in the knee-bend score of
the ipsilateral knee in the OA 3 mg group, from 2.7 �
0.8 at day 0 to 12.4 � 2.3 at day 3, which was main-
tained at all time points studied (Fig 2C).
In both OA groups, the ipsilateral score was signifi-
cantly different from the contralateral score at all time
points (P � .01; Figs 2B and 2C), whereas the scores of
contralateral knees were maintained in the range of
baseline values throughout the study.
The scores of the ipsilateral knee of both OA groups
were also significantly different from the control animals
at all time points (P� .05), but no significant differences
were observed between the 2 OA groups.
CatWalk
There were no significant changes in the paw print
total intensity of control animals throughout the study
(Fig 3A). On the contrary, animals from both OA
groups showed decreased intensity on the ipsilateral
paw print (Fig 3B). Mean intensity of the ipsilateral
paw print for control animals throughout the study
was 49.3% � 0.6% of the paw print intensity of both
hind paws (Fig 4A). At 3 days after injection, the area/
pressure of the ipsilateral paw in contact with the floor
was statistically reduced to 23.7% � 3.6% and to
23.4% � 3.2% in the OA 2 mg (Fig. 4A) and the OA 3
mg animals (Fig 4B), respectively (P � .01). In both
groups, at day 6 after injection, the values of the ipsi-
lateral hind paw print were slightly less decreased,
with values remaining stable thereafter and signifi-
cantly reduced throughout the study (P � .05; Fig 4),
with the exception of day 13 in the OA 2 mg group,
Figure 3. Image of the paw prints of control (A) and osteoar-
thritis animals injected with 2 mg of monosodium iodoacetate
(B) at 31 days after injection.
Figure 4. Percentage of the ipsilateral paw print total intensity
assessed in the CatWalk test. Animals were injected with saline
(control,A and B), 2 mg (osteoarthritis [OA] 2mg),A), or 3 mg of
monosodium iodoacetate (MIA) (OA 3 mg), B). Paw print total
intensity was assessed before the injection (day 0) and on vari-
ous days after the injection. *P � .05, **P � .01, ***P � .001,
significantly different from baseline levels (repeated-measures
ANOVA plus LSD post hoc test). †P � .05, ††P � .01, †††P � .001,
significantly different from the control animals (1-way ANOVA
plus LSD post hoc test).
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which was not statistically significant from the base-
line values but was statistically different from control
rats at that time (P � .05). Values of OA animals were
significantly different from the control rats at all times
(P � .05). There were no significant differences be-
tween the 2 OA groups, with the exception of day 10,
when animals from the OA 2 mg showed a smaller
total intensity of the ipsilateral paw print than did the
OA 3 mg animals (P � .05).
Cutaneous Hyperalgesia at the Paw and
Knee Joint
Pin-Prick
In saline-injected control animals, the withdrawal du-
ration (in seconds) after a pin-prick stimulus applied to
the plantar surface of the hind paw or to the knee was
always less than 1 second. No differences were observed
in the OA animals, and response duration was usually
also less than 1 second.
Secondary Mechanical
Allodynia/Hyperalgesia in the Hind Paw
von Frey Filaments
In the control animals of both sets of experiments, no
difference was observed in PWT before and after saline
injection; as well, no difference was observed between
the ipsilateral and the contralateral side throughout the
study (Fig 5A).
In animals from both OA groups, the PWT values of the
contralateral side were similar throughout the study and
equal to what was observed before the injection and to
control animals (Figs 5B and 5C). The reductions ob-
served on the ipsilateral side after day 3 were statistically
significant when compared with the contralateral side
(P� .01) andwith the ipsilateral side before the injection
(P � .001). In fact, the ipsilateral PWT of all animals in-
jected with MIA was less than 6 g of force, which has
been considered to represent the threshold of pro-
nounced allodynia.17
In theOA 2mg group of the second set of experiments,
animals had a PWT of 3.5� 0.9 g of force at day 3, which
was further reduced after day 10 to a PWT less than 3 g,
which was maintained until the end of the study (P �
.001 when compared with baseline value; Fig 5B). The
values of the OA 2 mg group of the first set of experi-
ments were similar (data not shown).
In the OA 3 mg animals, maximal mechanical allodynia
was evident at day 3, with a PWT of 2.8 � 0.5 g of force
(P � .001 when compared with the baseline value; Fig
5C). Afterward, values slightly increased but remained
significantly reduced until day 31 (P � .001 when com-
pared with baseline value).
Ipsilateral PWT from both OA groups were signifi-
cantly different from control animals (P� .01), but there
were no statistically significant differences between the
2 groups of OA animals.
Figure 5. Paw withdrawal thresholds (PWT) to von Frey filaments
assessed in control animals (A) and in osteoarthritis (OA) animals in-
jected with either 2 mg (B) or 3 mg (C) of monosodium iodoacetate
(MIA), before and after injection (second set of experiments).
***P � .001, significantly different from baseline levels (repeated-
measures ANOVA plus LSD post-hoc test). ††P� .01, †††P� .001, sig-
nificantly different from contralateral paw (paired-samples t test).
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Randall-Selitto
PWT determined by the Randall-Selitto test was as-
sessed in a group of animals injected with 2 mg of MIA
and in a group of saline-injected animals. OA animals did
not show any significant changes in PWT when com-
pared with control animals at any time of evaluation (Fig
6). No differences between the ipsilateral and contralat-
eral sides could also be found (except for a value on day
13 that may correspond to an outlier; Fig 6).
Correlation Analysis
Correlation analysis between tests showed that the
highest correlation coefficient was observed between
CatWalk and knee-bend tests with a value of –0.704, as
can be observed in Table 1.
Discussion
Movement-Evoked Measurements
Most nociceptive behavioral tests used in OA models
depend on the measurement of secondary hyperalgesia
and allodynia, using methods such as the paw pressure
test and von Frey hairs. However, these tests do not eval-
uate the primary hyperalgesia that occurs in OA joints,
nor the movement related nociception. The lack of
methods measuring primary hyperalgesia/allodynia
drove us to try to find methods that would be effective
for that purpose.
The ankle-bend test has been used for evaluating noci-
ception in monoarthritic animals and was shown to be an
appropriate procedure to assess the antinociceptive effects
of analgesics.7,33 Therefore, it was decided to adapt it to
OA animals by replacing the flexion and extension of the
ankle by flexion and extension of the knee. We then ob-
served that ipsilateral knee bend had statistically signifi-
cant higher score when compared with the contralateral
side and with the control animals. The elevated score was
consistent throughout the study. Furthermore, in the first
days after saline injection of control animals, the injected
knee showed slightly higher scores, which can account for
the reaction of the intra-articular injection, thus showing
this to be a sensitive test. Hence, the knee-bend test was
shown to be a useful, sensitive and reliable test to evaluate
nociception exacerbated by the movement of a diseased
joint, which is a common trait in OA.
The CatWalk has been suggested as an alternative tool
for objective assessment of mechanical allodynia and a
marker of chronic persistent pain in several neuropathic
or inflammatory pain models.10,18,29,40 However, in the
context of OA, this methodology has only been used for
gait analysis, without any correlation with pain behav-
ior.8 Interestingly, the gait analysis in OA animals re-
vealed that none of the parameters measured, such as
velocity of locomotion, stride length, and stance, stride
and swing times, were altered, with the exception of
load bearing.8 Thus, in the present studywe investigated
whether increased mechanical sensitivity could be eval-
uated in the OA model by using this apparatus. This was
done bymeasuring the signal intensity during placement
of the paw, which is an estimate of paw pressure, since
less pressure applied in the pawwill lead to a decrease of
signal intensity2 and of the area of the paw in contact
with the floor.
Our data show that OA animals minimize contact with
the floor and exert less pressure on the painful limb dur-
Figure 6. Paw withdrawal thresholds (PWT) to paw pressure as
assessed by the Randall-Selitto test in control animals (A) and in
osteoarthritis (OA) animals injected with 2 mg of monosodium
iodoacetate (MIA) (B) before (day 0) and after the injection.
†P � .05, significantly different from the contralateral paw
(paired-samples t test).
Table 1. Pearson Correlation Coefficient for
Comparisons Among Knee-Bend, CatWalk,
and von Frey Tests at Day 31
PEARSON CORRELATION COEFFICIENT
von Frey vs CatWalk 0.578
von Frey vs knee bend �0.631
CatWalk vs knee bend �0.704
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ingwalking, thus showing a decreasedweight bearing in
the osteoarthritic limb. This is probably due to an in-
creased sensitivity to mechanical stimuli and avoidance
of noxious mechanical stimulation resulting from dam-
age of the knee articulation induced by OA.
In an animal model of neuropathic pain,40 paw pres-
sure (measured through signal intensity in the CatWalk
test) has been shown to have a high degree of correla-
tionwith the von Freywithdrawal thresholds, suggesting
that mechanical allodynia in the paw parallels with a
decrease of pressure exerted by the paw during walking.
However, in our model, this does not necessarily seem to
be the case. Correlation analysis between tests showed
that CatWalk results correlate higher with results of the
knee-bend test rather than those of von Frey, suggesting
that the decreased weight bearing observed originates
from the knee joint and less to the cutaneous hyperalge-
sia observed in the hind paw.
A non-noxious mechanical distortion of the hind paw
induced solely by the reduction of articular cartilage or
decreased muscle tone is an unlikely explanation for our
findings because no changes were detected in gait anal-
ysis as referred above.8 Furthermore, preliminary phar-
macological results have shown that at day 3 of OA, sub-
cutaneous injection of morphine induces an increase of
the ipsilateral paw pressure, indicating that nociception
is an important factor for the decreased paw pressure
observed in the CatWalk test.
Previous studies have described measurements of
weight distribution as a reliable and practical method to
assess pain associated with experimental OA.4,9,17,32 Our
results are in accordance with those studies, especially
with Pomonis et al,32 who, as we did, showed the most
pronounced effect onweight bearing at the earliest time
point and remaining similarly reduced for the rest of the
experimental period. Furthermore, and in comparison
with those previous studies,17,32 the values observed in
control animals in our study were more stable through-
out time, probably reflecting fewer effects of stress. The
non–statistically significant difference between day 13
of OA 2 mg group and the baseline values was probably
due to an incidental stress condition that all animals
were subjected to on that day, which was also reflected
by an increase in the control animals. Nevertheless, there
was a statistically significant difference from control an-
imals at that time (P � .05).
Thus, CatWalk seems to be a good test to evaluate
nociception in OA models by indirectly measuring
weight load that may infer mechanical allodynia. This
test avoids the pain-induced actions of the commonly
used tests and the stress imposed on the animal during
testing. Moreover, there is a good correlation with the
daily situation of OA patients, in which walking causes
the most severe mechanical stimulation and a shift in
weight bearing off the affected leg occurs. In fact, in
human unilateral knee OA, an increased loading rate
in the contralateral leg after heel strike was observed,28
and patients with arthritis in the lower limb(s) report
higher pain intensity when they are walking than when
not moving.22
Cutaneous Hyperalgesia at the Paw and
Knee Joint
Secondary hyperalgesia in the paw, measured by pin
prick, was not consistently observed. Occasionally, OA
animals responded to the pin prick with higher flexion
duration and typical pain behavior such as squeaking,
licking the paw, and flinching before putting it into
the floor. Although these observations are subjective
and not statistically significant, they may reflect varia-
tions of the animals’ response to an ongoing chronic
noxious stimulation. Pin prick in the knee showed no
differences between control and OA animals. Variabil-
ity of secondary hyperalgesia has also been reported in
humans, using intramuscular infusion of hypertonic
saline.1 This was probably related to the fact that stim-
ulation was made on superficial tissues and not in the
joint, where nociception is primary elicited, although a
number of patients had increased pain in adjacent ar-
eas of the joint.1,6,25
Secondary Mechanical
Allodynia/Hyperalgesia in the Hind Paw
Punctatemechanical allodynia, asmeasured by the von
Frey filaments, was evident in OA animals, from day 3
onward, irrespective of the MIA dose. Using the same
method, some authors have also reported secondary al-
lodynia in the paw of OA animals injected with 2 mg of
MIA, with values similar to those that we observed.9,17
This allodynia was referred to an area distant from the
knee, the plantar surface of the hind paw; therefore, it is
termed secondary, as opposed to the primary allodynia
detected on the lesion site. In addition, this method is
unable to detect movement-induced primary allodynia
in OA animals.
Although some authors describe secondarymechanical
hyperalgesia in MIA-induced OA animals, using the paw
pressure technique,3,17 we did not observe blunt re-
ferred hyperalgesia, using the Randall-Selitto test. Like-
wise, Pomonis et al32 in preliminary experiments could
not observe secondary hyperalgesia by using the paw
pressure technique in MIA-induced OA. Moreover, no
blunt pressure mechanical hyperalgesia has been ob-
served in animals with a medial meniscal tear.5,17 This is
also in agreement with Koltzenburg et al,24 who showed
that in human hairy skin, blunt-pressure mechanical hy-
peralgesia does not extend outside the injured skin, thus
in the area of secondary hyperalgesia.
The fact that we, like others,5,17 have found secondary
allodynia but not hyperalgesia suggests that the mecha-
nisms involved may be differently altered in OA induced
nociception. It should be recalled that light touch detec-
tion to von Frey hair seems to be transmitted mainly by
A�-fiber mechanoreceptors, whereas hyperalgesia to
punctuate stimuli is mainly mediated by capsaicin-insen-
sitive A�-fiber nociceptors.27,41
Comparison of MIA Doses
Finally, it has been shown that the severity of carti-
lage lesions and subsequent development of OA and
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nociception related behaviors are directly related to
the injected dose of sodium mono-iodoacetate, at
least in some doses such as 0.1, 0.3, 1, and 3 mg of
MIA.4 Although some authors use 2 mg of MIA for
pharmacological and nociception behavior-related
studies,9,17 others have used 3 mg.23,32 However, there
was no study directly comparing the 2 doses as in the
present report. We could not observe statistically sig-
nificant differences between the 2 OA groups in any of
the behavioral tests, with the exception of day 10 in
the CatWalk test, as referred above. This seems to re-
flect a small difference in the onset of the disease,
resulting in a difference of the values in the first days
after injection (Fig 2). Nevertheless, we may conclude
that the 2 doses of MIA used in the present study (2 or
3 mg) have similar effect on the nociception induced in
this model. This is corroborated with the histopathol-
ogy of knee sections because the 2 concentrations
caused similar degenerative findings (Fig 6).
In conclusion, the CatWalk and knee-bend test are use-
ful methods for the evaluation of nociceptive symptoms
and weight-bearing distribution in movement and
movement-related nociception, thereby allowing an in-
direct assessment of the activation of joint nociceptors in
OA. These assays are alternative, nonreflexive, and non-
referred feasible methods to measure nociception in a
more clinically relevant way than the traditional hind
paw cutaneous measures. Studies are already being per-
formed to better validate the usefulness of these tests
for pharmacological studies. Close association between
evaluation of disease progression in the animal model
and information of the molecular mechanisms involved
in OA pain will be essential to elucidate the pathophysi-
ology of this disease.
Acknowledgments
The authors thank Vasco Galhardo and Paulo Aguiar
for their help assembling the CatWalk apparatus.
References
1. Bajaj P, Bajaj P, Graven-Nielsen T, Arendt-Nielsen L: Os-
teoarthritis and its association with muscle hyperalgesia: An
experimental controlled study. Pain 93:107-114, 2001
2. Betts RP, Duckworth T: A device formeasuring plantar pres-
sures under the sole of the foot. Eng Med 7:223-228, 1978
3. Beyreuther B, Callizot N, Stöhr T: Antinociceptive efficacy
of lacosamide in themonosodium iodoacetate ratmodel for
osteoarthritis pain. Arthritis Res Ther 9:1-8, 2007
4. Bove SE, Calcaterra SL, Brooker RM, Huber CM, Guzman
RE, Juneau PL, Schrier DJ, Kilgore KS: Weight bearing as a
measure of disease progression and efficacy of anti-inflam-
matory compounds in amodel of monosodium iodoacetate-
induced osteoarthritis. Osteoarthritis Cartilage 11:821-830,
2003
5. Bove SE, Laemont KD, Brooker RM, Osborn MN, Sanchez
BM, Guzman RE, Hook KE, Juneau PL, Connor JR, Kilgore KS:
Surgically induced osteoarthritis in the rat results in the de-
velopment of both osteoarthritis-like joint pain and second-
ary hyperalgesia. Osteoarthritis Cartilage 14:1041-1048,
2006
6. Bradley LA, Kersh BC, DeBerry JJ, Deutsch G, Alarcon GA,
McLain DA: Lessons from fibromyalgia: Abnormal pain sen-
sitivity in knee osteoarthritis. Novartis Found Symp 260:258-
270, 2004
7. Butler SH, Weil-Fugazza J: The foot-bend procedure as
test of nociception for chronic studies in a model of mono-
arthritis in the rat. Pharmacol Commun 4:327-334, 1994
8. Clarke KA, Heitmeyer SA, Smith AG, Taiwo YO: Gait anal-
ysis in a rat model of osteoarthrosis. Physiol Behav 62:951-
954, 1997
9. Combe R, Bramwell S, Fielf MJ: The monosodium iodoac-
etate model of osteoarthritis: A model of chronic nocicep-
tive pain in rats? Neurosci Lett 370:236-240, 2004
10. Coulthard P, Simjee SU, Pleuvry BJ: Gait analysis as a
correlate of pain induced by carrageenan intraplantar injec-
tion. J Neurosci Methods 128:95-102, 2003
11. Creamer P, Lethbridge-Cejku M, Hochberg MC: Where
does it hurt? Pain localization in osteoarthritis of the knee.
Osteoarthritis Cartilage 6:318-323, 1998
12. Decosterd I, Buchser E, Gilliard N, Saydoff J, Zurn AD,
Aebischer P: Intrathecal implants of bovine chromaffin cells
alleviate mechanical allodynia in a rat model of neuropathic
pain. Pain 76:159-166, 1998
13. Dieppe PA, Lim K: Osteoarthritis and related disorders:
Clinical features and diagnostic problems, in Dequeker J,
Dieppe PA (eds): Rheumatology. London, UK, Mosby, 2000,
pp 831-836.
14. Dumond H, Presle N, Pottie P, Pacquelet S, Terlain B,
Netter P, Gepstein A, Livne E, Jouzeau JY: Site specific
changes in gene expression and cartilage metabolism dur-
ing early experimental osteoarthritis. Osteoarthritis Carti-
lage 12:284-295, 2004
15. Dunham J, Hoedt-Schmidt S, Kalbhen DA: Prolonged
effect of iodoacetate on articular cartilage and its modifica-
tion by an anti-rheumatic drug. Int J Exp Pathol 74:283-289,
1993
16. Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick
CG, Jordan JM, Kington RS, Lane NE, Nevitt MC, Zhang Y,
Sowers M, McAlindon T, Spector TD, Poole AR, Yanovski SZ,
Ateshian G, Sharma L, Buckwalter JA, Brandt KD, Fries JF:
Osteoarthritis: New insights, I: The disease and its risk fac-
tors. Ann Intern Med 133:635-646, 2000
17. Fernihough J, Gentry C, Malcangio M, Fox A, Rediske J,
Pellas T, Kidd B, Bevan S,Winter J: Pain related behavior in two
models of osteoarthritis in the rat knee. Pain 112:83-93, 2004
18. Gabriel AF, Marcus MA, Honig WM, Walenkamp GH,
Joosten EA: The CatWalk method: A detailed analysis of
behavioral changes after acute inflammatory pain in the rat.
J Neurosci Methods 163:9-16, 2007
19. Gronblad M, Liesi P, Korkala O, Karaharju E, Polak J:
Innervation of human bone periosteum by peptidergic
nerves. Anat Rec 209:297-299, 1984
20. Guccione AA, Felson DT, Anderson JJ, Anthony JM,
Zhang Y, Wilson PW, Kelly-Hayes M, Wolf PA, Kreger BE,
953Ferreira-Gomes et al
92
NEUROBIOLOGICAL MECHANISMS OF PAIN ASSOCIATED WITH OSTEOARTHRITIS
KannelWB: The effects of specific medical conditions on the
functional limitations of elders in the Framingham Study.
Am J Public Health 84:351-358, 1994
21. Heppelmann B: Anatomy and histology of joint inner-
vation. J Peripher Nerv Syst 2:5-16, 1997
22. Kebin GM, Gene GH: Examination of the joint, in Shaun
R, Edward DH, Clement BS (eds): Kelley’s Textbook of Rheu-
matology. Vol 1. Philadelphia, PA, WB Saunders Company,
2001, pp 347-365
23. Kobayashi K, Imaizumi R, Sumichika H, Tanaka H, Goda
M, Fukunari A, Komatsu H: Sodium iodoacetate-induced ex-
perimental osteoarthritis and associated pain model in rats.
J Vet Med Sci 65:1195-1199, 2003
24. Koltzenburg M, Lunderberg LE, Torebjörk HE: Dynamic
and static components ofmechanical hyperalgesia in human
hairy skin. Pain 51:207-219, 1992
25. Kosek E, Ordeberg G: Lack of pressure pain modulation
by heterotopic noxious conditioning stimulation in patients
with painful osteoarthritis before, but not following, surgi-
cal pain relief. Pain 88:69-78, 2000
26. Mach DB, Rogers SD, Sabino MC, Luger NM, Schwei MJ,
Pomonis JD, Keyser CP, Clohisy DR, Adams DJ, O’Leary P,
Mantyh PW: Origins of skeletal pain: Sensory and sympa-
thetic innervation of the mouse femur. Neuroscience 113:
155-166, 2002
27. Magerl W, Fuchs PN, Meyer RA, Treede RD: Roles of
capsaicin-insensitive nociceptors in cutaneous pain and sec-
ondary hyperalgesia. Brain 124:1754-1764, 2001
28. Messier SP: Osteoarthritis of the knee and associated
factors of age and obesity: Effects on gait. Med Sci Sports
Excerc 26:1446-1452, 1994
29. Min SS, Han JS, Kim YI, Na HS, Yoon YW, Hong SK, Han
HC: A novel method for convenient assessment of arthritic
pain in voluntarily walking rats. Neurosci Lett 308:95-98,
2001
30. Niv D, Gofeld M, Devor M: Causes of pain in degenera-
tive bone and joint disease: A lesson from vertebroplasty.
Pain 105:387-392, 2003
31. Pitcher GM, Ritchie J, Henry JL: Paw withdrawal thresh-
old in the von Frey hair test is influenced by the surface on
which the rat stands. J Neurosci Methods 87:185-193, 1999
32. Pomonis JD, Boulet JM, Gottshall SL, Phillips S, Sellers R,
Bunton T, Walker K: Development and pharmacological
characterization of a rat model of osteoarthritis pain. Pain
114:339-346, 2005
33. Potes CS, Neto FL, Castro-Lopes JM: Administration of
baclofen, a gamma-aminobutyric acid type B agonist in the
thalamic ventrobasal complex, attenuates allodynia in
monoarthritic rats subjected to the ankle-bend test. J Neu-
rosci Res 83:515-523, 2006
34. Randall LO, Selitto JJ: A method for measurement of
analgesic activity on inflamed tissue. Arch Int Pharmacodyn
Ther 111:409-419, 1957
35. Rejeski WJ, Craven T, Ettinger WH Jr, McFarlane M, Shu-
maker S: Self-efficacy and pain in disability with osteoarthri-
tis of the knee. J Gerontol B Psychol Sci Soc Sci 51:24-29, 1996
36. Schwab W, Bilgicyildirim A, Funk RHW: Microtopogra-
phy of the autonomic nerves in the rat knee: A fluorescence
microcopic study. Anat Rec 247:109-118, 1997
37. Smith MD, Triantafillou S, Parker A, Youssef PP,
ColemanM: Synovial membrane inflammation and cytokine
production in patientswith early osteoarthritis. J Rheumatol
24:365-371, 1997
38. Tal M, Bennett GJ: Extra-territorial pain in rats with a
peripheral mononeuropathy: Mechano-hyperalgesia and
mechano-allodynia in the territory of an uninjured nerve.
Pain 57:375-382, 1994
39. van Baar ME, Dekker J, Lemmens JA, Oostendorp RA,
Bijlsma JW: Pain and disability in patients with osteoarthritis
of hip or knee: The relationship with articular, kinesiologi-
cal, and psychological characteristics. J Rheumatol 25:125-
133, 1998
40. Vrinten DH, Hamers FF: ’CatWalk’ automated quantita-
tive gait analysis as a novel method to assess mechanical
allodynia in the rat: A comparison with von Frey testing.
Pain 102:203-209, 2003
41. Ziegler EA, Magerl W, Meyer RA, Treede RD: Secondary
hyperalgesia to punctate mechanical stimuli: Central sensi-
tization to A-fibre nociceptor input. Brain 122:2245-2257,
1999
42. Zimmermann M: Ethical guidelines for investigations of
experimental pain in conscious animals. Pain 16:109-110,
1983
954 Nociception in Experimental Osteoarthritis
93
NEUROBIOLOGICAL MECHANISMS OF PAIN ASSOCIATED WITH OSTEOARTHRITIS
PUbLICATION II
ANALGESIC EFFECTS OF LIDOCAINE, MORPHINE AND DICLOFENAC ON 
MOVEMENT-INDUCED NOCICEPTION, AS ASSESSED By THE KNEE-BEND 
AND CATWALK TESTS IN A RAT MODEL OF OSTEOARTHRITIS
Pharmacology Biochemistry and Behavior 2012; 101(4):617-24

95
PUbLICATION II
ANALGESIC EFFECTS OF LIDOCAINE, MORPHINE AND DICLOFENAC ON MOVEMENT-INDUCED NOCICEPTION, 
AS ASSESSED By THE KNEE-BEND AND CATWALK TESTS IN A RAT MODEL OF OSTEOARTHRITIS
Author's personal copy
Analgesic effects of lidocaine, morphine and diclofenac on movement-induced
nociception, as assessed by the Knee-Bend and CatWalk tests in a rat model
of osteoarthritis
Joana Ferreira-Gomes ⁎, Sara Adães, Marcelo Mendonça, José Manuel Castro-Lopes
Department of Experimental Biology, Faculty of Medicine of Porto and IBMC — Institute for Molecular and Cell Biology, University of Porto, Alameda Prof. Hernani Monteiro,
4200 Porto, Portugal
a b s t r a c ta r t i c l e i n f o
Article history:
Received 3 November 2011
Received in revised form 22 February 2012
Accepted 3 March 2012
Available online 9 March 2012
Keywords:
Osteoarthritis
Pain
CatWalk
Knee-Bend
Pharmacological modulation
Lidocaine
Morphine
Diclofenac
Pain is the major symptom of osteoarthritis (OA) and the main reason for patients seeking medical care, but
its treatment is not optimal. Animal studies are necessary to elucidate mechanisms underlying OA-induced
pain and assess analgesics' efﬁcacy. Previously, we showed that the Knee-Bend test and dynamic weight
bearing by the CatWalk test are clinically relevant methods for assessing movement-induced nociception
in the mono-iodoacetate (MIA) OA model. Using the same tests, in the present study we investigate the
effects of lidocaine (5 mg, 10% solution, intra-articular), morphine (6 mg/kg, subcutaneous) and diclofenac
(30 mg/kg per os) on nociceptive behavior in OA animals, on days 3 and 20 of OA evolution.
Morphine reduced nociceptive behavior in both tests at both time-points. Lidocaine also decreased nocicep-
tive behavior in both tests on day 3, but on day 20 only reduced the Knee-Bend score. Diclofenac was highly
effective in both tests on day 3, while on day 20 it induced a less pronounced decrease in the Knee-Bend score
and was ineffective in the CatWalk test.
The results showed that the Knee-Bend and CatWalk tests are reliable alternative methods for evaluating
movement-induced nociception in OA animals, and measure nociception in a clinically relevant way, since
an analgesic proﬁle similar to the one described in humans was observed. Therefore, these tests might be
important as good predictors of drug efﬁcacy.
© 2012 Elsevier Inc. All rights reserved.
1. Introduction
Osteoarthritis (OA) is the most common articular pathology (Kidd,
2006). It is characterized by articular cartilage degradation and changes
in the underlying subchondral bone (Felson et al., 2000). The major
symptom of OA is pain at rest that typically worsens with weight bear-
ing andmovement (Creamer et al., 1998; Dieppe and Lim, 2000). Pain is
responsible for a high rate of disability and impairment of quality of life,
especially in the elderly (Rejeski et al., 1996; van Baar et al., 1998).
The management of OA-associated chronic pain is far from optimal
and the current pharmacological approaches do not provide adequate
pain relief in many cases (Kidd, 2006). Accordingly, OA patients refer
to pain as their worst symptom, reinforcing the need to develop new
therapeutic strategies.
Animal models of experimental OA are used to study the mecha-
nisms underlying pain in this pathology. Such models are also useful
for screening novel mechanism-based therapies. Accordingly, it is of
outmost importance that nociception evaluated in animal models
correlates with the ﬁndings in human pathology. Several behavioral
tests were used to evaluate nociception in OA animal models (Bove
et al., 2003; Fernihough et al., 2004; Pomonis et al., 2005). However,
commonly used tests, such as application of von-Frey hairs in the
paw, or pressure pain threshold measurement by the Randall–Sellito
test, are not the most adequate because they rely on stimuli that are
not applied to the affected joint, hence evaluating referred nocicep-
tion (Combe et al., 2004; Fernihough et al., 2004). Furthermore,
they do not evaluate movement related nociception, a hallmark of
OA-induced pain, typically described as activity related or mechanical
(Hunter et al., 2008). Taking into account these characteristics, we
used two behavioral tests that can be applied to evaluate nonreﬂexive
and nonreferred OA-induced nociception in a more clinically relevant
way, the Knee-Bend test and the dynamic weight bearing in the
CatWalk test (Ferreira-Gomes et al., 2008). In the Knee-Bend test,
the stimulus applied to the animal is the movement per se, through
ﬂexions and extensions of the affected joint, while in the CatWalk
test the movement-induced nociception is evaluated in a free-moving
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walking animal by measuring the placement of the paw on the surface
(Ferreira-Gomes et al., 2008).
In the present study, the effects of three analgesic drugs from
different pharmacological classes and with different modes of action
were analyzed: a local anesthetic, lidocaine; an opioid, morphine; and
a non-steroidal anti-inﬂammatory drug (NSAID), diclofenac. Testing
was performed on day 3 after OA induction, an early inﬂammatory
stage, and on day 20, a late/chronic phase, when the disease is fully
established in the MIA model (Bove et al., 2003; Combe et al., 2004).
This evaluation allowed us to verify if, in this model of OA, these drugs
change the movement-induced nociception behavior detected by the
Knee-Bend and CatWalk tests in a reproduciblemanner, thus supporting
their usefulness for evaluating OA-induced nociception. Furthermore,
lidocaine allowed us to evaluate the contribution of intra-articular
nerve terminals as the primary source of nociception, whilewith diclofe-
nac we assessed the involvement of the inﬂammatory component.
2. Material and methods
2.1. Animals
Adult male Wistar rats (Charles River, France), weighing 230±30 g
at the beginning of the experiments, were used in this study. Animals
were housed in solid bottom cages, with water and food ad libitum,
and the animal room was kept at a constant temperature of 22 °C and
controlled lighting (12 h light/12 h dark cycle).
All experimental procedures were performed in accordance with
the ethical guidelines for the study of experimental pain in conscious
animals (Zimmermann, 1983), as well as with the EU Directive 2010/
63/EU for animal experiments, with all adequate measures being
taken to minimize pain or discomfort of the animals.
2.2. Induction of osteoarthritis
Animals were injected intra-articularly with 25 μl of either saline
(control group), or 2 mg of MIA dissolved in saline (Sigma-Aldrich,
St. Louis,MO, USA), under brief isoﬂurane anesthesia. Injectionwas per-
formed using a Hamilton syringe (Hamilton, Nevada, USA) inserted
through the patellar ligament into the joint space of the left knee.
2.3. Behavioral testing
Movement-induced nociception was evaluated in all animals by
the CatWalk and Knee-Bend tests, before MIA or saline injection
(day 0), and 3 and 20 days post-injection, the time-points chosen
for pharmacological evaluation. Testing was blind and always done
by the same experimenter in order to minimize variability in the
application of the tests. Tests were performed as described previously
(Ferreira-Gomes et al., 2008). Brieﬂy, the Knee-Bend test consists of
recording the number of squeaks and/or struggle reactions in response
toﬁve ﬂexions andﬁve extensions of the knee joint. The score of the test
is determined according to the following evaluation scale: score 0 is
given to no responses to any kind of extension or ﬂexion of the joint;
score 0.5 when struggle happens at full range ﬂexion/extension; score
1 when struggle happens at medium range ﬂexion/extension and also
in vocalizations to full range ﬂexion/extension; the highest score
(score 2) is given to squeak reactions in response to medium rangema-
nipulations (ﬂexions or extensions) of the joint. The sum of the animal's
reactions, giving maximum values of 20, represents the Knee-Bend
score, an indication of the animal's nociception induced by movement
of the affected joint.
For the CatWalk test, animals were placed on a glass platform illu-
minated such as to reﬂect the light downwards only at the points of
contact of the paw with the glass surface, resulting in a bright sharp
image of the paw print. The intensity of the paw print signal increases
with the area of the paw in contact with the platform and with the
pressure applied by it. Therefore, the total ipsilateral paw print inten-
sity is quantiﬁed by determining the area of the paw in contact with
the platform, in number of pixels, and multiplying it by the mean
intensity of each pixel, giving us the overall intensity of the paw print.
The platform was monitored by a video camera with a wide-angle ob-
jective, placed under the glass platform and connected to a computer
equipped with video acquisition software (Ulead Video Studio, USA).
Six random frames of the videos recorded during the rat evaluation
were obtained, 3 frames with the animal walking and 3 frames with
the animal standing still. The number and intensity of pixels above a de-
ﬁned threshold were quantiﬁed using Image J 1.37 (available at www.
tucows.com/preview/510562), allowing the comparison between the
area/pressure applied by each paw. Results were expressed in total
intensity of the ipsilateral hindpawas a percentage of the total intensity
of both hind paws.
2.4. Pharmacological evaluation
The anti-nociceptive effects of the administration of the local
anesthetic lidocaine, the opioid morphine and the NSAID diclofenac,
were assessed by the Knee-Bend and Catwalk tests on days 3 and
20 post MIA or saline injection. Baseline values for behavioral data
were determined before MIA or saline injection, on day 0. Behavioral
assessment of nociception was also performed before the administra-
tion of the drug (t=0 min). For determining the effect of lidocaine, an
intra-articular injection of 50 μL of a 10% solution containing 5 mg of
lidocaine dissolved in saline was performed under brief isoﬂuorane
anesthesia, both in OA (n=5) and control animals (n=5), which had
been intra-articularly injected with saline instead of MIA. Additionally,
a group of OA animals was similarly injectedwith saline (n=5). Behav-
ioral assessment was performed 10, 20 and 30 min after lidocaine or
saline injection.
Morphine was administered to OA animals (n=5) by subcutaneous
injection of a 6 mg/mL solution dissolved in saline, in a ﬁnal dose of
6 mg/Kg (Fernihough et al., 2004). Behavioral tests were performed at
30, 60, 90, 120 and 180 min aftermorphine administration. Additionally,
a group of OA animals was similarly injected with saline (n=4).
Diclofenac was orally administered to OA animals (n=5), in a
10 mg/mL aqueous solution, in a ﬁnal dose of 30 mg/Kg (Fernihough
et al., 2004). Behavioral assessment was performed at 30, 60, 90 and
120 min after diclofenac administration. Distilled water was orally
administered to a group of OA animals (n=4), following the same pro-
cedures. Time points for behavioral assessment for each drug were de-
termined in preliminary experiments (in house data). The CatWalk test
was always performed prior to the Knee-Bend test in order tominimize
the effect of the manipulation of the affected knee joint on the animals'
gait.
2.5. Histological analysis of the knee joint
Following the pharmacological evaluation of day 20, all animals
were deeply anesthetized with intraperitoneal sodium pentobarbital
and perfused with 4% paraformaldehyde. Their knee joints were
dissected, post-ﬁxed for 72 h, and decalciﬁed for 8 h in a solution con-
taining 7% AlCl3, 5% formic acid, and 8.5% HCl, as previously described
(Ferreira-Gomes et al., 2008). Knee joints were then washed in 0.1 M
phosphate buffer, pH 7.2, and kept in 30% sucrose with 0.01% sodium
azide for at least 24 h, until they were cut into 20μm sections, in a
Microm HM 560 cryostat (Microm International GmbH, Walldorf,
Germany). Knee joint sections were stained by the Fast Green and
Safranin-Omethod. Slidesweremountedwith Eukitt (Kindler, Freiburg,
Germany) and photographed using a Nikon Eclipse E200 microscope
with a DFK 41F02 color digital camera (Imaging Source, Bremen,
Germany) attached.
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2.6. Statistics
Animals were randomly assigned to each group. Results are
presented as mean±SEM. Time course evaluation was analyzed by
Repeated Measures ANOVA, followed by the post-hoc test Fisher's
least signiﬁcant difference (LSD). A P value of b0.05 was accepted as
statistically signiﬁcant.
3. Results
3.1. Histological analysis of the knee joint
To conﬁrm the induction of OA and determine its extension, knee
joint sections were stained by the Fast Green and Safranin O method.
The histopathological changes observedwere very similar in all animals
injectedwithMIA, with pronounced erosion of the hyaline cartilage and
extensive loss of chondrocytes and proteoglycans from the extracellular
matrix, as indicated by the marked reduction of the Safranin O staining
(Fig. 1B). In addition, the articular surface of the OA joints showed
ﬁssures and thickening of the subchondral bone. No changes were
observed in the joints of saline-injected control animals (Fig. 1A).
3.2. Nociception evaluation
Both on days 3 and 20 after MIA injection, all OA animals showed a
signiﬁcant increase in the Knee-Bend score and a signiﬁcant decrease
in the total ipsilateral paw print intensity on the CatWalk test, when
compared with day 0 (before MIA injection), thereby demonstrating
movement-induced nociception as a consequence of OA induction.
The effect of lidocaine, morphine and diclofenac on such movement-
induced nociceptionwas evaluated by both tests at the two time points.
3.2.1. Lidocaine
Lidocaine was administered by intra-articular injection of 50 μL of
a 10% solution, and its effect on OA-induced nociception was evaluated
at 10, 20 and 30 min after the injection. In general, the maximum anti-
nociceptive effect was observed 10 min after lidocaine injection in both
tests. Thereafter, the effect started to revert, returning to pre-injection
values at 30 min after lidocaine administration.
On day 3, lidocaine caused a signiﬁcant (Pb0.01) reduction in the
Knee-Bend score of the ipsilateral knee from11.2±1.5, before injection,
to 1.2±0.7, at 10 min (Fig. 2A). On day 20, the Knee-Bend score was
signiﬁcantly (Pb0.01) reduced from 10.4±0.7 to 3.8±0.6 at 10 min
(Fig. 2C). In the CatWalk test, a signiﬁcant increase of the total ipsilateral
paw print intensity was observed on day 3, from 25.2±4.8% before in-
jection to 38.2±4.4% at 10 min (Pb0.05; Fig. 2B). A similar increasewas
observed onday 20, from a value of 28.3±2.4% to 36.3±2.2% at 10 min,
but this increase did not reach statistical signiﬁcance (Fig. 2D).
Lidocaine injection in the affected knee joint did not produce any
effect in the contralateral knee of the animals (Fig. 2). A group of control
animals (saline injection on day 0) was also injected with lidocaine
(data not shown) and an additional group of OA animals was injected
with saline (Fig. 5A and B), and their nociception was evaluated at the
same time-points. Neither of these two groups showed signiﬁcant
differences in both the Knee-Bend score and the total ipsilateral paw
print intensity at any time-point, when compared with pre- lidocaine
or saline injection values.
3.2.2. Morphine
Morphine was administered subcutaneously in a dose of 6 mg/kg,
and its effects on OA-induced nociception were evaluated at 30, 60,
90, 120 and 180 min after the injection. In general, the maximum
effect on the Knee-Bend test was observed between 30 and 90 min
after the injection, both on days 3 and 20, reverting thereafter. In
fact, on day 3, morphine induced a signiﬁcant (Pb0.001) decrease in
the Knee-Bend score, from 11.4±0.7 before its administration to
0.2±0.2 at 30 min (Fig. 3A). This reduction was maintained until
90 min after morphine administration, starting to revert at 120 min
and having returned to pre-administration values at 180 min. On
day 20, the Knee-Bend score signiﬁcantly (Pb0.001) decreased from
11.4±0.9 to 0.6±0.4 at 30 min, and this reduction was maintained
until 90 min (Fig. 3C). Values obtained from testing the contralateral
knee showed no signiﬁcant differences.
In the CatWalk test, maximum effect was observed from 60 to
90 min reverting thereafter. Total ipsilateral paw print intensity was
29.5±3.9% before morphine administration on day 3, and this value
increased gradually until 41.8±1.8% (Pb0.05) at 90 min (Fig. 3B).
On day 20, ipsilateral paw print intensity gradually increased from
35.2±2.7% before the injection to a maximum of 42.3±3.0% at 60 min
(Pb0.001) (Fig. 3D).
The group of OA animals injected subcutaneouslywith saline showed
no signiﬁcant differences in both the Knee-Bend score (Fig. 5C) and the
total ipsilateral paw print intensity (Fig. 5D) at any time-point, when
compared with baseline values.
3.2.3. Diclofenac
The effect of the NSAID diclofenac, administered orally in a dose of
30 mg/kg, was evaluated at 30, 60, 90 and 120 min after administration.
On day 3, diclofenac's maximum effect was observed 30 min after ad-
ministration. Knee-Bend score values signiﬁcantly (Pb0.001) decreased
from 14.8±1.0 before administration to 2.6±0.9 at 30 min (Fig. 4A),
starting to revert thereafter. On day 20, diclofenac's effect in the Knee-
Bend score was less pronounced, but still signiﬁcantly different from
pre diclofenac administration values (10.6±1.8) at 30 (6.2±1.1) to
Fig. 1. Histopathology of knee sections from control (A) and OA animals (B). Sections
were stained with Safranin O and Fast Green. The control animals showed a normal
structure of the cartilage and subchondral bone. OA animals showed a discontinuity
and erosion of the superﬁcial zone, with depletion of chondrocytes and proteoglycans
from the extracellular matrix. C — cartilage; SB — subchondral bone; M — meniscus.
Scale bar: 100 μm.
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90 (8.9±2.1) minutes (Pb0.01, Fig. 4C). No changes were observed
when testing the contralateral knee.
As to the CatWalk test, total ipsilateral paw print intensity signiﬁ-
cantly (Pb0.01) increased on day 3, from 22.6±4.0% before diclofenac
administration to 37.8±6.2% at 30min, starting to revert thereafter
(Fig. 4B). On day 20 no signiﬁcant differences were observed in the total
ipsilateral paw print intensity after diclofenac administration (Fig. 4D).
The group of OA animals that received oral distilled water, by the
same procedure as the other animals received diclofenac, exhibited
no signiﬁcant differences in both the Knee-Bend score (Fig. 5E) and
the total ipsilateral paw print intensity at any time-point (Fig. 5F).
4. Discussion
Joint pain in OA is typically described as exacerbated by activity or
mechanic stimulation, with some of the patients describing pain relief
with rest. Although the source of pain is not completely determined,
ultimately primary afferent activity is responsible for the generation
Fig. 2. Lidocaine effect on nociceptive behavior of OA animals assessed by the Knee-Bend and CatWalk tests. Intra-articular injection of lidocaine was performed on days 3 (A and B)
and 20 (C andD) afterMIA injection and its effect assessed by theKnee-Bend (A and C) and CatWalk (B andD) tests. Knee-Bend score and pawprint total intensitywere determined for all
animals prior to drug administration (time 0).*Pb0.05, **Pb0.01 signiﬁcantly different from pre-drug levels (Repeated Measures ANOVA plus LSD post-hoc test).
Fig. 3.Morphine effect on nociceptive behavior of OA animals assessed by the Knee-Bend and CatWalk tests. Morphinewas administered to OA animals by sub-cutaneous injection on
days 3 (A and B) and 20 (C and D) after MIA injection and its effect was assessed by the Knee-Bend (A and C) and CatWalk (B and D) tests. Knee-Bend score and paw print total
intensity were determined for all animals prior to drug administration (time 0).*Pb0.05, **Pb0.01, ***Pb0.001 signiﬁcantly different from pre-drug levels (Repeated Measures
ANOVA plus LSD post-hoc test).
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Fig. 4. Diclofenac effect on nociceptive behavior of OA animals assessed by the Knee-Bend and CatWalk tests. Diclofenacwas orally administered to OA animals on days 3 (A and B) and 20
(C and D) after MIA injection and its effect assessed by the Knee-Bend (A and C) and CatWalk (B and D) tests. Knee-Bend score and paw print total intensity were determined for all
animals prior to drug administration (time 0).*Pb0.05, **Pb0.01, ***Pb0.001 signiﬁcantly different from pre-drug levels (Repeated Measures ANOVA plus LSD post-hoc test).
Fig. 5. Vehicle effect on nociceptive behavior of OA animals assessed by the Knee-Bend and CatWalk tests. Saline was intra-articularly injected (A and B) or subcutaneously injected
(C and D) and distilled water was orally administered (E and F). Knee-Bend (A, C and E) and CatWalk (B, D and F) tests were performed 3 days after MIA injection. Knee-Bend score
and paw print total intensity was determined for all animals prior to vehicle administration (time 0).
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of joint pain. This neuronal activity occurring at the periphery may
cause plastic changes in the central nervous system further exacer-
bating pain perception (Hunter et al., 2008).
The features on physical examination that suggest a diagnosis of OA
include pain on passive range of motion of the affected joint and altered
gait (Hunter et al., 2008). Therefore, it is important that these same fea-
tures are the ones evaluated when animal models are used. The Knee-
Bend test provides important information concerning the nociception
exacerbated by the movement of a diseased joint (Ferreira-Gomes et
al., 2008), the predominant symptom of OA patients. In the CatWalk
test, movement-induced nociception is evaluated without any external
stimulation, by measuring the signal intensity during placement of the
paw and the area of the paw in contact with the ﬂoor, which give us
an estimate of paw pressure (Ferreira-Gomes et al., 2008). These
parameters of gait have been described as those more prone to change
in OA rats (Clarke et al., 1997). Changes in locomotion parameters are
expected to be associated with enhanced nociception and respective
guarding behavior. OA animals minimize contact with the ﬂoor and
exert less pressure on the painful limb during walking, probably due
to an increased sensitivity to mechanical stimuli and avoidance of
noxious mechanical stimulation at the knee joint (Ferreira-Gomes et
al., 2008). This is correlated with the daily situation of OA patients, in
which walking causes severe mechanical stimulation leading to a shift
in weight bearing off the affected leg (Messier, 1994; Kebin and Gene,
2001). Therefore, the dynamic weight bearing measure in the CatWalk
test is clinically relevant.
In this study, we tested the pharmacological modulation of OA-
induced nociception in the MIA model of OA, evaluated by the Knee-
Bend and CatWalk tests, using for that purpose lidocaine, morphine and
diclofenac. The aim was to verify if those drugs affected movement-
induced nociception in OA and, simultaneously to evaluate the sensitivity
of the tests. It should be noted that the time-points chosenwere based on
previous results that showed that pain behavior associated with intra-
articular MIA injection is biphasic in nature, with an early inﬂammatory
phase that lasts until day 7 and a second, chronic phase, beginning on
day 14 (Bove et al., 2003; Combe et al., 2004). Consequently, the effects
of the drugs on the behavioral tests were evaluated on day 3, an early
and inﬂammatory stage of the disease, and on day 20, when the disease
is chronic and fully established, presenting the typical degenerative
changes of the knee joint. Further studies are needed to investigate the
pharmacologic proﬁle of the drugs in this OA model, which was beyond
the scope of the present study.
4.1. Lidocaine
To our knowledge, intra-articular administration of lidocaine had
not been previously tested in this model. This drug effectively reverted
the nociception-related behavior as assessed by the Knee-Bend test at
both time-points studied, which is consistent with its mode of action.
Lidocaine exerts its anesthetic effects by blocking the fast voltage-gated
sodium (Na+) channels in the neuronal membrane (Butterworth and
Strichartz, 1990), thus blocking the signal transmission from primary
joint afferents to the central nervous system.
In what concerns the lidocaine effect on the dynamic weight bear-
ing, evaluated by the CatWalk test, on day 3 lidocaine reverted the
nociception-related behavior efﬁciently, but on day 20 its effect was
less pronounced and not statistically signiﬁcant. CatWalk provides an
indirect weight-load analysis in the context of movement-related noci-
ception. On day 20, the animal has been for some days with a painful
condition that altered its leg kinematics, needing time to adapt to a
“non-painful” state induced by the local anesthetic. In fact, an increase
in the contralateral leg load is observed in patients with unilateral
knee OA (Messier, 1994). OA patients' gait depends on the primary
joint pain, but also on the combination of that movement restraining
factor with complex neuronal pathways, some of them of supraspinal
origin (Jahn et al., 2008). A change in one of the locomotion modulator
stimuli, such as the absence of nociceptive stimuli, and thus a change in
theweight load of the affected leg, implies the reorganization of the gait
related pathways and the subsequent acquisition of a new walking
pattern, or the reactivation of the previous motor patterns. Such loco-
motor improvementsmay be time-dependent. Therefore, the quick act-
ing lidocaine, with its effect peaking at 10 min and starting to revert
20 min after the administration, might not provide the necessary time
period for the correct motor pattern improvement, explaining its
weaker effect observed in the present study on day 20. A continuous in-
fusion of lidocaine would possibly provide a more sustained analgesic
effect, since higher lidocaine synovial levels for a prolonged time period
would be attained.
With the results observed in this study we can also infer a very im-
portant contribution of the intra-articular nerve terminals for pain
transmission in the MIA model of OA especially on day 3. On day 20,
the effect of lidocaine was less pronounced, possibly reﬂecting activa-
tion of other structures, peripheral or central, that may be engaged in
pain transmission and modulation later during the development of
the disease. In fact, it is known that although total knee arthroplasty
leads to a signiﬁcant reduction of pain inmost patients, some still report
signiﬁcant postsurgical pain (Jones et al., 2000; Robertsson et al., 2000;
Dunbar, 2001). However, further studies will be necessary to conﬁrm
this.
The administration of lidocaine was performed under brief isoﬂuor-
ane anesthesia. In order to evaluate the possible interference of this vol-
atile anesthetic on the nociception parameters evaluated, a group of OA
animals was injected intra-articularly with saline, under isoﬂuorane an-
esthesia. No differences in nociception values were observed indicating
that this brief anesthesia does not affect the nociceptive effect observed
with lidocaine.
A group of saline injected animals was also injected with lidocaine
and evaluated at the same time-points. These control animals were im-
portant to assure that the local anesthetic lidocaine would not compro-
mise the tests, specially the CatWalk, since a loss of postural sensation
could happen and compromise the locomotion of the animals therefore
affecting the test results. No differenceswere observed after the lidocaine
injection in these animals in both tests, thus indicating that the effect
observed in OA animals is due to the reduction of nociception.
4.2. Morphine
Morphine is an opioidwith strong analgesic properties that exerts its
effects mainly at the central nervous system (Yaksh, 1997). It activates
the inhibitory mu-opioid receptor located at spinal and supraspinal
levels, leading to a decrease in the transmitter release from nociceptive
afferent ﬁbers and attenuation of neuronal transmission of pain mes-
sages both spinally and supraspinally, also interacting with descending
control pathways (Yaksh, 1997). In addition, the opioid receptors pre-
sent in the peripheral nervous system can modulate the excitability of
the small afferent terminals and exert an anti-hyperalgesic action
(Przewlocki and Przewlocka, 2001).
In our study, systemic morphine administration provided a complete
reduction of the Knee-Bend score of OA animals to values similar to naive
rats. The ipsilateral paw print intensity values, observed in the CatWalk
test in the OA animals that received morphine, could also be compared
to that of control animals. As expected, morphine effect was more sus-
tained than lidocaine effect. Therefore, the longer time period of action
might allow the animal to adapt to its new “non-nociceptive” situation,
resulting in the signiﬁcant acquisition of a new weight-load pattern
60 min after the drug administration.
The efﬁcacy of morphine in this OAmodel is in accordancewith pre-
vious results where similar doses had an anti-nociceptive effect on me-
chanical hyperalgesia and tactile allodynia, bothmeasured in the pawof
the animals (Fernihough et al., 2004). Other authors have also shown an
effect on the weight bearing (Combe et al.;, 2004; Pomonis et al., 2005)
and a reduction of cold hypersensitivity and ambulatory-evoked pain
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behavior (Vonsy et al., 2009), using other doses of morphine. In humans,
a study onmorphine efﬁcacy revealed reduced pain and improvement in
the overall quality of sleep in patients with moderate-to-severe OA pain
(Caldwell et al., 2002).
The antinociceptive effect of morphine provides further support to
the Knee-Bend and CatWalk tests as reliable methods to evaluate
MIA-induced OA-related pain.
A group of OA animals was injected subcutaneously with saline, to
serve as controls for the effect of the vehicle, and evaluated at the
same time-points. No differences in nociception values were observed
in both tests indicating that this procedure per se does not affect the no-
ciceptive effect observed with morphine. Furthermore, no behavior of
learning effect was observed in the animals for both tests.
4.3. Diclofenac
The NSAID diclofenac, is a common therapeutic option in the man-
agement of mild to moderate OA pain. In the present study, diclofenac
had a marked antinociceptive effect on day 3, a period characterized
by an inﬂammatory state, in both tests. However, its efﬁcacy on day
20 was reduced, since only a slight decrease of the Knee-Bend score
was observed, while there was no signiﬁcant change in the CatWalk
test. A rise in prostaglandins levels following MIA injection, that return
to baseline values by day 7, has been previously reported (Pulichino et
al., 2006). Histological analysis also revealed the presence of early
inﬂammation in the MIA model, with subsequent resolution by day 7
(Bove et al., 2003; Combe et al., 2004; Fernihough et al., 2004). The
absence of inﬂammation on day 20 may well explain the decrease of
efﬁcacy of diclofenac in this model at this time-point.
Other authors have reported the use of diclofenac on pharmacological
studies in this OAmodel. Fernihough et al. (2004) described a signiﬁcant
reduction of secondary mechanical hyperalgesia on day 3, but no effect
on secondary mechanical hyperalgesia or secondary tactile allodynia on
days 14 and28. Beyreuther et al. (2007), however, have shown that diclo-
fenac signiﬁcantly reduced secondary mechanical hyperalgesia on day
14, but with no effect on secondary mechanical allodynia. Chandran et
al. (2009) also reported, using the grip-force test, an antinociceptive
effect of diclofenac on day 20. The difference in results observed may be
owed to the fact that different parameters are being evaluated, since
most of the previous studies evaluate secondarymechanical hyperalgesia
and allodynia at rest, while the tests used in the present study measure
nociception related to activity. A difference in pharmacological proﬁle
for pain relief dependent on the type of pain being evaluated has been
reported (Petrella et al., 2002). In that study, pain at rest respondeddiffer-
ently from pain following physical activity (Petrella et al., 2002). In the
same line of thought, it is different to evaluate a drug response innocicep-
tion elicited on the affected joint or nociception in a referred location, i.e.
the paw.
The administration of diclofenac was performed by gavage. In
order to evaluate the possible interference of this procedure on the
nociception parameters evaluated, a group of OA animals followed
the same procedure with the administration of the vehicle alone. No
differences in nociception values were observed indicating that this
procedure does not affect the nociceptive effect observed with diclofe-
nac. This allows us to ensure that the effect observed in OA animals is
due to the drug used and not to phenomena such as stress-induced
analgesia. Furthermore it also shows that the vehicle per se has no effect
on the parameters evaluated.
5. Conclusions
In conclusion, novel andeffective pharmacological therapeutic options
to treat pain in OA patients are needed. However, when using animal
models of OA, it is essential to evaluate nociception parameters rele-
vant to the human condition. Our study showed that the Knee-Bend
and CatWalk tests are useful and reliable methods for the evaluation
of movement-related nociception, the most appropriate parameter
to evaluate the anti-nociceptive efﬁcacy of analgesic drugs in animal
models of OA.
Furthermore they allow themeasurement of nociception in a clinically
relevant way, since an analgesic proﬁle similar to the one described in
humans was observed, therefore indicating their being good predictors
of drug efﬁcacy.
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Phenotypic Alterations of Neurons That Innervate
Osteoarthritic Joints in Rats
Joana Ferreira-Gomes, Sara Ada˜es, Jana Sarkander, and Jose´ M. Castro-Lopes
Objective. Pain is a prominent feature of osteoar-
thritis (OA). To further understand the primary mech-
anisms of nociception in OA, we studied the expression
of the phenotype markers calcitonin gene-related pep-
tide (CGRP), isolectin B4 (IB4), and neurofilament 200
(NF200) in sensory neurons innervating the OA knee
joint in rats.
Methods. OA was induced in rats by intraarticu-
lar injection of 2 mg of mono-iodoacetate (MIA) into the
knee. Neurons innervating the joint were identified by
retrograde labeling with fluorogold in dorsal root gan-
glia (DRG) and colocalized with neurochemical markers
by immunofluorescence. The total number of DRG cells
was determined by stereologic methods in Nissl-stained
sections.
Results. A 37% decrease in the number of
fluorogold-backlabeled cells was observed in rats with
OA when compared with control rats, even though no
decrease in the total number of cells was observed.
However, an increase in the number of medium/large
cell bodies and a decrease in the number of the smallest
cells were observed, suggesting the occurrence of
perikarya hypertrophy. The percentage of CGRP-
positive cells increased significantly, predominantly in
medium/large cells, suggesting the occurrence of a phe-
notypic switch. Colocalization of CGRP and NF200
revealed no significant changes in the percentage of
double-labeled cells, but an increase in the number of
medium/large double-labeled cells was observed. No
differences in the expression of either IB4 or NF200
were observed in fluorogold-backlabeled cells.
Conclusion. These results indicate that MIA-
induced OA causes an up-regulation of CGRP in differ-
ent subpopulations of primary afferent neurons in DRG
due to a phenotypic switch and/or cell hypertrophy
which may be functionally relevant in terms of the onset
of pain in this pathologic condition.
Osteoarthritis (OA) is a highly prevalent chronic
degenerative joint disorder characterized by destruction
of articular cartilage and remodeling of subchondral
bone, leading to structural and functional degradation of
the affected joint (1). Altered joint biomechanics con-
tribute to the loss of joint function and disability (2). The
major symptom of OA is pain that worsens with weight-
bearing and movement (3). Although it has been sug-
gested that afferent innervation of the subchondral
bone, periosteum, synovium, ligaments, and joint cap-
sule could be sources of nociceptive stimuli (4), the
etiology of pain in OA has not been fully determined.
Currently available analgesics have limited efficacy for
OA-related pain; therefore, it is essential to increase the
knowledge of the basic mechanisms of such pain in order
to develop new, more efficient therapeutic strategies.
The generation of joint pain results from activa-
tion of primary afferent nerve fibers (5). Joint afferent
neurons are sensory neurons, the cell bodies of which
are located in the dorsal root ganglia (DRG). These cells
can be classified into various subpopulations based on
their morphology, physiologic characteristics, and neu-
rochemical characteristics (6,7). The large-diameter sen-
sory neurons with myelinated axons, which in physio-
logic conditions do not convey noxious input, and the
medium-diameter neurons with thinly myelinated (A)
axons can be distinguished by their content of phosphor-
ylated heavy-chain neurofilament 200 (NF200) (8). The
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small-diameter sensory neurons, with unmyelinated (C)
axons, can be further subdivided into peptidergic and
nonpeptidergic neurons. The former express neuropep-
tides, such as calcitonin gene-related peptide (CGRP)
and substance P, while nonpeptidergic neurons selec-
tively bind isolectin B4 (IB4) (9,10).
Substance P and CGRP, expressed by nocicep-
tors, are involved in the transmission of nociceptive
input (11–13). CGRP has been shown to be expressed in
fibers supplying the rat knee joint (14) and has been
proposed to be involved in peripheral and central sen-
sitization of joint afferent neurons in inflammatory
arthritis (15,16). In human OA, CGRP has been ob-
served in knee joint synovium (17) and is augmented in
the DRG cells of animals with sodium mono-
iodoacetate (MIA)–induced OA (18). Furthermore, pa-
tients with failed hip arthroplasties who experienced
pain had nerve fibers positive for substance P and CGRP
in the interface membrane (19), while those who did not
have pain lacked these neuropeptide-containing afferent
neurons (20).
It has been established that MIA injection into
the rat knee joint disrupts chondrocyte metabolism,
leading to cell death and subsequent disruption of
articular cartilage (21,22). This process results in his-
topathologic changes very similar to those seen in pa-
tients with OA (23).
To better understand and characterize the under-
lying nociceptive mechanisms in OA, we studied changes
in the sensory neurons innervating the knee joint of rats
with OA, identified by retrograde labeling with fluoro-
gold injected into the diseased knee. Neuronal popula-
tions were classified using antibodies against CGRP,
IB4, and NF200. We also analyzed the distribution of
these markers according to cell size and counted the
number of fluorogold-backlabeled cells and the total cell
number in L3, L4, and L5 DRG. Furthermore, to
investigate the possible occurrence of neurogenesis in
the DRG that contain neurons innervating OA joints, we
analyzed bromodeoxyuridine (BrdU) incorporation in
control rats and rats with OA.
MATERIALS AND METHODS
Animals. Adequate measures were taken to minimize
the pain or discomfort of the rats, and all experimental
procedures were performed in accordance with the European
Communities Council Directive 86/609/EEC and were ap-
proved by the Ethical Committee for Health of the Hospital
Sa˜o Joa˜o, Porto, Portugal.
Adult male Wistar rats (Charles River) weighing 230
30 gm (mean  SEM) were used for these experiments. Rats
were housed with water and food ad libitum and were kept at
a constant temperature of 22°C with controlled lighting (12-
hour light/12-hour dark cycle).
Induction of OA. After being anesthetized with isoflu-
rane, rats were injected, using a Hamilton syringe inserted
through the patellar ligament into the intraarticular space of
the left knee, with 25 l of saline (control group) or 2 mg of
MIA in saline (Sigma-Aldrich). Rats were randomly assigned
to each group.
Behavioral testing. All rats underwent the knee-bend
and CatWalk tests in order to evaluate nociception and
disability. Testing was done in a blinded manner and was
performed on days 0, 3, 6, 10, 13, 17, 20, 24, 27, and 31
postinjection, as described previously (24). Briefly, the knee-
bend test was used to assess the behavioral response to the
normal movement of each knee. The test involved recording
the number of squeaks and/or struggle reactions in response to
5 flexions and 5 extensions of the knee joint. The score for the
test is determined by the type of reaction to each movement of
the joint, according to the following scale: 0  no response,
0.5  struggle to maximal flexion/extension, 1  struggle to
moderate flexion/extension or vocalization to maximal flexion/
extension, and 2  vocalization to moderate manipulations of
the joint. The sum of the recorded reactions (maximum
possible score  20) represents the knee-bend score, an
indication of movement-induced nociception.
The CatWalk test was used to evaluate the disability of
the paw, by measuring the total intensity of the contact area of
each paw. Rats were placed on a glass platform illuminated in
such a way that light was reflected downward only at those
points where the paw touched the glass surface, resulting in a
bright sharp image of the paw print. The platform was moni-
tored by a video camera with a wide-angle objective connected
to video-acquisition software (Ulead VideoStudio). The inten-
sity of the signal depends on the area of the paw that is in
contact with the platform and increases with the pressure
applied by the paw. ImageJ version 1.37 (available at http://
rsbweb.nih.gov/ij/) was used to analyze the images obtained
from 6 random frames of the videos recorded during the rat
evaluation (3 frames with the rat walking and 3 frames with the
rat standing still). The number and intensity of pixels above a
defined threshold were quantified, allowing comparison of the
contact area of and pressure applied by each paw. Results were
expressed as the total intensity of the ipsilateral hind paw as a
percentage of the total intensity of both hind paws.
Retrograde neuron labeling. To identify the cell bodies
of knee joint afferent neurons, 5 l of 2% fluorogold (Fluo-
rochrome) was injected intraarticularly into the left knees of
the rats, 7 days prior to the end of the experiments.
Tissue processing. On day 31 after injection of saline
or MIA, all rats were perfused with 4% paraformaldehyde with
0.1% picric acid. The DRG from L3, L4, and L5 were
dissected, post-fixed, and stored in 30% sucrose with 0.01%
sodium azide. The DRG were sliced in 12-m sections, with
every tenth section collected in the same glass slide, using a
Microm HM 560 cryostat. The knees of the rats were also
dissected, post-fixed, and then decalcified with a buffer con-
taining 7% AlCl3, 5% formic acid, and 8.5% HCl, as described
previously (24). The joints were then cut into 20-m sections
using a cryostat. In order to evaluate the extent of the
histopathologic lesions, sections were then stained with fast
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green and Safranin O, and images were acquired with an
Axioskop 40 microscope equipped with an AxioCam MRc5
camera (Carl Zeiss MicroImaging).
Total cell count. In order to quantify the total number
of DRG neurons, slices of L3, L4, and L5 DRG were stained
by the Nissl method and analyzed using stereologic methods.
The number of neurons per ganglion, N, was estimated using
the formula described by De Hoff and Rhines (25), as follows:
N  Nv . V(ganglion), with V(ganglion) being the volume of the
ganglion, and N3v the numerical density of neurons. The
volume of each ganglion was estimated using a variation of
Cavalieri’s principle on systematic sectioning (26), as follows:
V(ganglion)  kta. The thickness, t, of each section was 12 m.
The reciprocal sampling fraction, k, was 10, because every
tenth section was used for measurements; therefore, the
sampling fraction was 1/10. The slice area, a, was measured
using ImageJ version 1.37. The Nv value was estimated using a
systematic random sampling procedure (26). The numerical
density was estimated as follows: Nv  NA/(d  t  2h), whereNA is the neuron density (number of neurons counted per
m2), d is the mean of the diameter of the counted neurons, t
is the thickness of every section, and h is the diameter of the
smallest counted neuron in the ganglion. The value for NA was
calculated according to the number of neurons that were
counted within a predefined area of a 2-dimensional counting
frame.
Immunohistochemical analysis. Slides containing ev-
ery tenth section of L3, L4, and L5 DRG were used for
immunofluorescence reactions for CGRP, IB4, and NF200, as
well as for double-labeling for CGRP and NF200. Sections
were incubated with one of the following: rabbit anti-CGRP
(1:500; Chemicon) overnight at room temperature, Alexa
Fluor 488–conjugated IB4 (1:750; Molecular Probes) for 1
hour at room temperature, and mouse anti-NF200 (1:400;
Sigma) for 48 hours at 4°C. For CGRP and NF200 double-
labeling, incubation was carried out overnight at room temper-
ature. Secondary detection was performed with Alexa Fluor
568–conjugated donkey anti-rabbit secondary antibody for
CGRP and with Alexa Fluor 488–conjugated goat anti-mouse
secondary antibody for NF200 (1:1,000 dilution) for 1 hour at
room temperature (Molecular Probes). Slides were mounted
with ProLong Gold antifade mounting medium (Molecular
Probes) and visualized using a Zeiss Imager Z1 fluorescence
microscope (Carl Zeiss MicroImaging). Images were acquired
at 100 magnification using an AxioCam MRm with AxioVi-
sion 4.6 software (Carl Zeiss MicroImaging) and analyzed with
Image Pro-Plus 6.0 (Media Cybernetics). The total number of
cells retrogradely labeled with fluorogold in each ganglion was
estimated using a stereologic method similar to that described
for counting the total cell number, in which neuron density was
calculated without using any sampling procedures. Every
fluorogold-backlabeled cell was counted, its area was mea-
sured, and the percentage of cells immunolabeled for CGRP,
IB4, and NF200 was determined.
BrdU incorporation and detection. Another group of
control rats (n  4) and rats with OA (n  4) was used for this
experiment, during which the same methods as previously
described were used for OA induction, behavioral assessment,
and tissue processing. After receiving an injection of either
MIA or saline, rats were injected intraperitoneally with 50
mg/kg BrdU (Sigma), twice daily from day 1 until day 28.
BrdU incorporation in neurons was detected by immu-
nofluorescence. Antigen retrieval was performed by incubating
the slides in HCl 1M at 60°C for 30 minutes. Slides were
incubated for 48 hours at 4°C in sheep anti-BrdU antibody
(Acris Antibodies) at a 1:100 dilution and co-labeled with a
mouse antibody for the neuronal nuclei marker NeuN (Chemi-
con) at a 1:200 dilution. Secondary detection was performed by
incubation with Alexa Fluor 488–conjugated donkey anti-
sheep and Alexa Fluor 594–conjugated donkey anti-mouse
secondary antibodies (Molecular Probes) at a 1:1,000 dilution.
Slides and images were processed as described above.
Statistical analysis. Results are presented as the
mean  SEM. For behavioral data, the comparison between
groups was performed with the Mann-Whitney test. The
Mann-Whitney test was also used to compare the cell count
and immunohistochemical data obtained from rats with OA
with that from control rats. P values less than 0.05 were
considered significant.
RESULTS
Histologic analysis of the knee joint. On day 31,
the structure of the cartilage and subchondral bone in
control rats was normal (Figure 1A). In contrast, all rats
with OA demonstrated erosion of the hyaline cartilage
with depletion of chondrocytes and proteoglycans from
the extracellular matrix, as indicated by the marked
reduction of Safranin O staining (Figure 1B). The
articular surface of the OA joints showed fissures, and
thickening of the subchondral bone was observed (Fig-
ure 1B).
Nociceptive evaluation. Movement-induced noci-
ception was evaluated through the knee-bend and Cat-
Walk tests. In control rats, scores for the knee-bend test
throughout the study did not differ overall from the
baseline value (Figure 1C). There was a slight increase in
the knee-bend score beginning on day 3 after injection,
which may have resulted from the knee injection itself.
In the OA group, there was an increase in the knee-bend
score for the injected knee, from 2.2  0.8 (mean 
SEM) on day 0 to 12.5  2.3 on day 3 (Figure 1C). The
knee-bend test values for the injected knee in the OA
group were significantly different (P  0.05) from those
for the control group at all time points after injection
(Figure 1C).
In the CatWalk test, the ipsilateral paw print
intensity in control rats was a mean  SEM of 49.3 
0.6% of the paw print intensity of both hind paws, and
no change was observed throughout the study (Figure
1D). In the rats with OA, there was a significant
decrease in the total intensity of the ipsilateral paw print
when compared with the control group (P  0.05). The
intensity of the ipsilateral paw print was reduced from a
mean  SEM of 46.9  1.2% on day 0 to 24.0  4.3%
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on day 3 after injection (Figure 1D) and remained
significantly reduced compared with controls throughout
the study (P  0.05) (Figure 1D).
Retrograde labeling of afferent neurons. Retro-
grade labeling through intraarticular injection of fluoro-
gold allowed identification of the cell bodies of knee
joint primary afferent neurons in L3, L4, and L5 DRG.
The mean  SEM total number of backlabeled cells in
the DRG of control rats was 598  34 (40% in L3, 46%
in L4, and 14% in L5) (Table 1 and Figure 2A). The rats
with OA showed a 37% decrease in the total number of
fluorogold-labeled cells (P 0.01), to a mean SEM of
376  47 (Table 1 and Figure 2A). This decrease in the
number of fluorogold-labeled cells that innervate the
OA knee was more pronounced in small cells (perikarya
section area750 m2), although it was also observed in
the medium-sized cells (750–1,500 m2) (Figure 2B).
The decrease was statistically significant for cells with a
perikarya section area 1,000 m2. There was a slight
increase, although it was not statistically significant, in
Figure 1. Histopathology and nociceptive behavior of rats with osteoarthritis (OA) and control
rats. A and B, On day 31, the structure of the cartilage (C) and subchondral bone (SB) in control
rats was normal (A). In contrast, rats with OA demonstrated discontinuity (arrows) and erosion of
the superficial zone, with depletion of chondrocytes and proteoglycans from the extracellular
matrix, as indicated by a marked reduction in Safranin O staining (B).M  meniscus. C, Rats with
OA showed an increase in the knee-bend score for the injected knee from day 3 onward, while
scores for the control rats did not differ throughout the study. D, In control rats, no change in the
percentage of the ipsilateral paw print total intensity as assessed by the CatWalk test was observed.
Rats with OA showed a decrease in the total ipsilateral paw print intensity from day 3 onward.
Values in C and D are the mean  SEM.   P  0.05;   P  0.01 versus controls, by
Mann-Whitney test. Bar  100 m.
Table 1. Characteristics of the cell bodies of knee joint primary
afferent neurons in L3, L4, and L5 dorsal root ganglia*
Control rats Rats with OA
Total cells, no. 14,594  805 16,844 776
FG-backlabeled cells, no. 598 34 376 47†
CGRP positive, % 43.4  2.0 55.9 0.9†
IB4 positive, % 1.5  0.5 3.0 1.3
NF200 positive, % 54.8  2.3 52.8 2.7
CGRP positive/NF200 23.4  3.0 29.9 3.3
positive, %
* Values are the mean SEM. OA osteoarthritis; FG fluorogold;
CGRP  calcitonin gene-related peptide; IB4  isolectin B4;
NF200  neurofilament 200.
† P  0.01 versus controls, by Mann-Whitney test.
Figure 2. Total number (A) and distribution (B) of fluorogold (FG)–
backlabeled cells in the L3, L4, and L5 ipsilateral dorsal root ganglia of
control rats and rats with osteoarthritis (OA). Bars show the mean and
SEM.   P  0.05;   P  0.01 versus controls, by Mann-Whitney
test.
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the number of fluorogold-labeled cells larger than 1,500
m2.
Total cell number. The total DRG cell number,
as determined by stereologic methods in Nissl-stained
sections, was similar in control rats and rats with OA
(Figure 3A). However, the distribution of these cells per
perikarya section area showed some differences (Figure
3B). There was a small decrease in the total number of
the smallest cells (250 m2) and an increase in the
number of medium-to-large cells (1,000 m2) in rats
with OA compared with control rats. The increase was
statistically significant only in cells with a size of 1,000–
1,250 m2 and those with a size 1,500 m2 (P  0.05).
Immunohistochemical analysis of immunoreac-
tivity to CGRP, IB4, NF200, and CGRP plus NF200.
Cells backlabeled with fluorogold were analyzed for
immunoreactivity to the neurochemical markers CGRP,
IB4, and NF200, as well as for CGRP plus NF200. The
percentage of CGRP-positive retrogradely labeled cells
in rats with OA was increased compared with that in
control rats (Figures 4A and B and Figure 5A). In
control rats, 43.4  2.0% (mean  SEM) of the
fluorogold-labeled cells were CGRP positive, while the
value in rats with OA was to 55.9  0.9% (Table 1 and
Figure 5A). Such an increase was more pronounced in
small cells (0–250 m2) and medium/large cells (1,000
m2) (Figure 5B); this difference was statistically signif-
icant for cells with a size of 1,000–1,250 m2 and those
with a size 1,500 m2 (P  0.05).
The mean  SEM percentage of IB4-positive
retrogradely labeled cells in control rats was 1.5 0.5%,
which was not significantly different from the percentage
in rats with OA (Table 1). In addition, no significant
differences between control rats and rats with OA were
observed within each area range. The percentage of
NF200-positive backlabeled cells also was not different
in control rats and rats with OA, with mean  SEM
values of 54.8  2.3% and 52.8  2.7%, respectively
(Table 1).
Figure 4. Images representative of immunofluorescence reactions for calcitonin gene-related peptide (CGRP; red) (A and B) and CGRP plus
neurofilament 200 (green) (C and D) in sections of ipsilateral dorsal root ganglia obtained from control rats (A and C) and rats with osteoarthritis
(B and D). Fluorogold labeling is shown as blue. Bar  50 m.
Figure 3. Total number (A) and distribution (B) of cells in the L3, L4,
and L5 ipsilateral dorsal root ganglia of control rats and rats with
osteoarthritis (OA). Bars show the mean and SEM.   P  0.05
versus controls, by Mann-Whitney test.
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In the double-immunofluorescence reactions for
CGRP and NF200 (Figures 4C and D), no significant
difference was observed in the percentage of double-
labeled cells between the 2 groups of rats (Figure 5C),
with 23.4 3.0% (mean SEM) double-labeled cells in
control rats and 29.9  3.3% in rats with OA (Table 1).
Despite no significant difference in the total percentage
of double-labeled cells, differences were observed within
each perikarya area range (Figure 5D). In rats with OA,
the percentage of cells ranging in size from 250 m2 to
500 m2 decreased, and the percentage of larger-sized
cells increased, although this difference was significant
only for cells with a size of 1,000–1,250 m2 and those
larger than 1,750 m2 (P  0.05) (Figure 5D).
BrdU incorporation in DRG. Neuronal prolifer-
ation was assessed using the thymidine analog BrdU,
which incorporates into DNA during mitosis. Cellular
colocalization of BrdU and NeuN was not observed in
the DRG of either control rats or rats with OA.
DISCUSSION
Chronic pain is the most prominent symptom of
OA, but it is also the least-studied symptom. In this
study, intraarticular injection of MIA produced a stable
model of knee OA. Using the knee-bend and CatWalk
tests, we were able to assess movement-related nocicep-
tion, the principal trait of OA, which occurred in all rats
that underwent injection of MIA into the knees, as
previously described (24).
In control rats, cells that were retrogradely la-
beled with fluorogold were present mainly in L3 and L4,
and to a lesser degree, in L5, which is consistent with the
findings of previous studies (27). Conversely, when the
injection of fluorogold was into the epiphysis, there was
a predominance of cells in L3 and fewer in L4 and L5
(27). This finding provided indirect evidence of the
accuracy of the intraarticular injection and the retro-
grade labeling. Surprisingly, there was a 37% decrease in
the number of fluorogold-backlabeled cells in the rats
with OA. This reduction may be attributable to cell loss,
axonal loss or retraction, or a change in the uptake of
fluorogold, as discussed below.
The physical dissector principle (28), which was
used in this study, is an unbiased stereologic method
involving systematic sampling that can be used for
estimating neuron density. The total cell numbers in the
DRG obtained in our control rats was consistent with
those observed by other investigators (29,30). Using
Figure 5. Immunoreactivity of calcitonin gene-related peptide (CGRP) and CGRP plus neurofilament 200 (NF200) in
the L3, L4, and L5 ipsilateral dorsal root ganglia of control rats and rats with osteoarthritis (OA). A, Percentage of
CGRP-positive fluorogold (FG)–backlabeled cells. B, Percentage of CGRP-positive FG-backlabeled cells per neuronal
perikarya cross-sectional area range. C, Percentage of CGRP plus NF200–positive FG-backlabeled cells. D, Percentage
of CGRP plus NF200–positive FG-backlabeled cells per neuronal perikarya cross-sectional area range. Bars show the
mean and SEM.   P  0.05;   P  0.01 versus controls, by Mann-Whitney test.
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slices adjacent to those in which the number of
fluorogold-backlabeled cells was counted, we observed
no decrease in the total cell number in the DRG of rats
with OA, thus excluding the possibility of cell loss.
Although there was no decrease in the total cell
number, changes in the distribution of cell sizes were
observed, namely, a decrease in the number of the
smallest cells and an increase in the number of medium/
large cells, suggesting that cell hypertrophy may be
occurring in the DRG innervating OA joints. Because
there was a small (although not statistically significant)
increase in the total cell number in the DRG of rats with
OA, and because postnatal neurogenesis in the DRG
has been described (31,32), we evaluated BrdU incorpo-
ration into the neurons of the DRG to verify whether
this small increase could be attributable to neurogenesis
occurring during disease progression. However, no co-
localization of BrdU with NeuN was observed, indicat-
ing that neurogenesis in the DRG did not occur in rats
with OA during the time period studied.
Changes in the fluorogold-uptake mechanism
could explain the reduced retrograde labeling observed
in rats with OA. Although this possibility was not
addressed in our study, because the decrease was ob-
served only in a subset of neurons innervating the knee
joint (predominantly the small but also the medium-
sized cells), axonal loss or retraction or another form of
injury in the nerve terminals may be occurring. The
presence of activating transcription factor 3, a marker of
neuron damage, in the DRG neurons of rats treated with
MIA (33) also suggests that peripheral nerve injury may
be occurring, leading to increased expression of this
transcription factor in the cell body.
In the present study, we demonstrated CGRP
and NF200 expression in DRG neurons that innervate
the rat knee joint. Mach et al (4) also showed that the
mouse femur was innervated by CGRP-expressing fibers
and myelinated primary afferent nerve fibers immuno-
reactant for the mouse monoclonal antibody RT97.
These include A, A, and C fibers that transmit sensory
input from the periphery to the central nervous system.
In control rats, 43% of the total fluorogold-
backlabeled neurons were CGRP positive, and these
cells were mainly small and medium-sized. CGRP-
containing neurons convey nociceptive information to
the dorsal horn (7,34), and CGRP is known to be
increased in DRG and spinal cord dorsal horns in
different pain models (35,36). In rats with OA, the
percentage of CGRP-positive backlabeled cells in-
creased to 56%. This increased CGRP expression,
which was also observed by Fernihough et al (18), may
be one of the factors leading to pain in this pathologic
process. Administration of a CGRP antagonist reduced
the response of hyperexcitable spinal neurons to both
innocuous and noxious pressure applied to the inflamed
joint (37). Furthermore, extracorporeal shock wave ther-
apy improved the walking ability of and pain relief for
rats with OA, possibly by reducing the ratio of CGRP-
positive DRG neurons in these rats when compared with
controls (38). Therefore, one could expect that a CGRP
receptor antagonist would cause an attenuation of the
mechanical allodynia observed in this model.
We observed an alteration of the CGRP cell size
distribution pattern in rats with OA that has not been
reported previously. CGRP expression was increased
mainly in the population of cells that were medium/
large. Moreover, expression of CGRP was observed in
cells bodies with a cross-sectional area1,750 m2 from
rats with OA, but such expression was not observed in
control rats. The fact that large cells start to express
CGRP was surprising, and this could result from a
phenotypic switch of these cells to assume the charac-
teristics of nociceptors. A phenotypic switch has already
been observed in rats with cervical facet injury, in which
the mean cross-sectional area of fluorogold-labeled
CGRP-immunoreactive cells increased (39). Further-
more, peripheral nerve injury evokes a phenotypic
switch in brain-derived neurotrophic factor expression,
in which small neurons switch off their normal synthesis
of brain-derived neurotrophic factor, whereas large ones
acquire a brain-derived neurotrophic factor phenotype
(40,41).
The observed expression of CGRP in large cells
may also be attributable to hypertrophy of small or
medium-sized cells that already expressed CGRP. This
hypertrophy could also account for the alteration of the
cell size distribution pattern observed in Nissl-stained
sections, as discussed previously. Neuronal hypertrophy
has already been observed in DRG neurons that project
to the obstructed ileum of rats (42). Other investigators
have also described neuronal hypertrophy in other ner-
vous system areas and suggest that this event is induced
by nerve growth factor (NGF) (43,44). Very recently,
NGF overexpression in the knee has been reported in
another experimental model of OA, elicited by destabi-
lization of the medial meniscus, in which case anti-NGF
therapy had an analgesic effect (45). We can speculate
that if the fibers expressing CGRP are damaged, NGF
may act on them with a protective role, promoting their
survival and, as a result, neurons bearing TrkA receptors
may hypertrophy. However, cell swelling has also been
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observed and described as being part of cromatolysis, a
neuronal response to axonal injury (46,47).
Neurons binding IB4 belong to a population of
small nonpeptidergic neurons that normally account for
32% of DRG neurons (7). These neurons are observed
mainly in cutaneous afferent neurons and rarely in joints
(48). Hence, the scarce binding of IB4 in the DRG
neurons of control rats is not surprising. The number of
IB4-positive neurons remained unaltered in rats with
OA. In contrast, this marker was useful to ensure that
the fluorogold injection was articulation specific. In fact,
if there had been leakage of fluorogold into the skin, the
number of IB4-positive neurons would have been much
higher.
NF200 is a marker of large and small myelinated
neurons. In general, large NF200-positive neurons trans-
mit proprioception, while small NF200-positive neurons
transmit nociception (49). No differences were observed
in the number of NF200-positive neurons in rats with
OA compared with controls. In the double immunore-
action for NF200 and CGRP, there was not a significant
difference in the total number of backlabeled cells that
were positive for the 2 markers, but there were differ-
ences in the pattern of cell size distribution between the
2 groups. Because the observed decrease in the percent-
age of triple-labeled neurons in the size range 250–500
m2 does not seem sufficient to account for the increase
observed in larger cells, it is likely that there is a small,
nonsignificant increase in the total number of CGRP
plus NF200–backlabeled neurons. We can also speculate
that neuronal cell hypertrophy may coexist with a phe-
nomenon in which large cells switched to a CGRP
phenotype.
Joint afferent neurons show increased activity
when a noxious stimulus is applied, leading to the
activation of central mechanisms and the initiation of
pain (50). Unique and specific neurochemical/
morphologic changes are involved in the generation and
maintenance of pain. Having insight into the neurobio-
logic mechanisms that underlie each pain state, particu-
larly OA-related pain, is crucial for developing more
efficient therapeutic strategies. The present study indi-
cates that MIA-induced OA causes a differential regu-
lation of CGRP in different subpopulations of sensory
neurons in the DRG. The phenotypic switch and/or cell
hypertrophy and the differential increase in CGRP
expression, shown here for the first time, may have
functional implications in neuronal plasticity and gener-
ation of pain in this pathologic condition that require
further studies. In contrast, cell hypertrophy and de-
creased fluorogold uptake point to neuronal or peri-
pheral axonal injury, which is currently being investi-
gated.
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Dose-dependent expression of neuronal injury
markers during experimental osteoarthritis
induced by monoiodoacetate in the rat
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Abstract
Background: It was recently reported that the mono-iodoacetate (MIA) experimental model of osteoarthritis (OA)
courses with changes of neurons innervating the affected joints that are commonly interpreted as a neuronal
response to axonal injury. To better characterize these changes, we evaluated the expression of two markers of
neuronal damage, ATF-3 and NPY, and the growth associated protein GAP-43, in primary afferent neurons of OA
animals injected with three different doses of MIA (0.3, 1 or 2 mg). Measurements were performed at days 3, 7, 14,
21 and 31 post-MIA injection.
Results: OA animals showed the characteristic histopathological changes of the joints and the accompanying
nociceptive behaviour, evaluated by the Knee-Bed and CatWalk tests. An increase of ATF-3 expression was detected
in the DRG of OA animals as early as 3 days after the injection of 1 or 2 mg of MIA and 7 days after the injection of
0.3 mg. NPY expression was increased in animals injected with 1 or 2 mg of MIA, at day 3 or in all time-points,
respectively. From day 7 onwards there was a massive increase of GAP-43 expression in ATF-3 cells.
Conclusions: The expression of the neuronal injury markers ATF-3 and NPY as well as an up-regulation of GAP-43
expression, indicative of peripheral fibre regeneration, suggests that axonal injury and a regeneration response may
be happening in this model of OA. This opens new perspectives in the unravelling of the physiopathology of the
human disease.
Keywords: Osteoarthritis, Pain, Mono-iodoacetate, ATF-3, NPY, GAP-43, Neuronal injury
Background
Osteoarthritis (OA) is a chronic degenerative joint dis-
order that affects a large proportion of the population,
being the most common type of articular disorders.
Patients’ major clinical manifestation is chronic pain that
typically worsens with weight bearing and activity or
movement of the affected joint [1]. Joint pain results
from the activation of primary afferent nerve fibres at
the joint, but the exact mechanisms of pain in OA re-
main inadequately understood [2,3].
Several studies in animal models of OA have been per-
formed to unravel the nociceptive mechanisms in this
pathology. The experimental model most commonly used
is the intra-articular injection of the metabolic inhibitor
mono-iodoacetate (MIA) into the knee joint of the rat.
This compound inhibits the activity of glyceraldehyde-3-
phosphate dehydrogenase of articular chondrocytes, lead-
ing to disruption of glycolytic energy metabolism and syn-
thetic processes and eventually to cell death [4,5]. Hence,
a progressive loss of articular cartilage and lesions of the
subchondral bone are observed in this model, which have
been described as closely resembling those observed in
OA patients [4].
A marker of neuronal damage, ATF-3, has been shown
in dorsal root ganglia (DRG) neurons, 8 and 14 days
post-MIA injection [6]. Moreover, we observed an in-
crease in CGRP in DRG cells 31 days after MIA injec-
tion, which occurred mainly in the medium and large
cell size population that in control animals did not ex-
press this peptide [7]. This phenomenon could result
from a phenotypic switch of these cells to assume char-
acteristics of nociceptors, or from a hypertrophy of small
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or medium size cells that already expressed CGRP, since
an alteration of the total cell size distribution pattern
was also observed [7]. Notwithstanding, both phenom-
ena have been described as a neuronal response to
axonal injury [8-11]. Furthermore, we also observed a
reduced retrograde labelling of Fluorogold in DRG neu-
rons of OA animals following injection of the tracer into
the affected knee, which could be due to axonal loss or
retraction, or another form of injury of the nerve term-
inals [7]. These data raise the question of a possible
damage of the joint afferents that would provoke
changes in the soma of these neurons, at the DRG level,
that resemble those occurring during a peripheral
neuropathy.
To better understand and characterize the possible oc-
currence of neuronal injury in the MIA model of OA,
we evaluated the expression of ATF-3 and NPY in DRG
neurons at different time-points of disease progression,
from 3 days after MIA injection until 31 days. ATF-3 is
a transcription factor that, as previously mentioned, has
been considered a marker of neuronal damage since it is
elevated in the DRG neurons following peripheral axonal
injury [12,13]. Similarly, NPY is a neurotransmitter that
under normal conditions is barely detected in DRG neu-
rons [14,15], but peripheral nerve injury induces its ex-
pression in their cell bodies [16,17]. Additionally, we
investigated whether a regeneration process was
occurring as part of a neuronal response to a hypothet-
ical injury of peripheral nerves. The growth-associated
protein GAP-43 served that purpose since its expression
is up-regulated in regenerating peripheral fibres [18-20].
Finally, since there is a correlation between MIA con-
centration and the degree of sensitization of afferent
nerve fibres [21], three different doses of MIA were used
in this study in order to investigate whether the
observed effects were dose-dependent.
Results
Histological analysis of the knee joint
No damage of the knee joint could be observed in
saline-injected control animals at all time-points studied
(data not shown). In contrast, the histopathological find-
ings observed in OA animals were dose and time-
dependent. At day 3, no alteration or a minimal decrease
in the proteoglycan staining was observed in animals
injected with 0.3 mg of MIA, resulting in a slight de-
crease of Safranin-O staining (Figure 1A). This became
more apparent at day 14, when some irregularity in the
superficial zone of the articular cartilage was observed
(Figure 1C). At day 21, chondrocyte death and loss of
intercellular matrix was observed (Figure 1D), and this
was more pronounced and accompanied by a marked
decrease of the thickness of the articular cartilage at day
31 (Figure 1E).
Figure 1 Histopathology of knee sections of OA animals. Rats received an intra-articular injection of 0.3 (A-E), 1 (F-J) or 2 mg (K-O) of MIA
and were sacrificed at 3 (A, F, K), 7 (B, G, L), 14 (C, H, M), 21 (D, I, N) and 31 days (E, J, O) post-MIA injection. Each rat knee image is representative
of a group of 5 animals. The sections were stained with Safranin-O that stained cartilage and its proteoglycan content and Fast Green, which
stains bone. Histopathological alterations, namely decrease in proteoglycan staining, chondrocyte death, loss of intercellular matrix, decrease of
the thickness of the articular cartilage, erosion of the hyaline articular cartilage and exposure of the subcondral bone, were dose and
time-dependent. C indicates cartilage; SB, subchondral bone; M, meniscus. Scale bar: 200 μm.
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A minimal decrease in the proteoglycan staining was
observed at day 3 in animals injected with 1 mg of MIA,
becoming more pronounced at day 7 (Figure 1F-G). At
day 14, some chondrocyte death and loss of matrix led
to decreased thickness of the articular cartilage, that was
more evident at day 21 (Figure 1H-I). At day 31, the ar-
ticular surface showed fissures and subchondral bone
become exposed (Figure 1J).
With the higher dose of MIA (2 mg), proteoglycan
staining loss from the extracellular matrix of the articu-
lar cartilage was more pronounced at day 3 than with
the lower doses (Figure 1K). Moreover, chondrocyte
death was already apparent at day 7, and at day 14 there
was a marked loss of extracellular matrix and a decrease
of the thickness of the articular cartilage, which pre-
sented some fissures (Figure 1L-M). A complete erosion
of the hyaline articular cartilage and exposure of the
subcondral bone was observed at day 21, while thicken-
ing of the subchondral bone was apparent at day 31
(Figure 1N-O).
Behavioural testing
Knee-Bend and CatWalk tests were used to evaluate the
movement-induced nociception caused by different
doses of MIA. Overall, changes in nociception were
concentration- and time-dependent (Figures 2 and 3).
Knee-Bend scores of saline-injected control animals
were similar to those observed at baseline in all time-
points studied. When compared to the baseline values
and to the control animals, an increase in the Knee-
Bend score was evident as early as day 3 post-injection
for the 3 concentrations of MIA (Figure 2). The animals
receiving 0.3 mg of MIA showed the lowest Knee-Bend
score. The score, which was significantly higher than
baseline levels at all time-points studied (P<0.05;
Figure 2), was increased at day 3, slightly reducing from
then until day 17, when it started to increase again.
Animals receiving 1 or 2 mg of MIA showed a similar
high Knee-Bend score at day 3 (Figure 2). After this ini-
tial phase of disease progression, Knee-Bend scores of
animals injected with 2 mg were higher than those of
animals injected with 1 mg, while at latter stages no dif-
ferences were observed. In fact, the Knee-Bend scores of
animals injected with 1 mg of MIA showed an evolution
pattern similar to that observed with the 0.3 mg con-
centration (Figure 2), with a marked increase at day 3,
reducing from that time-point till day 13, and a fur-
ther increase at day 17, reaching values similar to day
3 from day 24 onwards. The evolution pattern of the
animals injected with 2 mg of MIA was smoother, re-
ducing very slightly after day 3 and returning to these
levels from day 24 onwards (Figure 2). At day 31, ani-
mals receiving the three different doses showed similar
Knee-Bend scores.
The percentage of ipsilateral paw-print intensity, as
measured by the CatWalk test, followed a pattern that
was also concentration- and time-dependent (Figure 3).
Figure 2 Evolution of the Knee-Bend score of animals injected
with saline (control; n = 5) or 0.3, 1 or 2 mg of MIA (OA; n = 25/
group) on various days after the injection until the day of
sacrifice (3, 7, 14, 21, 31). At each sacrifice time-point 5 animals
per group were euthanized. Baseline score was determined for all
animals prior to the injection (day 0). * P < 0.05, ** P < 0.01,
*** P < 0.001 significantly different from baseline values for the
0.3 mg dose of MIA; ## P < 0.01, ### P< 0.001 significantly different
from baseline values for the 1 mg dose of MIA; } P < 0.05, }} P < 0.01,
}}} P < 0.001 significantly different from baseline values for the 2 mg
dose of MIA (Repeated Measures ANOVA followed by LSD post-hoc
test).
Figure 3 Evolution of the percentage of the ipsilateral
paw-print total intensity, assessed in the CatWalk test, of
animals injected with saline (control; n = 5) or 0.3, 1 or 2 mg of
MIA (OA; n = 25/group) on various days after the injection until
the day of sacrifice (3, 7, 14, 21, 31). At each sacrifice time-point,
5 animals per group were euthanized. Baseline score was
determined for all animals prior to injection (day 0). * P < 0.05,
*** P< 0.001 significantly different from baseline values for the 0.3 mg
dose of MIA; # P< 0.05, ## P< 0.01, ### P<0.001 significantly different
from baseline values for the 1 mg dose of MIA; } P<0.05, }}} P<0.001
significantly different from baseline values for the 2 mg dose of MIA
(Repeated Measures ANOVA followed by LSD post-hoc test).
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Animals injected with 0.3 mg of MIA showed the least
decrease in the ipsilateral paw-print intensity. At most
time-points, the ipsilateral paw-print intensity of these
animals were significantly below baseline levels and
below levels of control animals, being not significantly
different from baseline values only at days 17 and 24
(Figure 3). Animals injected with 1 or 2 mg of MIA
showed a reduced ipsilateral paw-print intensity signifi-
cantly different from baseline levels and from control
animals at all time-points evaluated (P<0.05; Figure 3),
which was more pronounced in the animals injected
with 2 mg (with the exception of day 24 that was not
significantly different for this dose).
The temporal profile observed in the CatWalk test was
similar for the three MIA doses. There was an initial de-
crease in the ipsilateral paw-print intensity at day 3, fol-
lowed by a slight increase until days 13–17, decreasing
thereafter. At day 31, the ipsilateral paw-print intensity
observed was similar for the OA animals injected with
the different MIA doses (Figure 3).
No differences in the ipsilateral paw-print intensity
were observed in the saline-injected animals throughout
the study.
Immunohistochemistry
The number of neurons expressing ATF-3 and NPY was
analysed in animals injected with saline and with 0.3, 1
or 2 mg of MIA, at days 3, 7, 14, 21 and 31 post-injec-
tion. FG was injected in all animals 7 days prior to sacri-
fice. Because both ATF-3 and NPY expression was
observed in both FG positive and FG negative cells, and
since, as already mentioned, a reduced retrograde
labelling of FG in the DRG of OA animals was observed
[7], we chose to show the numerical data as the total
number of neurons expressing ATF-3 or NPY per sec-
tion rather than the percentage of FG labelled cells that
were immunopositive. The temporal profile and dose-
related expression was different for the two markers
evaluated (Figures 4C and 5C).
The expression of GAP-43 was evaluated in ATF-3
positive cells, in animals injected with saline and
with 2 mg of MIA, at days 3, 7, 14 and 21 post-injection
(Figures 6). Since at 31 days ATF-3 expression in the
2 mg group of animals is at baseline levels, this time-
point was excluded in this analysis.
Expression of ATF-3 in DRGs during MIA-induced OA
Baseline ATF-3 expression was similar in control ani-
mals at all time-points studied in both the ipsilateral and
contralateral DRG, as well as in the contralateral DRG
of OA animals. There was an increase of the number of
neurons expressing ATF-3 in ipsilateral DRG of MIA-
injected animals, which was dose and time-dependent
(Figure 4). At day 3, no changes were observed in ani-
mals injected with 0.3 mg of MIA, but at day 7 there
was an upregulation of the number of neurons expres-
sing ATF-3 in the DRG (P<0.05; Figure 4). This upregu-
lation was maintained at day 14, increasing further at
days 21 and 31.
Animals injected with 1 mg of MIA showed an in-
crease of the number of neurons expressing ATF-3 sig-
nificantly different from control animals as early as day
3 (from 0.8 ± 0.1 cells/section in control animals to
2.4 ± 0.4 cells/section in OA animals; P<0.01). The
Figure 4 ATF-3 expression in L3, L4 and L5 ipsilateral DRG. Animals received an intra-articular injection of saline (control) or 0.3, 1 or 2 mg of
MIA (OA) and were sacrificed at 3, 7, 14, 21 and 31 days post-injection. A and B are images representative of immunofluorescence reactions for
ATF-3 from control rats (A) and rats injected with 2 mg of MIA (B) sacrificed at 7 days. * P < 0.05, ** P < 0.01 significantly different from controls
(Mann–Whitney test).
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number of neurons expressing ATF-3 declined slightly
until day 14, increasing again at day 21. At day 31, the
number of neurons expressing ATF-3 decreased again,
though it was significantly higher than the baseline ex-
pression observed in control animals (P<0.01; Figure 4).
The dose of 2 mg of MIA induced a marked increase
in the number of neurons expressing ATF-3 at day 3
(from 0.8 ± 0.1 cells/section in control animals to
4.8 ± 0.9 cells/section in OA animals; P<0.01). This
upregulation was maintained at day 7, decreasing signifi-
cantly to baseline levels at day 14. At day 21, a further
increase of the number of neurons expressing ATF-3
was observed (2.9 ± 0.7 ATF-3 positive cells/section),
significantly different from control animals (P<0.05;
Figure 4). At day 31, the number of neurons expres-
sing ATF-3 returned again to baseline levels.
The number of neurons expressing ATF-3 was higher
with the 2 mg dose of MIA, therefore evaluation of cell
Figure 5 NPY expression in L3, L4 and L5 ipsilateral DRG. Animals received an intra-articular injection of saline (control) or 0.3, 1 or 2 mg of
MIA (OA) and were sacrificed at 3, 7, 14, 21 and 31 days post-injection. A and B are images representative of immunofluorescence reactions for
NPY from control rats (A) and rats injected with 2 mg of MIA (B) sacrificed at 7 days. * P < 0.05, ** P < 0.01 significantly different from controls
(Mann–Whitney test).
Figure 6 GAP-43 expression in ATF-3 positive cells in L3, L4 and L5 ipsilateral DRG. Animals received an intra-articular injection of saline
(control) or 2 mg of MIA (OA) and were sacrificed at 3, 7, 14 and 21 days post-injection. A and B are images representative of
immunofluorescence reactions for ATF-3 plus GAP-43 in sections of ipsilateral DRG from control rats (A) and rats injected with 2 mg of MIA (B)
sacrificed at 7 days. .
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size range was performed in these animals. ATF-3 ex-
pression was observed across all neuronal size ranges
(Figure 7). At 3 and 7 days the expression followed the
normal distribution pattern, but at day 14, when there
was a decrease of the number of neurons expressing
ATF-3, it was as a consequence of decreased expression
in small and medium size cells (Figure 7).
Expression of NPY in DRGs during MIA-induced OA
Similarly to ATF-3 expression, the increase of NPY ex-
pression profile was dose and time-dependent (Figure 5).
A very low baseline expression was observed in control
animals at all time-points studied, and in the contralat-
eral DRG of OA animals (data not shown). In the ani-
mals injected with 0.3 mg of MIA, the number of
neurons expressing NPY in the ipsilateral DRG was at
baseline levels at day 3. Thereafter, a slight increase of
the number of neurons expressing NPY occurred until
days 14 and 21, decreasing again at day 31. Nevertheless,
none of these very modest differences reached statistical
significance (Figure 5).
Conversely, an increase in the number of neurons
expressing NPY was observed at day 3 in the animals
injected with 1 mg of MIA (from 0.1 ± 0.0 cells/section
in control animals to 0.5 ± 0.1 cells/section in OA ani-
mals; P<0.01). The number of neurons expressing NPY
maintained thereafter, returning to baseline levels at
31 days (Figure 5).
The dose of 2 mg of MIA induced a significant in-
crease of the number of neurons expressing NPY imme-
diately at day 3, which was more striking at day 7 (with
5.0 ± 2.1 cells/section; P<0.01; Figure 5). At day 14, the
number of NPY cells were similar to that observed at
day 3, remaining sustained at day 21. At day 31, the
number of neurons expressing NPY was similar to con-
trol animals.
As for ATF-3 expression, NPY expression was
observed across all neuronal size range and at all time-
points followed the normal distribution pattern (data
not shown).
Correlation between ATF-3 and NPY with behavioural
data during MIA-induced OA
In an attempt to identify a possible correlation between
behaviour and the markers of neuronal damage studied,
a Pearson’s correlation coefficient was calculated for all
time-points and doses studied. Occasional isolated para-
meters show significant correlation but overall no sig-
nificant correlation was found between the parameters.
Expression of GAP-43, in ATF-3 positive cells, in DRGs
during MIA-induced OA
The number of neurons expressing ATF-3 was similar in
single and double immunohistochemistry reactions
(Figures 4 and 6). Control animals showed a very low
baseline number of neurons expressing ATF-3, an aver-
age of 0.4 cells/section, and of this between 33-47%
of ATF-3 positive cells were also immunoreactive for
GAP-43 (0.1 ± 0.02 cells/section to 0.3 ± 0.02 cells/sec-
tion) (Figure 6).
In OA animals injected with 2 mg of MIA, at 3 days
post-injection of the 4.0 ± 1.2 ATF-3 cells/section, 34%
were also GAP-43 positive (1.4 ± 0.6 ATF-3 +GAP43
cells/section; Figure 6), a percentage similar to that of
controls. However, at day 7, of the 4.8 ± 1.6 ATF-3 cells/
section, 3.6 ± 1.3 were also GAP-43 positive, which cor-
responds to 75% of the total ATF-3 cells. This percent-
age was very similar at 14 days (71%) and at 21 days
(76%), despite the oscillations of the ATF-3 expression,
due to the biphasic pattern observed (Figure 6).
Analysis of cell size distribution showed that ATF-3
cells that are GAP-43 positive followed the same pattern
as total ATF-3 cells (Figure 7).
Discussion
Animal models are important and essential tools to un-
ravel the molecular mechanisms of pain in OA and for
pre-clinical testing of new therapies. The MIA model
has been widely used in pain associated studies and to
test potential analgesic agents, since it is a rapid and eas-
ily reproducible method, and has been described as the
one that best mimics the histopathology of human OA
[22-26]. The severity of the MIA-induced OA has been
shown to be concentration and time-dependent in a
range of concentrations [22,26,27]. Upon evaluation of
the histopathology profile with different doses across a
time period of 31 days, we observed a pattern of lesions
clearly dependent of MIA concentration. Behavioural
findings also showed a dose and time-dependent pattern
on nociception, when evaluated by the Knee-Bend and
CatWalk tests. Moreover, the ipsilateral paw-print inten-
sity profile here observed with the three doses of MIA
was comparable to the weight bearing evaluation
described by Pomonis et al. [26] using similar doses.
Neuronal hypertrophy and phenotypic alterations in
animals injected with 2 mg of MIA [7], along with data
revealing ATF-3 expression in DRG neurons of animals
with MIA-induced OA [6], suggested that neuronal
damage might be occurring in this experimental model.
In the present study, we further evaluated this possibility
by investigating the expression of two widely used neur-
onal injury markers, ATF3 and NPY, in the DRG neu-
rons, at different time-points of the OA evolution and
using different doses of MIA.
The presence of ATF-3 has been reported in L5 DRG
neurons of OA animals injected with 1 mg of MIA at
day 8 and 14 [6]. In another study ATF-3 expression has
been reported in FG labelled L4 DRG neurons of OA
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animals injected with 2 mg of MIA only from day 14 on-
wards [28]. However, in the present study, we observed
ATF-3 expression in L3, L4 and L5 DRG as early as
3 days post-MIA injection, at doses routinely used to in-
duce OA (1 and 2 mg). Moreover, ATF-3 expression was
dose and time-dependent, with a biphasic pattern, and
occurred in various sized neurons as previously
described in axotomized DRG neurons [13].
ATF-3 has been described by several authors as a sen-
sitive marker of nerve damage [12,13]. This transcription
factor, barely present in the DRG of naive animals, is
dramatically induced in DRG neurons following
Figure 7 ATF-3 and GAP-43 plus ATF-3 expression per neuronal perikaria cross-sectional area range of control and 2 mg of MIA OA
animals. The DRGs were evaluated at 3, 7, 14 and 21 days post-injection.
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peripheral axotomy [13]. Therefore, the induction of
ATF-3 seems to be a cellular response to some types of
stress, and nociceptive stimuli without nerve injury does
not seem to induce ATF-3 in sensory neurons [12,13].
This has been corroborated in studies where sciatic
nerve transection induced strong ATF-3 expression,
while intra-plantar inflammation induced by Complete
Freund’s Adjuvant did not [12,13]. As Braz and Basbaum
[12] stress, ATF-3 expression is not triggered only by the
increased activity of sensory fibres due to the lesion,
nerve damage being mandatory for such expression. In
MIA-induced OA there is no damage of the nerve per
se, but there might be injury of nerve endings located at
the joint that trigger a similar response but at a smaller
scale. Similarly, intraplantar injection of formalin, caus-
ing not only tissue inflammation but also injury of local
nerve endings, causes ATF-3 expression in some neu-
rons [13]. Also, Hill et al. [29] reported that skin incision
without real nerve damage induces nerve injury-like
responses such as ATF-3 expression.
ATF-3 is also expressed in the DRG neurons in
collagen-induced arthritis [30] and in monoarthritis fol-
lowing complete Freund´s adjuvant injection in the
tibiotarsal joint [31]. A possible role of positive regula-
tory factors, such as tumour necrosis factor α (TNF-α)
present in the neuroinflammatory environment, could
account for the activation of ATF-3 in those conditions,
as previously suggested by others [29,32]. However, it
should be noted that in collagen-induced arthritis ATF-3
expression was not affected by anti-TNF therapy [30].
Furthermore, bone destruction occurs in both models
[33,34] and in CFA induced arthritis there is a highly
significant correlation between pain behaviour and joint
destruction [34].
NPY expression in DRG neurons is evoked by injury
to sensory neurons [16,17,35], therefore, expression of
NPY was also evaluated in the present study. NPY has
been described to contribute to the excitability of axoto-
mized sensory neurons, which in turn could invoke ab-
errant spontaneous activity in damaged sensory nerves
that contribute to neuropathic pain [35,36]. Further-
more, it has been suggested that NPY can be released
intraganglionically, especially after peripheral nerve in-
jury, and act as a mediator of chemical cell-to-cell sig-
nalling [15]. Conversely, painful inflammation of rats’
hind paw does not induce NPY expression in DRG neu-
rons [37,38]. In our study, NPY expression was induced
by 1 or 2 mg of MIA immediately at day 3. From day 3
forward, NPY expression was only significantly different
from controls with the 2 mg dose, while the lowest dose
used (0.3 mg) never induced sufficient NPY expression
to reach statistical significance.
The temporal profile and dose related expression was
different for the two markers evaluated in this study,
which may be due to different activation mechanisms. In
fact, while ATF-3 expression is a transcription factor
that may be elicited immediately in DRG neurons, NPY
expression might need more time since it could be
dependent of sympathetic-sensory coupling within the
DRG [39].
Interestingly, a biphasic pattern was observed both on
behavioural data and on the expression of the injury
related molecules, though no significant correlation be-
tween them was found.
Injury due to mechanical activation of the primary af-
ferent endings present in subcondral bone has been pro-
posed as one of the important mechanisms for the
generation of pain in OA [40-42]. Considering that ATF-
3 and NPY expression are signalling neuronal injury,
that could explain the second wave of increased expres-
sion of ATF-3 and NPY observed in the present study at
latter time points of the disease, when erosion of the
cartilage and exposure of subcondral bone occurs. The
absence of articular cartilage leads to bone-to-bone ar-
ticulation and exposure of nociceptor endings in the
bone to biomechanical forces associated with weight
bearing [42]. However, both neuronal injury markers
showed increased expression at day 3 with the higher
doses of MIA. Day 3 corresponds to an initial phase of
the disease when an inflammatory component has been
described by some authors [22,23,26], and no degener-
ation of the cartilage is present, even with the dose of
2 mg, as observed in the histopathological analysis. A
possible explanation for the increased expression of
ATF-3 and NPY at this early time point could be an in-
jury to nerve endings in the capsule and synovium. As
mentioned above, some authors propose that the neu-
roinflammatory environment could be the trigger to this
increased expression [29,31,32], but another possibility is
that MIA itself may cause a chemical injury of nerve
terminals in the injected knee. In fact, MIA is an inhibi-
tor of glicolysis that ultimately leads to the necrosis of
chondrocytes, but is not cell specific, and depending on
the concentration used different degrees of cell death
can be achieved. Actually, we observe that increasing
doses of MIA induce the expression of ATF-3 and NPY
in further neurons, which suggests that the chemical
stimuli might induce some axonal damage producing a
nerve-injury like response. In what concerns the reduc-
tion in ATF3- and NPY-expressing neurons in some
time-points, the possibility of loss of knee-joint afferent
neurons does not seem to explain it, since in our previ-
ous study [7] we did not observed a reduced number of
neurons in DRG of MIA injected animals, when total
counts were performed at 31 days.
The lack of correlation between neuropathic markers
and pain behaviours previously referred, indicate that
although a nerve injury may be important for pain
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derived from OA, other mechanisms might also con-
tribute for nociception. In this context, the inflamma-
tory component is likely to cause a rise in the activation
of joint nociceptors, that in turn lead to an increased
sensitivity of spinal cord neurons, resulting in enhanced
nociception.
After peripheral axonal injury, the perikaria of affected
neurons and the surrounding glial cells respond to the
insult with morphological, metabolic and biochemical
changes [43], in order to promote survival and regener-
ation of the lesioned nerves [44]. ATF-3, besides being
implicated in cell death, may also have a role in inhib-
ition of apoptosis and induction of neurite elongation,
and thus promote neuronal survival, depending on the
stress signal, cell type and intracellular pathway activated
[45]. In fact, in the oncology field, where ATF-3 has
been extensively studied, it seems that the cellular con-
text strongly influences its role in cancer development,
acting as an oncogene or as a tumour suppressor [46].
Actually, it is possible that the fluctuation of ATF-3 over
time has to do with the trigger signal, and also derives
from the fact that ATF-3 expression is transient and reg-
ulates the balance between proliferative and apoptotic
signals.
On the other hand, GAP-43 expression seems to peak
when axons are elongating [47]. Therefore, GAP-43 ex-
pression was analysed in order to evaluate whether an
enhanced growth state had been activated. An increased
expression of GAP-43 in ATF-3 positive neurons was
observed immediately at day 3, but that became more
pronounced from day 7 onwards. The distance of the
axotomy site from the cell body seems to be important
in determining GAP-43 expression and the speed of its
up-regulation [18,48,49]. This could explain the delayed
expression in OA animals, since the damage is far from
the cell body. It should also be noted that GAP-43 was
expressed in all cell size DRG cells, as occurs after per-
ipheral axotomy [18]. The augmented expression of
GAP-43 reinforces the hypothesis of nerve damage.
ATF-3 along with other factors might be involved in the
fate of these neurons after injury [13], and in some cases
it might be having pro-survival, axonal-regeneration
effect.
Conclusions
In summary, MIA injection evokes dose-dependent ex-
pression of neuronal injury markers in DRG neurons, as
well as a regeneration protein expression, indicating that
axonal injury and a regeneration response may be hap-
pening in this model of OA. Two different phases were
observed. In the initial days, a chemically-induced neur-
opathy may be occurring, possibly with the contribution
of an inflammatory component, while at latter stages the
mechanical activation of exposed primary afferents could
be involved, but additional experiments are required to
provide further evidence of this hypotheses. Actually, a
neuropathic component in human OA has also been
suggested [50-52]. Finally, correlation between this OA
model and human disease must be cautious, because
Barve et al. [53] analyzed and compared the transcrip-
tional profile generated in OA rats induced by MIA with
that of human OA and observed little similarity between
the two.
Methods
Animals
Adult male Wistar rats (Charles River, France) weighing
230 ± 20 g were used in this study. Animals were housed
in solid bottom cages, with water and food ad libitum,
and animal room was kept at a constant temperature of
22 °C and controlled lighting (12 h light/12 h dark
cycle).
All experimental procedures were performed in ac-
cordance with the ethical guidelines for the study of ex-
perimental pain in conscious animals [54], as well as the
European Communities Council Directive 86/609/EEC,
with all adequate measures being taken to minimise pain
or discomfort of the animals.
Induction of osteoarthritis
Under brief isoflurane anaesthesia, animals were injected
intra-articularly with 0.3, 1 or 2 mg of MIA (Sigma-
Aldrich, USA) dissolved in 25 μl of saline, or with only
25 μl of saline (controls). The syringe was inserted
through the patellar ligament into the intra-articular
joint space of the left knee. Animals were randomly
assigned to each group (n = 5/experimental group).
Behavioural testing
Nociception was evaluated in all animals by the Knee-
Bend and CatWalk tests as previously described [55].
Testing was performed blind at days 0, 3, 6, 10, 13, 17,
20, 24, 27 and 31 post-injection. However, the number
of animals in the behavioural assessment was not the
same at the different time-points, since animals were
pulled out at each sacrifice time-point resulting in a pro-
gressively decreasing number of animals, up to a mini-
mum of 5 animals per group at day 31. Briefly, the
Knee-Bend test consists on the recording of the squeaks
and/or struggle reactions in response to five flexions and
five extensions of the knee joint. The score of the test is
determined by the type of reaction to each movement of
the joint, according to the following evaluation scale: 0 -
no responses to any kind of extension or flexion of the
joint; 0.5 - struggle to maximal flexion/extension; 1 -
struggle to moderate flexion/extension and also vocaliza-
tions to maximal flexion/extension; 2 - squeak reactions
to moderate manipulations of the joint. The sum of the
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animal reactions, giving maximal values of 20, represents
the Knee-Bend score, an indication of the animal’s
movement-induced nociception.
For the CatWalk test, animals were placed in a glass
platform illuminated such as to reflect light downwards
at the points of contact of the paw with the surface,
resulting in a bright sharp image of the paw-print. The
platform was monitored by a video camera placed under
the platform and connected to a computer equipped
with video acquisition software (Ulead Video Studio,
Corel Corporation, Canada). The intensity of the signal
depends on the area of the paw in contact with the plat-
form and increases with the pressure applied by the paw.
Image J 1.37 (www.tucows.com/preview/510562) was
used to analyse the images obtained from the videos
recorded during the animal evaluation. The number and
intensity of pixels above a defined threshold were quan-
tified, allowing the comparison of the area/pressure ap-
plied by each paw. Results were expressed in total
intensity of the ipsilateral hind paw as a percentage of
the total intensity of both hind paws. Therefore, as
alterations in the ipsilateral limb are in fact made up by
the contralateral hindlimb, the weight applied to the
contralateral paw may be inferred.
Tissue processing
Seven days prior to the end of the experiments 5 μl of
2% Fluorogold (FG) (Fluorochrome, Denver, CO, USA)
was injected intra-articularly in the left knee of the ani-
mals. This difference in the timing of FG injection was
done to ensure the same migration time of FG in all ani-
mals, but, as a consequence animals sacrificed at day 3
had the FG injection before the MIA injection, as
opposed to the others. At 3, 7, 14, 21 and 31 days after
saline or 0.3, 1 or 2 mg of MIA injection, animals were
anaesthetised and perfused with 4% paraformaldehyde
with 0.1% of picric acid. Their DRG from lumbar seg-
ments 3, 4 and 5 (L3, L4 and L5) were dissected, post-
fixed for 4 hours in the same fixative and kept in 30%
sucrose with 0.01% sodium azide. DRG were serially
sliced in 12 μm sections using a cryostat (Microm Inter-
national GmbH, Germany), and every 10th section was
collected in the same glass slide (8–10 sections from
each DRG, on average). DRGs were oriented to ensure
that longitudinal sections were made, and the number of
sections obtained from each DRG was similar between
animals, giving an indirect measure of this consistency.
The cutting process was always performed by the same
person and with the same method to ensure the
consistency of the procedure throughout the study. The
injected knees were also dissected, post-fixed for 72
hours and then decalcified for 8 hours in a buffer con-
taining 7% AlCl3, 5% formic acid and 8.5% HCl, as pre-
viously described [55]. The joints were then washed in
0.1 M phosphate buffer saline (PBS) pH 7.2, and kept in
30% sucrose with 0.01% sodium azide until they were
cut in 20 μm sections using the cryostat.
Histological analysis of the knee joint
Knee joint sections were stained by the Fast Green and
Safranin-O method in order to evaluate the extent of the
histopathological lesions. Slides were mounted with
Eukitt (Kindler, Germany) and images acquired with an
Axioskop 40 microscope equipped with an AxioCam
MRc5 camera (Carl Zeiss MicroImaging).
Immunohistochemistry
Slides containing every tenth section of L3, L4 and L5
DRG of animals injected with saline or 0.3, 1 and 2 mg of
MIA and sacrificed at 3, 7, 14, 21 and 31 days post-
injection were used for immunofluorescence reactions
for ATF-3 and NPY. Slides from animals injected with
2 mg of MIA were also used for double immunofluores-
cence reactions for ATF-3 and GAP-43 at the same time
points after MIA injection. The immunohistochemistry
reactions for each marker were performed in adjacent
sections. DRG sections were rinsed in 0.1 M PBS pH 7.4,
followed by PBS + 0.3% triton-X (PBST), and incubated
in 10% normal serum in PBST for 90 min. Sections were
then incubated overnight at room temperature with one
of the following antibodies: rabbit anti-ATF-3 (1:500,
Santa Cruz Biotechnology Inc, USA); rabbit anti-NPY
(1:2000, Sigma-Aldrich, EUA). For double immunofluor-
escence reactions, sections were incubated overnight at
room temperature with the antibodies rabbit anti-ATF-3
(1:500, Santa Cruz Biotechnology Inc, USA) and mouse
anti-GAP-43 (1:500, Chemicon, EUA). After thorough
PBST washing, sections were incubated with Alexa-Fluor
568 donkey anti-rabbit secondary antibody (1:1000, Mo-
lecular Probes, USA) 1 h at room temperature. For
double immunofluorescence reactions, sections were
incubated with Alexa-Fluor 488 donkey anti-rabbit and
Alexa-Fluor 568 donkey anti-mouse secondary anti-
bodies (1:1000, Molecular Probes, USA) 1 h at room
temperature. Slides were then rinsed in PBST followed
by PBS, mounted with Prolong Gold Antifade medium
(Molecular Probes, USA) and coverslipped. Negative
control immunohistochemistry reactions, where the pro-
cedure was the same with the exception of the absence of
the primary antibodies, were performed to test for the
specificity of the primary antibodies. Slides were viewed
using a Zeiss Imager.Z1 fluorescence microscope (Carl
Zeiss MicroImaging GmbH, Germany) and all neurons
were identified based on morphological criteria and, in
the ATF-3 reaction, counted as positively labelled only if
the immunostained nucleus was clearly darker than the
surrounding cytoplasm. Countings were done blind as to
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the experimental group and always by the same experi-
menter to assure reproducibility.
Cell size distribution was determined in the animals
injected with 2 mg of MIA, by measuring their cross
sectional area.
Statistics
Results are presented as mean ± SEM. For behavioural
data, the temporal profile evaluation was analysed by
Repeated Measures ANOVA, followed by the Fisher's
least significant difference (LSD) post-hoc test. Immu-
nohistochemical data obtained from OA animals was
compared with data from control animals using the
Mann–Whitney test. A P value < 0.05 was accepted as
statistically significant.
To examine the correlation between the behavioural
measurements and ATF3 expression or NPY expression,
the Pearson’s correlation coefficient was calculated by
comparing the number of ATF3 or NPY in L3, L4 and
L5 DRGs versus the Knee-Bend score and the ipsilateral
paw print intensity measured by the CatWalk, at all
time-points and for the three MIA doses.
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BEHAvIOURAL TESTS THAT MEASURE MOvEMENT-EvOkED 
NOCICEPTION OF THE kNEE JOINT IN A MODEL OF OA
The assessment of OA pain is of critical importance for the understanding of 
the underlying mechanisms and for evaluating the potential efficacy of therapeutic 
drugs. The main challenge of assessing OA pain in animal models has been to 
develop tests that actually measure nociception of the knee joint rather than that 
of the hind paw (Neugebauer et al, 2007). Our results have shown that Knee-bend 
and CatWalk behavioural tests allow a non-reflexive, and non-referred evaluation 
of the joint movement-related nociception, therefore being useful methods for 
the evaluation of the nociceptive symptoms in the MIA model of OA. These assays 
are more clinically relevant than the widely used referred hind paw measures, 
such as mechanical and heat sensitivity of the paw, because although secondary 
hyperalgesia or allodynia have been reported in patients with OA (Bajaj et al., 2001; 
Kosek and Ordeberg, 2000), these are not the most common symptoms by far. 
When using an animal model to investigate human pathologies, one has to take in 
consideration that experimental conditions resemble as much as possible what 
happens in patients. In that sense, if the main feature of the clinical presentation 
of OA is pain localized to the joint typically aggravated by joint use, particularly for 
tasks involving knee bending, and relieved by rest (Creamer et al., 1998; Sinkov 
and Cymet, 2003), those are the features that should be analysed in the animal 
model.
Knee-Bend allows a direct assessment of mechanical sensitivity of the knee 
joint by measuring the struggle and vocalizations evoked by flexion and extension 
of the knee. When evoked by noxious stimuli, audible vocalizations were found to 
indicate a nociceptive response (Han et al, 2005; Jourdan et al., 1995).
The struggle reaction for knee extension has been observed in inflammatory 
arthritic models and taken as an arthritic pain index (yu et al., 2002). Struggle 
reaction has been considered an integrated behaviour, interpreted, at least in 
part, as modification or modulation in pain transmission pathway (Jourdan et al., 
2000). The response of OA animals to the physiological range of motion of the 
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affected joint seems to be a good index of arthritic pain and mimics the decreased 
mechanical pain threshold upon movement of the joint found in patients suffering 
from OA (Neugebauer et al., 2007). 
The CatWalk test is useful in the assessment of weight bearing. It allows 
to evaluate the weight distribution while the animal is walking freely (dynamic 
weight bearing) or standing still, in the four paws (static weight bearing), and with 
no constraint of the animal. OA animals shift the weight from the osteoarthritic 
hindpaw to the contralateral hindpaw, and this weight-bearing deficit is taken 
as a pain measure. One potential problem in the traditional CatWalk method is 
that the animals are required to cross a runway, and this can be influenced by 
a number of factors such as motivation. In our study, rats were allowed to walk 
freely, overcoming that drawback. Obviously, this test does not only reflect joint 
pain but also pain emanating from periarticular structures, which correlates with 
the fact that OA patients may have pain from periarticular structures (Felson, 
2009). Moreover, a similar method is used in patients with OA to evaluate gait 
pattern changes and in some studies a correlation between these alterations and 
pain assessment in self-report questionnaires is shown (van der Esch et al., 2011; 
Zifchock et al., 2011). Analysis of the pressure map of OA patients showed that 
the percentage of hindfoot pressure during standing and peak pressure of the 
forefoot during walking were lower when compared to the controls, reflecting 
weight bearing changes (Kul-Panza and Berker, 2006; Neugebauer et al., 2007). In 
another study, Stauffer and colleagues (1977) have shown that patients with knee 
OA attempt to avoid pain by decreasing loads from the affected joint. Patients 
can achieve this by decreasing the single limb support, which has been shown 
to correlate with the pain evaluation through the Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC) (Debi et al., 2011). Computerized 
gait analysis also revealed various mechanical abnormalities accompanying 
patients with knee OA at an early stage, such as reduction of the walking velocity, 
cadence and stride length, increasing of stride time and double support time and 
prolongation of the overall stance phase, among others alterations (Gok et al., 
2002). These gait parameters were not evaluated in our study, because Clarke 
et al. (1997) demonstrated that in OA animals only load bearing is changed. Gait 
alterations, such as stance time imbalance, were found in the rat surgical medial 
meniscus transection model, but this can be partially due to the joint instability 
induced as part of the surgical procedure and thus might not correlate with 
nociceptive behaviour (Allen et al., 2012). 
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The pharmacological experiments allowed us to evaluate the sensitivity 
of the behavioural measures used, from the Knee-Bend and CatWalk tests, for 
evaluating OA-induced nociception at different stages of disease progression. The 
drugs used reverted the movement-induced nociceptive behaviour of OA animals, 
in accordance to the mechanism of action of each drug and what is known about 
OA pathology. 
With all the drugs used, the Knee-Bend score was significantly reduced and 
the ipsilateral paw print intensity significantly increased at day 3. In this initial 
phase of the MIA-induce OA pathology, excitability changes in peripheral afferents 
are already observed (Kelly et al., 2012) and an inflammatory component has been 
described (Bove et al., 2003; Combe et al., 2004). The effect of lidocaine, a non-
subtype selective, state-dependent NaV1 channel blocker (Priest, 2009), at day 3 
in both tests, suggests that the peripheral input arising from intra-articular nerve 
terminals drives movement-induced nociception that depends on the presence 
of functional voltage-gated sodium channels. In fact, recent studies have shown 
that the Nav1.8 sodium channel is part of the molecular machinery involved in the 
mechanotransduction of MIA-induced OA nociception (Schuelert and McDougall, 
2012). Intra-articular lidocaine produces relief of pain and increased joint loads 
during walking in OA patients (Henriksen et al., 2006). Furthermore, many patients 
show improvement in their pain after knee replacement, supporting the possibility 
that pain in OA is primarily driven from the joint (Nilsdotter et al., 2009).
Diclofenac was also effective in reverting the behavioural measures of MIA-
induced nociception at day 3, suggesting an important role for inflammation at this 
stage. NSAIDs, which act by blocking the production of prostaglandins, have been at 
the centre of current anti-inflammatory therapies for the treatment of OA symptoms. 
In the MIA model of OA, the levels of PGE2 and 6-keto-PGF1α (stable breakdown 
product of PGI2) were respectively found to be elevated by 10- and 3-fold in the 
synovial fluid of OA animals at day 3, when compared with saline controls (Pulichino 
et al., 2006). However, the levels of both prostaglandins returned to basal control 
levels by day 7 (Pulichino et al., 2006), which may explain the almost inefficacy of 
diclofenac at day 20. Others have also shown NSAID inefficacy in reversing the hind 
limb weight bearing or the number of rears in spontaneous activity evaluation 28 
days after MIA injection (Nagase et al., 2012; Pomonis et al., 2005). In the clinical 
setting, long-term use of NSAIDs fails to reduce mean pain levels beyond minimal 
clinically important thresholds (Bjordal et al., 2004). Patients experience ongoing 
pain that is generally resistant to NSAIDs and often intractable, and in many cases 
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must undergo joint replacement (Dieppe and Lohmander, 2005; Sinkov and Cymet, 
2003). The lack of efficacy of diclofenac on MIA nociception at a later stage is 
consistent with the low efficacy of NSAIDs in patients with advanced OA (Dieppe and 
Lohmander, 2005). In fact, one possible explanation for the suboptimal treatment 
of OA pain may be the mismatch between the drugs used and the underlying pain 
mechanisms (Hochman et al., 2010). Traditionally, pain associated with OA has 
been considered nociceptive in nature or even inflammatory (Hochman et al., 2010). 
However, cumulative data has suggested that OA patients can experience pain due 
to both nociceptive/inflammatory and neuropathic mechanisms to varying degrees 
(Hochman et al., 2010). 
The μ-opioid receptor agonist morphine provided a significant reversal of the 
nociceptive behaviour observed in both tests and at both time-points. Morphine 
is known to be effective against not only inflammatory pain but also nociceptive 
and neuropathic pain in animal models. Our results indicate that alterations in the 
Knee-Bend score and ipsilateral paw print intensity at both time-points are pain-
associated behaviours.
Overall, the pharmacological data allowed us to conclude that, in the MIA 
model of OA, analgesic drugs used in the clinical setting change the movement-
induced nociception behaviour detected by the Knee-Bend and CatWalk tests in a 
reproducible manner, thus supporting their usefulness for evaluating OA-induced 
nociception. Moreover, the observation that these pharmacological evaluations 
seem to reflect the clinical situation of OA, suggest that these behavioural 
tests can effectively be used as predictors of analgesic efficacy. Additionally, 
the observation that the nociceptive behaviour evaluated by the Knee-Bend and 
Catwalk tests depends on the concentration of MIA used, further indicates that 
these tests are sensitive tools.
Future studies aiming at developing behavioural tests that evaluate pain at 
rest and allow the differentiation between rest pain and movement pain would be 
very useful, since, as discussed, a continuous aching pain or pain at rest is the 
main clinical presentation in advanced OA (Creamer et al., 1998; Sinkov and Cymet, 
2003). Moreover, recent clinical studies in OA patients have reported a difference 
in the pharmacological profile for relief of pain at rest versus movement-induced 
pain (Petrella et al., 2002). Additionally, the development of behavioural tests that 
would differentiate pain at the joint from pain at periarticular structures, such 
as skin and muscle, would help us to better characterize the model used. These 
would allow a better understanding of the physiopathology of the model used and 
thus have important implications for the therapeutic management of the pain.
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PERIPHERAL MECHANISMS UNDERLyING PAIN IN OA
In an attempt to better understand the peripheral pathophysiological 
mechanisms of pain in OA, a series of immunohistochemical studies were 
performed in the DRGs. An increase in the percentage of CGRP in the FG 
backlabelled cells of OA animals with 31 days of disease evolution was found. This 
increased CGRP observed in DRG cell bodies may serve different functions. 
CGRP is known to be involved in peripheral and spinal pain mechanisms. 
Primary afferents release CGRP in the spinal cord dorsal horn (Ribeiro-da-Silva, 
1995; yashpal et al., 1992) where it is involved in the spinal processing of nociceptive 
mechanosensory input from the knee joint and in the generation and maintenance 
of joint inflammation-evoked hyperexcitability of spinal cord neurons (Neugebauer 
et al., 1996). In the MIA-model of OA, increased CGRP released in the spinal cord 
may act on CGRP receptors present in dorsal horn neurons and contribute to 
the generation and maintenance of the nociceptive behaviours observed. In the 
kaolin/carrageenan model of arthritis CGRP facilitated synaptic transmission and 
increased neuronal excitability through a postsynaptic site of action, in substantia 
gelatinosa neurons (Bird et al., 2006).
CGRP may also be released in the peripheral terminal and thus mediate 
efferent effects. In fact CGRP-immunoreactive fibres have already been observed 
in free nerve endings of synovial tissue of patients with knee OA (Saito and Koshino, 
2000). It has been shown that the release of neuropeptides/neurotransmitters, 
such as CGRP, from the sensory nerve endings contributes to neurogenic 
inflammation (Willis, 1999) and neurogenic inflammation has been postulated 
as a possible pain inducing mechanism in OA (Marshall et al., 1990; McDougall, 
2006). This neuropeptide, along with others, may stimulate chemotaxis, neutrophil 
activation, mast cell degranulation and fibroblast proliferation, features of the 
inflammatory response (Brandt, 2009). Besides its inflammatory effects, CGRP 
may potentially exert trophic effects on the innervation targets. Also in dental 
pulp CGRP fibres may subserve efferent roles not directly related to nociception 
(Silverman and Kruger, 1987). Acting on the vasculature CGRP is recognized as 
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the most potent vasodilator among sensory neuropeptides (García-Castellano et 
al., 2000). On bone cells, CGRP may exert a paracrine effect, since osteoblasts 
and osteoclasts express functional receptors for CGRP (Lerner and Persson, 
2008). In vitro, CGRP has been reported to increase osteogenesis on bone marrow 
cells, by stimulating stem cell mitosis, osteoprogenitor cell differentiation, or 
both (Bernard and Shih, 1990). This effect appears to be dose-dependent and a 
similar finding was obtained by intravenous injection of CGRP 2 hours before bone 
marrow cells were harvested (Bernard and Shih, 1990). In addition, CGRP also 
seems to act directly on osteoclasts to inhibit bone resorption (Zaidi et al., 1987). 
Therefore, CGRP increased expression in primary afferent neurons innervating 
OA joints may result in CGRP increased expression at the periphery in an attempt 
to regulate cellular activity underlying bone formation and resorption, which is 
essential for healthy bone maintenance (Lerner, 2002) and a critical process in 
OA development. 
We also observed that in OA animals a subpopulation of large-diameter DRG 
neurons begin to synthesize CGRP. This could be due to de novo expression or 
reflect swelling/hypertrophy of smaller neurons that expressed these peptides 
all along. The hypothesis of hypertrophy is also corroborated with the increased 
numbers of medium and large diameter neurons in the total DRG cell count in 
OA rats. However, we cannot rule out the possibility of change in gene expression 
of large diameter neurons be coupled with upregulation of CGRP expression in 
medium size neurons that suffer hypertrophy. 
The phenotypic change would have the potential to provide neurons that 
were originally LTMs with pain-signalling machinery. CGRP upregulation in large-
diameter neurons after nerve injury has been reported (Miki et al., 1998). More 
recently, Nitzan-Luques and colleagues (2011) have shown that after spinal nerve 
ligation in high autotomy rats, but not low autotomy ones, there is an increase 
in CGRP immunoreactivity in large diameter neurons suggestive of phenotypic 
switching. These could indicate that, such as with nerve injury models, Aβ fibres 
may suffer a functional change and start signalling pain in the MIA-model of OA. 
The involvement of Aβ primary sensory neurons in the pathogenesis of OA pain 
has been suggested by other authors in the unilateral derangement model of 
OA (Wu and Henry, 2009; Wu and Henry, 2010). These authors showed that Aβ 
LTMs exhibit electrophysiological changes that are consistent with observations 
in models of peripheral neuropathy but not of peripheral inflammation (Wu and 
Henry, 2010). Likewise, OA patients experience impairment of proprioception 
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(Barrett et al., 1991; Sharma, 1999) and reduced vibratory perception (Shakoor et 
al., 2008), which is may be due to alterations of Aβ LTMs. Furthermore, increased 
mechanical sensitivity after exacerbation of movement pain in OA of the hands 
was alleviated by Aβ fibre blockade (Farrell et al., 2000). Therefore, Aβ afferents 
in OA may directly drive CGRP-sensitive central nervous system pain-signalling 
neurons and contribute to central sensitization.
The shift observed in the cell-size histogram of Nissl stained sections to 
larger cell sizes, in the absence of neuronal death and neurogenesis, suggests 
a swelling of small/medium size neurons. This is the opposite to what has been 
described in neuropathic pain models where the perikarya mean volume is shifted 
to smaller values (Degn et al., 1999; Nitzan-Luques et al., 2011; Vestergaard et 
al., 1997). However, neuronal loss is observed in these models (Degn et al., 1999; 
Vestergaard et al., 1997), and thus loss of large-diameter neurons may contribute 
to that shift to smaller sizes. On the other hand, neuronal hypertrophy has been 
observed both in DRGs and in SNC in different conditions (Madeira et al., 2000; 
Williams et al., 1993) and has been described as part of chromatolysis, a neuronal 
cell body response after axonal injury (Hanz and Fainzilber, 2006).
Further evidence supportive of alterations of the joint innervation in this 
model of OA is the fact that a decrease in the number of FG backlabelled cells 
was observed in OA animals. Such decrease was mainly in small DRG neurons, 
but also observed in medium sized ones. This is suggestive of changes in afferent 
fibres that become unable to uptake the dye or to retrogradely transport it to the 
cell body. Kelly et al. (2012) observed that C-mechanosensitive fibres were less 
responsive to mechanical stimulation than A-mechanosensitive fibers in the MIA 
model of OA, which, together with our findings, may suggest a possible injury of 
articular C-fibre terminals in this model. 
Together, these observations suggest general changes in sensory neurons 
that may be far beyond simple changes in nociceptive neurons, and a possible 
injury to afferent nerve terminals in OA pain. Therefore, we went on to assess 
the possible existence of peripheral neural injury. We used the expression of 
ATF-3 and NPy in the DRGs, throughout time, to assess the degree of injury to 
primary afferent neurons following injection of different doses of MIA. ATF-3 and 
NPy expression was dose and time-dependent and showed a biphasic pattern, 
especially evident on ATF-3 expression. If in fact, as most authors claim, ATF-3 
and NPy expression in DRG are sensitive and robust markers of neuronal injury 
(Hokfelt et al., 2007; Shortland et al., 2006), their expression confirms the presence 
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of peripheral neuronal injury in the MIA model of OA. Both markers were observed 
as early as day 3 post-MIA injections in higher doses. At this time-point, as already 
discussed, the pathology is in its initial inflammatory stage where the degree of 
cartilage loss and of other histopathological alterations is modest, even with 2 mg 
of MIA. Therefore, initially these markers do not seem to reflect a peripheral neural 
injury due to the pathological process of OA development. A possible explanation 
could be injury to nerve endings in the capsule and synovium by the MIA itself. 
Petrescu and colleagues (2007) have shown that iodoacetate plus NaN3 induce 
massive Ca2+ influx in rat dorsal roots in vitro through inhibition of metabolism, 
and excessive accumulation of axoplasmic Ca2+ may be responsible for axonal 
damage (Stys, 2004). In this context, the eventual occurrence of neuronal injury 
due to MIA injection may question the clinical relevance of this animal model of 
OA due to non-specific effects. Induction of ATF-3 secondary to peripheral nerve 
damage induced by noxious chemical stimuli has also been reported after hindpaw 
injection with agents such as capsaicin, formalin, menthol and mustard oil (Braz 
and Basbaum, 2010). These same authors found that profound inflammation 
produced by hindpaw injection of CFA did not induced ATF-3 expression in the 
DRGs (Braz and Basbaum, 2010). However, other authors have shown that 
CFA (Complete Freund’s adjuvant) injection into the joint and collagen-induced 
arthritis induces ATF-3 expression, but not antigen-induced arthritis (Inglis et al., 
2007; Nascimento et al., 2011; Segond von Banchet et al., 2009). Therefore, it 
seems that some neuroinflammatory environments at the joints might also be 
able to trigger ATF-3 expression indirectly, most possibly through nerve damage. 
As referred in the introduction, pain originated from the joints has a different 
character of cutaneous pain probably reflecting a different neuronal organization 
(Schaible et al., 2009). Therefore, a neuroinflammatory environment that might 
not be neurotoxic for cutaneous afferents might do so for joint afferents leading 
to their damage. Hence, the neuroinflammatory environment present at the early 
stages of MIA induced OA might trigger the expression of ATF-3 and NPy. In fact, 
it is likely that the presence of the pro-inflammatory cytokines IL-1β and TNF-α 
observed in early OA (Benito et al., 2005; So et al., 2011) contribute to that since it 
has been shown that both are able to trigger ATF-3 (Lu et al, 2007). Furthermore 
the different profiles of ATF-3 expression that follow the different doses of MIA 
at this early stage seem to favour the hypothesis of the inflammatory mediators, 
since when using the lower dose of MIA the expression of ATF-3 was only observed 
at day 7, which could account for a less vigorous inflammatory response that 
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eventually takes more time to become “neurotoxic” and thus activate ATF-3 
expression. It should be noted that diclofenac was able to revert nociception at 
this stage, which further supports the contribution of an inflammatory milieu for 
the joint nociception. 
In the second wave of ATF-3 and NPy expression, histopathological 
changes are observed in OA joints, reflecting the development of OA. At this 
stage, expression of peripheral nerve injury markers may be due, not to directly 
axotomized or damaged nerve bundles, but to injury of nerve endings located at 
the joint. Particularly important may be the nerve endings of the subchondral 
bone, which has been considered one of the most important structures in the 
pain and structural progression of OA, that become exposed to mechanical and 
chemical factors (Dieppe, 1999; Niv et al., 2003). This is in line with the decreased 
FG backlabelled neurons in the OA animals 31 days post-MIA injection that, as 
already referred, suggest a possible injury of articular fibres terminals in this 
model. If this hypothetical injury impairs retrograde transport, which could 
account for the decrease in FG, this could be the trigger signal for ATF-3 induction 
(Tsujino et al., 2000). The second wave of injury markers expression may reflect 
a phenomenon of post-traumatic neuropathic pain that better correlates with the 
pharmacological data, since diclofenac showed poor efficacy in reverting that 
behaviour at this stage. 
ATF-3 and NPy expression was observed both on FG positive and negative 
cells. Always taking into consideration that during OA there is a decrease of FG 
backlabelled neurons, and thus some ATF-3 and NPy in FG negative cells may 
indeed represent joint neurons, it also seems that some of these markers are 
expressed in neighbouring cells that do not innervate the joints. This is in line 
with the observation that at least two subpopulations of primary afferents develop 
ectopic activity, which contributes to ongoing neuropathic pain, in the presence 
of nerve injury: injured afferents and their uninjured neighbours (Gold, 2000). 
Thus, both populations of afferents are hypothetically involved in the behavioural 
changes observed in OA, with changes in joint afferent neurons ultimately 
influencing neighbouring neurons altering also their gene expression. These 
could be achieved by an intraganglionic dialog, where DRG neurons participate 
in ongoing mutual interactions in which neuronal excitability is continuously 
modulated by afferent spike activity that may be mediated, at least in part, by 
substances released from neuronal somata and detected by neighbouring cell 
somata (Amir and Devor, 1996). In fact, this phenomenon of “cross-talking” within 
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the same ganglion increases in the setting of peripheral nerve injury but also in 
peripheral inflammatory condition (Amir and Devor, 2000; Xu and Zhao, 2003). 
Hokfelt and collaborators raised the possibility that NPy upregulation on DRG after 
nerve injury can serve that purpose, acting in a paracrine way on NPy receptors 
on adjacent neurons (Hokfelt et al., 2007). Therefore, besides the potential effects 
of NPy on spinal cord neurones and efferent role in mediating bone cell activity 
(Khor and Baldock, 2012), it may also be a mediator of chemical cross-signalling 
in this model of OA. The fact that no NPy expression was observed with this lower 
dose of MIA suggests that there might be a threshold of stress or axonal injury 
that a neuron needs to achieve before activating NPy. Wu and Henry (2010) also 
reported that in OA animals other sensory neurons within the same DRG, with 
receptive fields far beyond the knee joint, seemed to have undergone changes, 
which is consistent with pain referred to other areas beyond the joint, as reported 
by some OA patients (Hawker et al., 2008).
It is plausible that the changes observed after peripheral axonal injury are 
related mostly to cell survival and regeneration rather than degeneration and cell 
death. ATF-3, besides being implicated in cell death, may have a role in inhibition 
of apoptosis and induction of neurite elongation, and thus promote neuronal 
survival (Nakagomi et al., 2003). This possible anti-apoptotic, pro-survival effect 
is supported by the total DRG neuronal cell number that was not reduced in OA, 
indicating that no cell death occurred, and by the increased expression of GAP-43 
in ATF-3 positive cells, which point to an activation of the intrinsic growth state of 
DRG neurons in order to enhance peripheral nerve regeneration (Seijffers et al., 
2007). After peripheral axonal insult, the perikaria of affected and neighbouring 
neurons and the surrounding glial cells respond to the insult and prompt 
sensory neurons into an actively growing state by increasing the expression of 
regeneration-associated genes (Costigan et al. 2002) in order to promote survival 
and regeneration of the peripheral lesioned nerves. 
Our results and interpretations are consistent with the suggestion of a 
neuropathic component in the MIA model of OA. This is in conformity with the 
clinical picture of some OA patients who describe their pain with terms typically 
associated with neuropathic pain processes, such as moderate–severe pain that 
is shooting and hot-burning in quality, and sensitive to light touch and/or cold 
(Hawker et al., 2008; Hochman et al., 2010; Hochman et al., 2011). In one of these 
studies, the proportion of patients who used neuropathic pain descriptors was 
0.34 (Hochman et al., 2010). This is of clinical importance for the treatment of OA 
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pain, since a subset of patients with knee OA may have neuropathic mechanisms 
contributing to their pain experience, and may benefit from an alternative 
treatment.
Future studies are necessary to further evaluate the pain mechanisms 
operating in OA development. Primary, as most basic and pre-clinical 
pharmacological studies related to pain associated with OA have been performed 
using the MIA model of OA, the eventual occurrence of neuronal injury following 
MIA injection has to be addressed to evaluate the clinical relevance of this 
animal model. Subsequently, it would be important to better understand which 
mechanisms are causing the pain and when, why and what is responsible for 
the transition from nociceptive pain to neuropathic pain states. Furthermore, 
since not all patients report neuropathic pain symptoms, understanding why one 
individual develops those symptoms and another with an identical lesion does not, 
is obviously crucial to develop better and different strategies to treat OA pain.
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CONCLUSIONS
The studies included in this PhD thesis intended to improve our knowledge on 
the mechanisms of pain in OA. Our observations provide evidences of alterations 
at the DRG neuronal level, in the MIA model of OA, that point to a mechanism of 
peripheral axonal injury. The immunohistochemistry evaluation together with the 
pharmacological studies suggests that pain in OA can derive from several pain 
mechanisms. In early stages nociceptive/inflammatory noxious input from the 
periphery might be the driving force of pain perception, but in more advanced OA, 
injury of nerve terminals might lead to development of features of neuropathic 
pain. 
The findings of this study have potential clinical implications because of the 
importance of differentiating between nociceptive and neuropathic pain for effective 
pain treatment. OA has been traditionally treated as a nociceptive/inflammatory 
pain condition, with the use of NSAIDs. However, it is starting to be evident that 
these treatments fail to reduce OA pain in long term in the majority of patients. 
This inadequate response might be due to the neuropathic component present in 
some patients that are, so far, mistreated. 
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